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Abstract 
 Nutritional strategies which increase energy substrate availability enhance exercise 
capacity and affect cell signalling and muscle morphology. The co-ingestion of carbohydrate 
with creatine has been shown to enhance both intramuscular creatine as well as glycogen 
storage, with the former being thoroughly investigated with respect to resistance-based 
exercise. Despite evidence of synergy, the direct performance benefits of this co-
supplementation strategy on endurance-based exercise and its metabolic effect(s) on cellular 
signalling remained to be investigated. The work comprising this thesis represents a series of 
independent yet related studies that determined the effects of manipulating creatine along 
with carbohydrate (glucose) and/or insulin availability using both in vivo (human) and in 
vitro (rodent cell lines) models to better understand creatine‘s role in metabolism and 
performance.  
Study I determined the in vivo effects of a concurrent creatine and carbohydrate 
loading regimen on endurance cycling performance. A clinical trial was undertaken in which 
18 well-trained male cyclists completed three performance trials (PT) consisting of a 120-km 
time-trial with intermittent high-intensity sprints followed by an inclined ride to volitional 
fatigue. Participants were pair-matched following a baseline PT into creatine (20 g∙d-1 for 5 d 
+ 3 g∙d-1 for 9 d) or placebo loaded groups and consumed, in a cross-over allocation, either a 
moderate (6 g∙kg-1 BM∙d-1) or carbohydrate loaded (12 g∙kg-1 BM∙d-1) diet prior to the final 
two PTs. A significant treatment effect was observed with creatine on power output for both 
1-km (P<0.001) and 4-km (P<0.01), with a significant increase above baseline observed with 
creatine in the last 4-km sprint (P<0.05). No change in overall PT performance time was 
observed. Carbohydrate loading elevated intramuscular glycogen stores (P<0.01) with no 
difference between supplement groups. These results demonstrated that creatine loading may 
facilitate higher power outputs during sprints performed within a cycling time-trial. 
  XXII 
 
The effects of creatine and carbohydrate availability on skeletal muscle physiology 
have previously been independently investigated. However, the combined effects of this 
novel co-supplementation strategy on cellular signalling events had not been characterised. 
Study II developed an in vitro cell culture model to identify the metabolic influence of 
creatine, insulin and glucose, either independently or combined, on muscle growth in a 
controlled environment. C2C12 mouse myotubes were differentiated in low (1 g·L
-1
; LG) or 
high (4.5 g·L
-1
; HG) glucose DMEM supplemented with creatine, insulin, or creatine + 
insulin for 2 wk. HG with creatine potentiated the greatest myotube size (P<0.001) while 
creatine + insulin with both LG and HG concentrations increased myosin heavy chain 
(MHC) expression (P<0.001). Differences in MHC correlated with p38 MAPK expression 
but not mTOR, p70S6K or 4E-BP1. These outcomes determined that creatine‘s anabolic role 
in vitro is more dependent on the prevailing insulin than glucose concentration.  
Creatine uptake into muscle is mediated, in part, by insulin. To identify insulin‘s role 
in augmenting intramuscular creatine concentrations within a more acute timeframe, Study 
III compared the effect of insulin to fenugreek, a medicinal herb with a demonstrated 
insulin-mimicking profile, on creatine uptake.  Differentiated L6C11 rat myotubes were 
treated creatine, fenugreek seed extract, or insulin for 24 h. The combination of fenugreek, 
creatine and insulin increased total cellular creatine concentrations by 4 h (P<0.05) with no 
difference in creatine transporter expression observed between groups. This study 
determined that fenugreek alone cannot modulate creatine uptake but when added to creatine 
and insulin treatments, augments total intramuscular creatine levels independent of changes 
in creatine transport.  
Collectively, these studies present novel insights into the interactive effects of 
creatine combined with other anabolic agents in vivo and in vitro. The conclusions arising 
from this research are: 1) in vivo, creatine facilitates the ability to generate greater cycling 
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power output during time-trial cycling; 2) in vitro, creatine treatment results in greater 
myotube size while the addition of insulin results in greater contractile protein expression; 
and 3) in vitro, fenugreek has an additive effect on creatine uptake when co-treated with 
creatine and insulin. These findings may provide a catalyst for further research which delves 
into more integrative clinical applications for this beneficial nutritional supplement. 
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CHAPTER 1: Introduction and Overview  
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  Skeletal muscle plays a vital role in human energy metabolism and as such requires a 
readily available pool of energy-generating substrates to support skeletal muscle 
bioenergetics and maintain cellular homeostasis. A significant change in adenosine 
triphosphate (ATP) concentrations, the body‘s energy currency, affects skeletal muscle‘s 
ability to continue functioning. One compound necessary for the maintenance of skeletal 
muscle ATP levels is the non-essential amino acid creatine. Creatine is transported from the 
bloodstream into muscle tissue via an insulin-sensitive creatine transporter where it is then 
stored as phosphocreatine (PCr). During times of high energy demand and turnover, PCr 
replenishes intramuscular energy pools by donating a phosphate group to resynthesize ATP. 
In order to maintain a sufficient turnover of ATP to meet energy demands, a pool of 
substrates involved in energy regeneration are required to support the various cellular 
processes of skeletal muscle metabolism.  
  In athletic populations, the application of nutritional strategies that increase 
intramuscular pools of energy-generating substrates can help restore ATP concentrations and 
enhance exercise capacity and subsequent performance. The type of substrate utilized for the 
generation of energy is dependent on the duration and intensity of activity.  Athletes 
participating in prolonged endurance activity (> 90 min) benefit from carbohydrate-based 
fuels which increase intramuscular glycogen stores (Hawley et al. 1997), while at the 
opposite end of the training-spectrum, athletes undertaking brief or intermittent bouts (~10 
sec) of high-intensity activity (~95% of maximum heart rate) benefit from creatine 
supplementation which increases the concentration of muscle PCr available for the rapid 
resynthesis of ATP (Juhn and Tarnopolsky 1998a).  
   Creatine uptake into muscle is augmented, in part, by a carbohydrate-induced 
release of insulin from the pancreas. Moreover, insulin, whose metabolic actions also 
influence the uptake of glucose into muscle, has been implicated in decreasing proteolysis 
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and increases DNA replication and protein synthesis by promoting the uptake of circulating 
amino acids (Robergs and Roberts 2000). The ingestion of carbohydrate concomitant with 
creatine supplementation has been further reported to enhance both intramuscular creatine 
and glycogen storage through an increase in cell volume. Changes in cell volume have been 
associated with changes in signalling pathways involved in protein and glycogen synthesis 
(Safdar et al. 2008).  
  A plethora of information on creatine‘s ergogenic ability has been accumulated over 
the last two decades, primarily in vivo and in tandem with resistance exercise. However, the 
metabolic consequences of creatine-mediated increases in cell size when co-supplemented 
with carbohydrates have not been fully characterised. Few studies have looked to investigate 
the interaction of creatine and carbohydrate co-supplementation with regard to 1) benefits of 
creatine-mediated glycogen enhancement on endurance exercise performance, 2) alterations 
in skeletal muscle cell morphology and signalling as a result of hyperosmotic creatine-
induced cell swelling, and 3) the role of insulin and insulin-like compounds mediating cell 
growth in the presence of creatine. The subsequent review of literature will provide 
background on these matters. The topics addressed in the study chapters aimed to fill gaps in 
the present understanding of molecular and performance-based changes associated with the 
manipulation of creatine availability on muscle metabolism. 
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CHAPTER 2: Literature Review 
 
 
This chapter is comprised, in part, of the following commentary which under review in 
Sports Medicine: 
  
The Interactive Roles of Muscle Creatine and Glycogen: New Insights 
 
Tomcik KA, Hawley JA, Burke LM  
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2.1  Introduction 
  Ergogenic aids are techniques or substances used for the purpose of enhancing 
athletic performance. They can be classified as nutritional, pharmacological, physiological or 
psychological in nature and range from validated and legal techniques, such as whey protein 
supplementation, to harmful and illegal practices, such as anabolic steroid use (Thein, Thein, 
and Landry 1995). Athletes commonly utilise a variety of ergogenic aids in an attempt to 
gain a competitive edge over their opponents (Thein, Thein, and Landry 1995). Over the past 
two decades, one of the most commonly utilized, readily available and highly studied sports 
supplements is creatine (Figure 2.1). 
 
 
 
 
 
Figure 2.1: Schematic of the increase in creatine supplementation and sports performance-
related publications over the last 25 years. (Reproduced from PubMed Comma-Separated 
Values (CSV) using keywords ―Creatine Sports Performance‖) 
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  Creatine (N-(aminoiminomethyl)-N-methyl glycine) is a non-essential nitrogenous 
organic acid whose name is derived from the Greek word kreas meaning ―meat/flesh‖ 
(Maughan 2013). First discovered in 1835 by the French chemist Michel Eugene Chevreul, 
creatine is reportedly taken by up to 74% of individuals participating in athletic activities 
(Sobolewski et al. 2011) while amassing over US$400 million in global sales annually 
(Stephens and Greenhaff 2014). Creatine‘s appeal stems from its ability to act as a reservoir 
of energy-generating substrates  for the rapid resynthesis of  the molecular energy molecule 
ATP (Volek et al. 1997).  Skeletal muscle metabolism, especially during times of increased 
demand and turnover, requires a tightly coupled generation of energy from a number of 
substrates in order to maintain ATP stores within a narrow range (Berg, Tymoczko, and 
Stryer 2002). Creatine acts as an intermediary molecule by which ATP can be re-
phosphorylated via the donation of a phosphate group bound to creatine as phosphocreatine 
(PCr) (Greenhaff 1997). To this end, numerous studies have examined creatine‘s capacity for 
metabolic energy regeneration and subsequent role in increasing strength, decreasing fat 
mass, and altering muscle morphology, particularly when combined with resistance training 
(Cooper et al. 2012, Greenhaff 1995, Mujika and Padilla 1997, Feldman 1999, Kreider 
2003).  
Carbohydrates play an interactive role in enhancing creatine‘s ergogenic profile. The 
ingestion of carbohydrates increases blood glucose concentrations stimulating the release of 
insulin, which is able to modulate both glucose and creatine transport into muscle (Odoom, 
Kemp, and Radda 1996). Furthermore, the ingestion of carbohydrates with creatine has been 
shown to enhance intramuscular creatine storage (Steenge et al. 1998, Green, Hultman, et al. 
1996, Odoom, Kemp, and Radda 1996) while also facilitating greater glycogen storage as a 
result of increased water retention and augmented cell volume (Nelson et al. 2001, Robinson 
et al. 1999). Cellular swelling caused by the storage of additional water within the muscle 
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cells has been associated with the upregulation of protein and glycogen synthesis, muscle 
satellite cell proliferation and differentiation and DNA replication and repair (Kreider et al. 
1998, Powers et al. 2003, Ziegenfuss, Lowery, and Lemon 1998, Francaux and Poortmans 
1999, Olsson and Saltin 1970b, Baker and Jeukendrup 2014, Sherman et al. 1982, Juhn and 
Tarnopolsky 1998b, Safdar et al. 2008).   
 This review provides an overview of present knowledge on the interactive and 
metabolic effects of creatine. The practical application of creatine and the suggested 
mechanisms by which it governs activity at a molecular level is the foundation for the work 
presented in the subsequent chapters.  
2.2  Skeletal Muscle Energy Systems 
2.2.1  Generation of ATP 
The sole substrate that skeletal muscle utilizes for contraction is ATP (Stephens and 
Greenhaff 2014). Cleavage of a phosphate group from ATP results in  approximately 43.3 
kilojoules (kJ) of free energy release per mole of ATP broken down (Robergs and Roberts 
2000).  The concentration of ATP maintains a number of physiological process, including 
cell signalling, macromolecule synthesis, cell structure and muscle contraction while also 
protecting tissue from hypoxia-induced damage (Persky and Brazeau 2001). During times of 
energy surplus, either from high carbohydrate and/or fat intake, energy-yielding substrates 
(i.e. glycogen or triglycerides) are stored in various body tissues and mobilised for use 
during times when metabolic energy demands are high (Robergs and Roberts 2000). During 
exercise, ATP is hydrolysed to adenosine diphosphate (ADP) and adenosine monophosphate 
(AMP) (i.e. catabolism). As stores of ATP are limited in skeletal muscle, it must be 
continually resynthesized from its breakdown substrates ADP, AMP and inorganic 
phosphate (Stephens and Greenhaff 2014).  
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The production of ATP in skeletal muscle can occur via one or a combination of 
three different pathways: 1) the aerobic and anaerobic breakdown of glycogen (i.e. 
glycolysis), 2) the use of oxygen within the mitochondria (i.e. oxidative 
phosphorylation/mitochondrial respiration) and/or 3) the transfer of a phosphate group from 
PCr (i.e. phosphagen energy system). The end products of the anaerobic and aerobic 
substrate breakdown include molecules of pyruvate and acetyl coenzyme A (CoA), which 
enter the tricarboxylic acid (TCA) cycle, and/or reduced electron and proton donner 
molecules nicotinamide adenine dinucleotide (NADH) and flavin-adenine-dinucleotide 
(FADH) which facilitate the activity of the electron transport chain (Robergs and Roberts 
2000). This continual turnover allows for ATP production over the course of prolonged 
exercise efforts to continue even when more anaerobic means, such as PCr, become depleted. 
Therefore, the generation of ATP favours the utilization of PCr during times of increased 
energy turnover, such as during high-intensity exercise.  
2.2.2  Phosphagen Energy System 
The most rapid energy-generating pathway for ATP resynthesis is through the 
phosphagen energy system (Persky and Brazeau 2001). Creatine, endogenously synthesized 
or consumed in the diet, enters the bloodstream and is transported into muscle cells via a 
specific solute carrier family creatine transporter protein (SLC6A8).  Creatine and PCr act as 
a spatial energy buffer, shuttling ATP from the inner mitochondria into the cytosol (Meyer, 
Sweeney, and Kushmerick 1984). Once in the muscle cell, 65% of creatine is bound to a 
phosphate group donated by ATP in a reversible reaction catalysed by the enzyme creatine 
kinase (CK) and stored as PCr (Persky and Brazeau 2001). This reaction serves as a temporal 
energy buffer as the formation of PCr keeps creatine in muscle due to the charge that 
prevents partitioning through the creatine transporter (Greenhaff 1997)  (Figure 2.2). 
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Figure 2.2: The phosphagen energy system. Dietary and endogenously synthesized creatine 
enters skeletal muscle via transport through the sodium/chloride regulated SLC6A8 creatine 
transporter. Over 90% of total body creatine is stored in the muscle where ~60% is bound to 
a phosphate group  donated from free adenosine triphosphate (ATP) and stored as potential 
energy in the form of phosphocreatine (PCr); a reaction catalysed by creatine kinase (CK) 
During times of High energy demand, PCr  replenishes the pool of ATP by donating a 
phosphate group to adenosine diphosphate (ADP) (or adenosine monophosphate;  AMP) via 
a reversible reaction catalysed by CK, resulting in the generation of the energy molecule 
ATP. 
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The availability of PCr is a determining factor in maintaining the cellular 
ATP:ADP:AMP ratio (Takahashi et al. 1995). This ratio is physiologically relevant because 
it allows the cell to ―sense‖ the amount of available energy present and control the metabolic 
pathways that consume or produce ATP (Brooks, Fahey, and White 1996). In muscle 
(mainly the type II ―fast twitch‖ fibres), a large pool of PCr is available for the immediate 
regeneration of energy via a reaction catalysed by CK which cleaves the phosphate group 
allowing for the resynthesis of ATP hydrolysed during  short periods of intense work. The 
presence of inorganic phosphate is important in glycogenolysis (i.e. facilitate the cleavage of 
glucose residues from glycogen) under conditions in which skeletal muscle relies more on 
PCr as a means of resynthesizing ATP (Robergs and Roberts 2000). When stores of PCr 
become significantly depleted (from ~9 to 3 mM), skeletal muscles adapt by increasing the 
activity of oxidative enzymes (i.e. citrate synthase, hexokinase, phosphofructokinase) which 
promote aerobic metabolism as a means of generating ATP when anaerobic metabolism is 
lacking (Ren, Semenkovich, and Holloszy 1993, Berg, Tymoczko, and Stryer 2002).  The 
advantage of the phosphagen energy system is that it provides a large amount of ATP 
rapidly. As storage capacity is small, PCr  is depleted usually within ~10 sec of supra-
maximal exercise during short burst (~10 min), high intensity (85-90% maximum heart rate) 
activity (Kraemer and Volek 1999). Approximately 95% of  PCr is resynthesized within 3-4 
min following exhaustive exercise (Harris et al. 1976).  The pools of total body creatine 
stores can also be increased through oral supplementation and further augmented via a 
number of supplementation strategies (Kraemer and Volek 1999). 
2.3 Creatine Physiology  
Nutritional strategies that enhance energy availability in muscle, including increasing 
the size of the substrate pools or the efficiency with which they can restore ATP, may 
enhance subsequent exercise capacity and performance. While all muscle substrates and their 
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energy generating pathways contribute to the energy demands of most exercise tasks, their 
relative importance will vary according to the duration and intensity of the activity. 
Individuals undertaking brief or intermittent high-intensity exercise should therefore target 
strategies to increase their capacity to utilize the phosphagen pathway (Juhn and Tarnopolsky 
1998a). 
2.3.1  Creatine Biosynthesis  
  Approximately 50% of whole body creatine stores are obtained through the diet by 
the consumption of meat and fish (Balsom et al. 1993) or through dietary supplementation 
(Jager et al. 2011) with the remaining 50% being endogenously synthesised from the amino 
acids glycine, arginine and methionine (Kingsley et al. 2009, Schoch, Willoughby, and 
Greenwood 2006). Hence, creatine is sometimes designated as a non-essential amino acid. 
Endogenous synthesis of creatine occurs via two successive reactions in vivo (Walker 1979). 
The first step of creatine biosynthesis involves the reversible transfer of an amide group from 
arginine to glycine to form guanidinoacetate (GAA) via the enzyme arginine:glycine 
amidino-transferase (AGAT).  GAA is transferred via the blood to the liver where the 
irreversible donation of a methyl group from s-adenosyl methionine (SAM) to GAA forms 
creatine via the enzyme guanidinoacetate N-methyl transferase (GAMT) (Fitch 1977, Walker 
1979, Greenhaff 1997). GAA formation via AGAT is the rate-limiting step in the formation 
of creatine (Walker 1979). The localisation of AGAT and GAMT in tissue is a complex 
process, with  kidneys expressing high levels of AGAT activity but low or undetectable 
levels of GAMT, giving credence to the idea that endogenous creatine synthesis is a multi-
organ process (Brosnan and Brosnan 2007). The pancreas, brain and testes also express both 
AGAT and GAMT suggesting that these organs may be able to synthesise or play a 
permissive role in creatine synthesis. However, the majority of the body‘s creatine is 
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synthesised by the renal-hepatic axis (Braissant et al. 2001, Moore 2000, Brosnan and 
Brosnan 2007) (Figure 2.3).  
 
 
 
 
 
 
Figure 2.3:  Creatine biosynthesis. Endogenous creatine synthesis occurs via a 
transamination reaction between the amino acids arginine and glycine in the kidney 
facilitated by the enzyme arginine:glycine amidino-transferase (AGAT) resulting in the 
formation of guanidinoacetate (GAA). GAA is transported through the blood to the liver 
where a methylation reaction occurs with s-adenosyl methionine (SAM) catalysed by the 
enzyme guanidinoacetate N-methyl transferase GAMT, resulting in the formation of creatine 
which enters the bloodstream and is transported to other tissues including skeletal muscle. 
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  In humans, whole body creatine stores (~120 g) degrade at a rate of approximately 2 
g·d
-1
 and, therefore, pools need to be replenished daily either via ingested or resynthesized 
creatine (Hoberman, Sims, and Peters 1948).  Typically, organs that have high levels of the 
enzymes AGAT or GMAT have the lowest level of CK enzyme and thus contain very little 
creatine (Persky and Brazeau 2001, Greenhaff 1997). Coincidentally, tissues that contain the 
largest quantities of stored creatine, such as skeletal and cardiac muscle, have little capacity 
to synthesize their own creatine (Brosnan and Brosnan 2007). Therefore, transport from site 
of synthesis and/or dietary absorption to point of uptake and utilisation must occur 
(discussed in section 2.3.2).  
  Recent research has shown that skeletal muscle may be capable of some creatine 
biosynthesis even in the absence of creatine transport proteins which allow for the passage of 
endogenous creatine from the blood into skeletal muscle. Russell et al. (2014) identified 
detectable (albeit 80% lower) levels of intramuscular creatine in whole body creatine 
transporter knockout (CrT
−/y
)
 
mice. Surprisingly, this was concomitant with significantly 
elevated AGAT protein and mRNA expression and a 1.5 fold increase in biosynthesis of 
creatine in knockout compared to wild type mice (Russell et al. 2014). These findings 
suggest that a proportion of the creatine detected in the knockout mouse model is likely to 
have been synthesised within the muscle. While a small amount of creatine may be produced 
from skeletal muscle biosynthesis via elevated endogenous intramuscular creatine synthesis 
(i.e. some activity of AGAT as well as GAMT) (Van Pilsum et al. 1963, Cullen et al. 2006, 
Russell et al. 2014), its effects may be of little physiological significance. The substantial 
decrease in creatine content observed in this knockout mouse model suggests that  creatine 
uptake by diffusion (i.e. not transporter-mediated) is insufficient to overcome deficits in the 
absence of creatine transport machinery (Russell et al. 2014). This indicates that the creatine 
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transporter protein is important and necessary in maintaining skeletal muscle creatine 
homeostasis.   
2.3.2 Creatine Transport 
Approximately 95% of total body creatine stores are found within skeletal muscle 
(Greenhaff 1997). Endogenously-produced as well as exogenously-consumed creatine is 
shuttled through the bloodstream and transported into skeletal muscle tissue via a sodium-
chloride dependent creatine transporter (Persky, Brazeau, and Hochhaus 2003, Wallimann et 
al. 1992) (mechanism summarised in Figure 2.4). To date, two isoforms of the creatine 
transporter have been identified, both of which are members of solute-carrier family 6 
(SLC6), a group of membrane transporters that facilitate the transport of a number of solutes 
across plasma membranes via the co-transport of sodium and chloride across a chemical 
gradient (Chen, Reith, and Quick 2004, Salomons et al. 2001, ZORZANO, FANDOS, and 
PALACÍN 2000). The SLC6 member 8 (SLC6A8) creatine transporter gene is expressed in 
most tissues, with the highest levels found in skeletal muscle and kidney and lower levels 
expressed in the heart, brain, and testes (Salomons et al. 2001, Nash et al. 1993). A second 
creatine transporter gene, SLC6 member 10 (SLC6A10), is solely expressed in the testes. 
Despite a 97% similarity in coding between SLC6A8 and SLC6A10, (Eichler et al. 1996, 
Iyer et al. 1996), creatine ingested through the diet or endogenous biosynthesis is exclusively 
absorbed into skeletal muscle through the SLC6A8 transporter. As such, all subsequent 
references to creatine transporters will be to SLC6A8, unless otherwise stated.   
The SLC6A8 protein consists of 635 amino acids with 12 membrane-spanning 
domains whose structure is similar to members of the GABA family of neurotransmitters 
(Guimbal and Kilimann 1993, Sora et al. 1994, Nash et al. 1993, Saltarelli et al. 1996) with a 
~97% similarity at the amino acid level in creatine transporter amongst species (Guimbal and 
Kilimann 1993, Nash et al. 1993, Sora et al. 1994). The expression of different transporter 
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isoforms matches closely with the expression of the enzyme creatine kinase, which has been 
found in the kidney, heart, skeletal muscle, brain, testes and colon but not in the liver, 
pancreas or intestine (Persky and Brazeau 2001, Iyer et al. 1996).  
  A number of subsequently described factors regulate creatine transport (Loike, 
Somes, and Silverstein 1986, Willott et al. 1999, Murphy et al. 2001, Loike et al. 1988, 
Harris, Soderlund, and Hultman 1992) but the precise mechanism(s) that regulate flux via the 
creatine transporter are yet to be elucidated. Creatine is co-transported with two sodium and 
one chloride ions, an example of secondary active transport driven by a gradient established 
by Na
+
 + K
+
-ATPase (Dai et al. 1999). Creatine transport and uptake is further enhanced by 
hormones, such as insulin, which promote Na
+
 + K
+
-ATPase activity (Snow and Murphy 
2001). A seminal study by Loike et al. (1988) in L6 myoblasts showed that the nature of 
creatine transporter activity is sodium-dependent and further affected by extracellular 
creatine concentrations (Loike et al. 1988). Later work by Peral et al. (2002) identified 
increased creatine transporter activity and uptake in the presence of higher chloride 
concentrations in the small intestines of humans, rats, and chickens (Peral et al. 2002). In 
skeletal muscle, the content of the creatine transporter has also been shown to be dependent 
on muscle fibre type (Persky and Brazeau 2001) with greater total creatine and PCr 
concentrations observed in ―fast twitch‖ type II muscle in humans (Meyer, Brown, and 
Kushmerick 1985, Casey et al. 1996).  
  Creatine transport is highly substrate specific with the key feature of the carboxyl and 
guanidino groups of creatine separated by no more than 2-3 carbon atoms (Guimbal and 
Kilimann 1993, Christie 2007). As such, neither the breakdown product creatinine nor the 
storage molecule PCr is considered a substrate for creatine transport. However, transport of 
creatine through the creatine transporter can be saturated, suggesting that the amount of 
transporter localised to the cell membrane may limit creatine accumulation. The 
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concentration of intracellular creatine, rather than levels of PCr or extracellular creatine, 
regulates the rate of creatine uptake and creatine transporter expression (Murphy et al. 2001). 
Guerrero-Ontiveros and Wallimann (1998) investigated the effects of prolonged creatine 
supplementation (3-6 months) on creatine transporter expression in rodents. Although the 
dose used could be considered supra-physiological compared to that normally consumed by 
humans, their findings suggest that high doses of creatine ingested over an extended period 
(as practiced by athletes) down-regulates the expression of the creatine transporter due to an 
over-saturation of intracellular creatine (Schoch, Willoughby, and Greenwood 2006, 
Guerrero-Ontiveros and Wallimann 1998). Conversely, human investigations have 
demonstrated that individuals undertaking a 2 month resistance training program with 
concomitant creatine supplementation (0.125 g·kg
-1
·d
-1
) had significantly greater total 
creatine concentrations compared to placebo (142.9 ± 8.0 vs 124.1 ± 7.0 mmol·kg
-1
 dm; P < 
0.05) without reducing creatine transporter protein or mRNA expression (Tarnopolsky et al. 
2003). Whether differences in observations of these two studies was due to differences 
between human vs animal models as well as a comparative assessment of their intervention 
time period however was not expounded upon and warrants future investigation,.  
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Figure 2.4: A schematic summary of creatine metabolism. The reactions required for 
creatine synthesis, uptake, metabolism and excretion with the organ or fluid sites involved 
noted on the right. Solute carrier family 6 member 8 (SLC6A8), creatine transporter; ADP, 
adenosine diphosphate; AGAT, arginine glycine acyl transferase; ATP, adenosine 
triphosphate; CK, creatine kinase; GAMT, guanidinoacetic acid methyl transferase. 
(Reproduced from Clark and Cecil 2015. Pediatric Research) 
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2.3.3 Creatine Supplementation 
Basal muscle creatine concentrations in the adult male is about 120 mmol·kg
-1
 dry 
mass (dm) with an upper limit around 150-160 mmol·kg
-1
 dm (Harris, Soderlund, and 
Hultman 1992, Harris, Hultman, and Nordesjö 1974, Greenhaff 1996, Cooper et al. 2012). In 
healthy individuals, the turnover of creatine in the muscle is approximately 2 g·d
-1 
with 
excess creatine filtered in the kidney by simple diffusion and excreted in urine as creatinine 
(Walker 1979). Obtaining creatine from dietary sources is not essential for maintaining basal 
creatine levels because the body has all the necessary enzymes and substrates required for 
endogenous biosynthesis (Kraemer and Volek 1999). Meat products are a primary dietary 
source of creatine, ranging from trace amounts in prawn (shrimp) to ~5 g·kg
-1
 in pork, beef 
and salmon (Balsom, Söderlund, and Ekblom 1994). The absence of creatine from the diet, 
however, has been shown to augment creatine retention during subsequent creatine 
supplementation (Delanghe et al. 1989). This is especially evident in individuals who do not 
regularly consume meat (i.e. vegetarians). Watt et al. (2004) showed that a 5-d creatine 
supplementation protocol (0.4 g·kg
-1
·d
-1
) resulted in a greater increase in total intramuscular 
creatine content in vegetarians with lower baseline creatine concentrations compared to meat 
eaters (Watt, Garnham, and Snow 2004). Hence, total body creatine concentrations are 
significantly affected by dietary creatine ingestion (Crim, Calloway, and Margen 1976).  
With regard to individuals who respond best to creatine, a review by Cooper et al. (2012) 
states that responders are those individuals with a lower initial level of total muscle creatine 
content and tend to have a greater population of type II fibres, thereby possessing a greater 
potential to improve performance in response to creatine supplementation (Cooper et al. 
2012). 
The most readily available and widely defined form of creatine recommended for 
dietary supplementation is creatine monohydrate which is creatine chemically bound to a 
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molecule of water (Jager et al. 2011).  Harris et al. (1992) first showed that high-dose 
creatine monohydrate supplementation (20-30 g) for 5-d rapidly and significantly increases 
total intramuscular creatine content (Harris, Soderlund, and Hultman 1992). This 
supplementation protocol elicited an average between-subject rise in total intramuscular 
creatine concentration by 25 mmol·kg
-1
 dm or ~10% above basal levels (Harris, Soderlund, 
and Hultman 1992). Furthermore, this protocol identified that 20% of the increased total 
creatine content was stored as PCr which was saturated after only 2-3 d of supplementation 
(Harris, Soderlund, and Hultman 1992). These results suggest that the pre-supplementation 
status of total muscle creatine is an important determining factor for subsequent 
accumulation of creatine (Harris, Soderlund, and Hultman 1992, Greenhaff 1997). Owing to 
the constant rate of turnover,  it has been further suggested that following a period of 
increased creatine supplementation (~20 g·d
-1
), it may take up to 3 wk for intramuscular 
creatine levels to return to baseline levels (Hultman et al. 1996). 
Pioneering work by Hultman et al. (1996) established what is now deemed the 
―classic‖ model of creatine supplementation in humans, commonly known as creatine 
loading (Hultman et al. 1996). In their landmark study, participants were first supplemented 
with a loading dose of 20 g·d
-1 
of creatine for 6 d after which individuals were instructed to 
either cease creatine ingestion or were given a smaller maintenance dose of 2 g·d
-1 
for an 
additional 29 d (Hultman et al. 1996). Those participants who continued consuming the 
reduced dose of creatine maintained elevated intramuscular creatine levels, whereas creatine 
levels returned to baseline in individuals who ceased creatine supplementation (Hultman et 
al. 1996). The maintenance dose of 2-3 g of creatine was chosen because it was a slightly 
higher concentration than the rate at which creatine is turned over (Greenhaff 1997, Hultman 
et al. 1996) (Figure 2.5). Alternatively, a ―slower loading‖ protocol in which the 
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maintenance dose is taken daily has also been shown to elicit a similar enhancement of body 
creatine stores, albeit only after ~4 wk (Hultman et al. 1996). 
 
 
 
 
Figure 2.5: Total muscle creatine stores following creatine loading. This method consists of 
the ingestion of a high initial ―loading‖ dose, traditionally 20 g/d for 3-5 d. Following an 
initial high dose of creatine, failure to continue supplementing (A) eventually brings creatine 
levels back to basal levels (red dotted line). However, (B) supplementing with a smaller 2-3 
g ―maintenance‖ dose is sufficient to maintain elevated levels of intramuscular creatine for a 
prolonged period of time (black dotted line). (Reproduced from Hultman et al. 1996. Journal 
of Applied Physiology)  
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This strategy has become the gold standard for creatine supplementation among 
trained individuals with most studies distributing the 20 g·d
-1 
loading dose into lots of 4-5 g 
to be taken on multiple occasions throughout the day (Greenhaff 1997). Increased creatine 
ingestion has been shown to augment total intramuscular creatine levels toward a maximum 
―threshold‖ level of ~160  mmol·kg-1 dm (Greenhaff 1997). It is, however, important to note 
that 20-30% of individuals do not respond to creatine supplementation. Greenhaff et al. 
(1994) observed a <10 mmol·kg
-1
 dm increase in total muscle creatine accumulation in 
response to a similar (20 g·d
-1
) supplementation regimen (Greenhaff et al. 1994). This 
variability is likely to be attributed to individual differences in the regulation of the creatine 
transporter and suggests that some participants may simply be low-responders to creatine 
supplementation (Schoch, Willoughby, and Greenwood 2006, Greenhaff et al. 1994).  
2.3.4  Creatine and Carbohydrate Co-ingestion 
Green et al. (1996) were the first to show that the co-ingestion of carbohydrate (370 
g·d
-1
 for 5 d from an 18.5% wt·vol
-1
 glucose drink) with creatine (20 g·d
-1
 for 5 d) resulted in 
increased intramuscular creatine uptake, specifically 60% above that of creatine 
supplementation alone (Green, Hultman, et al. 1996) (Figure 2.6). Subsequent studies 
confirmed that the consumption of carbohydrate (~1 g·kg
-1
 BM) simultaneously with 
creatine (20 g) induced an insulin-mediated potentiation of intramuscular creatine which 
could, potentially, overcome the lack of responsiveness to creatine supplementation 
experienced by some individuals (Green, Simpson, et al. 1996, Robinson et al. 1999, Steenge 
et al. 1998). The combination of enhanced muscle PCr stores and resistance training leads to 
a greater increase in lean BM and strength than training alone (Juhn and Tarnopolsky 
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1998a), making the co-ingestion of carbohydrate and creatine a popular protocol for strength 
and power athletes. 
 
 
 
 
 
Figure 2.6: Muscle creatine concentrations following carbohydrate co-supplementation with 
creatine. The co-ingestion of carbohydrates (370 g·d
-1
 for 5 d from an 18.5% wt·vol
-1
 
glucose drink) with creatine (20 g·d
-1
 for 5 d) potentiates a reported insulin-mediated 
increase in creatine transport, maximizing intramuscular creatine stores by approximately 
60%. (Reproduced from Green et al. 1996. The American Journal of Physiology) 
 
 
2.4  Utilisation of Creatine as a Substrate for Exercise 
Increases in cellular stores of creatine can be expected to have independent and 
interactive effects on energy metabolism. Despite the distinction among athletes for either 
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creatine or carbohydrate loading, there is accumulating evidence that the co-supplementation 
of creatine and carbohydrate may have interactive and beneficial effects for both resistance- 
and endurance-based training as well as performance.  
2.4.1  Creatine Utilisation during Exercise 
The exercise-induced decline in creatine, specifically PCr, concentrations has been 
associated with a gradual reduction in performance of high-intensity exercise, particularly 
when undertaken as repeated bouts of exercise with short recovery periods (Kreider 2003). 
Current dietary patterns do not appear to fully maximise creatine stores in the muscle, since 
it is now well known that supplemental creatine intake can increase muscle concentrations 
by an additional ~25% towards the upper limit of creatine storage (150-160 mmol·kg
-1
 dm). 
as previously described(Greenhaff 1997, Hultman et al. 1996, Harris, Soderlund, and 
Hultman 1992, Harris, Hultman, and Nordesjö 1974, Greenhaff 1996, Cooper et al. 2012). 
While elevated intramuscular creatine/PCr concentrations increase fatigue resistance and 
enhance the capacity for repeated bouts of high intensity exercise (Balsom et al. 1995, Volek 
et al. 1997, McNaughton, Dalton, and Tarr 1998), short term creatine supplementation has 
been shown to significantly increase force and power output (Balsom et al. 1995) and 
enhance muscular strength (Casey et al. 1996, Vandenberghe et al. 1997, Volek et al. 1997). 
A meta-analysis by Branch et al. (2003) on 96 studies revealed that creatine‘s most marked 
effects were observed in high intensity exercise bouts shorter than 30 sec with no significant 
effect on exercise lasting longer than 2 min (Branch 2003). Greenhaff et al. (1993) 
determined that 5 d of creatine supplementation (20 g·d
-1
) increased the peak muscle torque 
of repeated isokinetic contractions (Greenhaff et al. 1993).  Furthermore, Volek et al. (1997)  
showed that supplementation of 25 g·d
-1 
of creatine, administered in conjunction with a 
traditional resistance training program over several weeks significantly increased strength in  
squat and bench press maximum exercises (Volek et al. 1997). These findings highlight the 
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benefits of rapid ATP resynthesis  by creatine for use during maximal intensity strength 
exercise (i.e. the rapid replenishment of ATP) (Kraemer and Volek 1999).  
2.4.2  Carbohydrate Utilization in Exercise 
Endurance athletes rely on carbohydrate-based fuels as the main source for muscle 
energetics during prolonged activities. Glycogen is a glucose polymer that provides the main 
form of carbohydrate storage in muscle, liver, and other insulin-sensitive tissues.  The 
branched structure of glycogen provides an efficient energy store within the muscle cell, with 
a large surface area allowing rapid degradation to provide a fuel source while having a small 
impact on cellular osmolarity. Glycogen‘s role as an energy substrate has been well-known 
for more than 150 years, but recent interest has identified glycogen‘s role as a regulator of 
cellular signalling underpinning protein synthesis and training adaptation in the muscle 
(Philp, Hargreaves, and Baar 2012, Hawley et al. 2011). The present understanding of 
glycogen storage has identified specific cellular pools of glycogen in tissue. Two 
metabolically distinct forms of glycogen, pro- and macroglycogen, which vary in their 
sensitivities to glycogen synthesis and degradation, have been identified (Shearer and 
Graham 2002). Additionally, recent studies in both exhaustive (Marchand et al. 2007, 
Nielsen et al. 2011) and non-exhaustive, but maximal, training bouts (Fridén, Seger, and 
Ekblom 1985) showed that muscle glycogen is preferentially depleted (and subsequently 
replenished) from the inter-myofibrillar space when compared to intra-myofibrillar and 
subsarcolemmal glycogen. This decrease in inter-myofibrilar glycogen may be related to an 
impedance of Na
+
, K
+
-ATPase activity affecting sarcoplasmic reticulum calcium release and 
thereby leading to a decrease in overall force production (Ørtenblad, Westerblad, and 
Nielsen 2013).  
Philp et al. (2012) highlight the importance of muscle glycogen not only as a 
substrate which determines exercise capacity but also as a substrate that directs the body‘s 
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response to exercise (i.e. regulating cellular signalling pathways associated with skeletal 
muscle metabolism) (Philp, Hargreaves, and Baar 2012). While trained individuals undergo a 
general increase in muscle glycogen stores with increased dietary carbohydrate intake, 
―super-compensation‖ above normal resting concentrations can be achieved by combining a 
carbohydrate intake of > 8 g·kg
-1
 BM for 24-48 h with an exercise taper (Bergström et al. 
1967).  This strategy, known as ―carbohydrate loading‖ can double muscle glycogen 
concentrations from ~400 mmol·kg
-1
 dry dm to ~800 mmol·kg
-1 
dm (Hawley et al. 1997) and 
is associated with significant improvement in endurance capacity and performance, 
particularly in continuous activities lasting >90 min (Hawley and Leckey 2015, Burke, van 
Loon, and Hawley 2016) (Figure 2.7). Sustained endurance exercise bouts of greater than 90 
min can deplete muscle glycogen stores to levels as low as 100 mmol·kg
-1
 dm (Hawley et al. 
1997). It should be noted that elevated pre-exercise muscle glycogen content results in a 
higher rate of muscle glycogenolysis during exercise, leading to a greater dependence on 
carbohydrate-derived fuel sources for subsequent ATP production(Goforth, Bennett, and 
Law 1997). 
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Figure 2.7: Protocols for carbohydrate loading illustrated by diet and training load prior to 
competition. The ―Classical‖ loading protocol for glycogen supercompensation was 
developed by Bergstrom et al (1967) in untrained active individuals and involved an intake 
of > 8 g·kg
-1
 BM carbohydrate several days before an event concomitant with a reduction in 
activity. (Reproduced from Burke, van Loon and Hawley 2016, Journal of Applied 
Physiology)  
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2.4.3 Combined Creatine and Carbohydrate Utilization in Exercise  
Changes in cellular substrates achieved by common practices in sports nutrition have 
been shown to cause unfavourable changes in BM. Balsom et al. (1993) conducted one of 
the first studies showing that subjects who followed a creatine loading protocol took 
significantly longer to complete a 6 km cross-country run than a placebo supplemented 
cohort (23.79 ± 0.85 vs. 23.36 ± 0.82 min; 1.8% Δ time) which was attributed to a 1.2% 
creatine-mediated increase in BM (74.4 ± 2.3 vs. 73.5 ± 2.3 kg) (Balsom et al. 1993). This 
has led to the current belief that creatine supplementation does not enhance endurance-based 
activities. Like creatine loading strategies, carbohydrate loading is associated with an 
increase in total BM. At a cellular level, ~3 g of water is bound to 1 g of glycogen in muscle 
(McBride, Guest, and Scott 1941). Early work by Olsson et al. (1970) found that glycogen 
was associated with the binding of 3-4 g of water, resulting in a 2.4 kg increase in BM in 
subjects who weighed ~75 kg, of which 2.2 L was attributed to an increase in total body 
water. (Olsson and Saltin 1970a).  Few studies, however, have investigated how changes in 
creatine and carbohydrate loading strategies affect body composition and subsequent 
performance in athlete populations, largely as a result of weight gain.  
The dietary ingestion of creatine (Kreider et al. 1998, Powers et al. 2003, Ziegenfuss, 
Lowery, and Lemon 1998, Francaux and Poortmans 1999) and carbohydrate (Olsson and 
Saltin 1970b, Baker and Jeukendrup 2014, Sherman et al. 1982) increase water retention 
resulting in osmotic swelling and augmented muscle cell volume. An increase in cell size as 
a consequence of creatine and/or carbohydrate-mediated water retention (Hultman et al. 
1996, Kreider et al. 1998) facilitates greater glycogen storage in muscle than has been 
reported previously by creatine and/or carbohydrate loading alone (Nelson et al. 2001, van 
Loon et al. 2004, Odoom, Kemp, and Radda 1996). Osmotic swelling in rat skeletal 
myotubes promotes glycogen synthesis (Low, Rennie, and Taylor 1996) and storage 
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(Robinson et al. 1999, Nelson et al. 2001, van Loon et al. 2004) independent of changes in 
glucose uptake (Low, Rennie, and Taylor 1996). Robinson et al. (1999) investigated the 
effects of 5 d of creatine (15 g) and carbohydrate (18.5% wt·vol-1 glucose drink) 
supplementation during recovery following one-legged submaximal cycling to exhaustion 
and observed increased glycogen storage in exercised muscle compared to carbohydrate 
supplementation alone (Robinson et al. 1999). Nelson et al. (2000) further reported that 
subjects who consumed a high carbohydrate diet following a traditional creatine 
supplementation strategy (20 g·d
-1
 for 5 d) had a 53% increase in muscle glycogen content 
over high carbohydrate consumption alone (Nelson et al. 2001). These findings were 
corroborated by van Loon et al. (2004) who demonstrated that 7 wk of prolonged creatine 
supplementation (20 g·d
-1
 for 5 d followed by 6 weeks of 2 g·d
-1
) resulted in an 18% increase 
in muscle glycogen content (van Loon et al. 2004) (Figure 2.8).  
While there is robust evidence of the enhanced glycogen storage capacity of the 
creatine-loaded muscle (van Loon et al. 2004, Nelson et al. 2001, Robinson et al. 1999), 
current studies have failed to systematically examine the effects of this co-supplementation 
strategy on endurance exercise capacity. The role of creatine for enhancing endurance 
performance is equivocal. However, there is some evidence showing that creatine 
supplementation may be of benefit in endurance events because of its effect on high-intensity 
efforts that occur during prolonged sports.  It should be noted that these only make up a 
small proportion of the overall workload but often determine the outcome of events (i.e. 
breaking away from the peloton in cycling or sprint finishes during a marathon) (Jeukendrup, 
Craig, and Hawley 2000).  
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Figure 2.8: Muscle glycogen content after 6 weeks of creatine supplementation. Muscle 
biopsies from 20 male subjects with no prior history of exercise training were taken before 
and after 5 d of creatine loading (20 g·d
−1
) and after 6 wk of continued supplementation (2 
g·d
−1
). Data were normalized to pre-supplementation values. ∗ represents significant 
difference compared with values observed at day 0 within group; ∧ represents significant 
difference compared with values observed at day 43 within groups; # represents significant 
difference between groups at day 6 (P < 0.05). (Reproduced from van Loon et al. 2004. 
Clinical Science) 
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Vandebuerie et al. (1998) reported that subjects who consumed creatine (25 g  for 5 
d) followed by carbohydrate ingestion (60 g·h
-1
) exhibited an 8-9% increase in power output 
during a set of sprint efforts (5 x 10 s with 2 min recovery) which followed a 2.5 h time trial 
cycling simulation (Vandebuerie et al. 1998). Oliver et al. (2013) reported that 6 d of 
creatine supplementation (20 g·d
-1
) and glucose (60 g·d
-1
) resulted in significantly reduced 
lactate concentrations during exercise, with a trend toward increased maximum power output 
and total time to fatigue (Oliver et al. 2013). With regards to its application to endurance 
exercise, Tang et al. (2013) examined the metabolic changes associated with creatine 
supplementation (12 g·d
-1 
 for 15 d) on a 60 min running protocol (65-70% maximum heart 
rate) followed by a 100 m sprint (Tang, Chan, and Kuo 2013) . They showed that the 
creatine-supplemented cohort displayed lower plasma lactate levels, suggestive of decreased 
muscle glycogen breakdown, as well as lower plasma purine metabolites, glutamine, urinary 
3-methylhistidine, and urea nitrogen, indicative of decreased muscle protein degradation, 
following the 60 min bout of endurance exercise (Tang, Chan, and Kuo 2013). Other studies 
have also reported that creatine can attenuate protein breakdown during endurance exercise 
(Roschel et al. 2010, Gualano et al. 2008, Robinson et al. 1999). These findings (summarised 
in Table 2.1) provide evidence that enhanced creatine availability in the muscle may spare 
glycogen and reliance on anaerobic glycolysis. Further studies need to be conducted to 
determine whether this effect persists with regard to prolonged exercise conducted at 
intensities around the so-called lactate threshold (the intensity at which lactate production 
exceeds lactate clearance).  
Creatine supplementation has been shown to lower muscle and blood lactate 
concentrations in individuals following high intensity (80-90% maximum heart rate) 
exercise, suggesting an alteration in the contribution of the non-oxidative pathways to the 
muscle‘s energy needs (Balsom et al. 1995). Balsom et al. (1995) reported that creatine 
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supplementation (20 g·d
-1 
for 6 d) increased total muscle creatine stores and lowered muscle 
lactate levels (26.2 ± 5.5 vs. 44.3 ± 9.9 mmol·kg
-1
 dm) following repeated bouts of fixed 
rate, high intensity cycling (Balsom et al. 1995). Additionally, total work and lactate 
threshold levels were improved following intravenous PCr injection 24 h and 30 min prior to 
incremental cycling bouts (Vorobiev et al. 1996).  
Lower lactate levels with pre-exercise creatine supplementation have also been 
observed during recovery from high-intensity exercise, suggesting, but not proving, that 
carbohydrate utilization and glycogen degradation is decreased after endurance exercise with 
creatine supplementation (Tang, Chan, and Kuo 2013). As such, it has been suggested that 
creatine may have a positive effect on short term anaerobic efforts within prolonged bouts of 
endurance exercise, as seen in subsequent studies with increased power during bouts of 
cycling (Balsom et al. 1995, Balsom et al. 1993, Birch, Noble, and Greenhaff 1994, Casey et 
al. 1996) and running (Harris et al. 1993, Bosco et al. 1997, Earnest, Almada, and Mitchell 
1997). It could be hypothesized that exercise capacity might be improved in events where 
glycogen availability is limiting, and can be further enhanced via creatine supplementation. 
Such findings would have practical significance for several scenarios in sports nutrition 
where greater glycogen availability is an important consideration for optimal performance. 
These include: 1) the optimization of glycogen storage capacity in individuals who are 
unable to obtain enough carbohydrate to maximize glycogen storage (e.g. athletes with low 
energy availability and sub-optimal intakes of carbohydrate due to physique management 
strategies (Mountjoy et al. 2014), or athletes with inadequate recovery time between 
glycogen-dependent events),  2) the further enhancement of glycogen super-compensation 
for prolonged events where glycogen depletion is likely, and/or 3) the reversal of the 
apparent inhibition on repeated attempts to carbohydrate load in a restricted time (i.e. 1 wk) 
(McInerney et al. 2005). Interestingly, a study by Sewell et al. (2008) demonstrated that 
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supplementation of a normal diet with additional carbohydrate (18.5% wt·vol
-1 
glucose drink 
for 3 d prior to exercise) in addition to creatine supplementation, has no effect on muscle 
glycogen concentrations (Sewell, Robinson, and Greenhaff 2008). The authors suggested 
that creatine supplementation alone is insufficient to influence muscle glycogen synthesis 
and that a major factor underpinning creatine‘s role in increasing muscle glycogen is 
glycogen-depletion via exercise undertaken prior to creatine supplementation (Sewell, 
Robinson, and Greenhaff 2008). Further studies examining creatine‘s application in 
glycogen-limiting scenarios (i.e. endurance exercise) are therefore required.  
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Table 2.1:  The effect of creatine supplementation on intramuscular glycogen storage 
Study Subjects Exercise Creatine Carbohydrate Effect 
 
Robinson et al., 1999 
 
14 healthy male (~23 y) 
 
One-legged cycling bought (70 
RPM) to exhaustion 
 
20 g·d-1 Cr for 5 d 
 
High carb diet 
(80% of daily 
energy intake) 
 
Glycogen was increased above non-exercised concentrations 
in the exercised limb to a greater degree in the CHO + Cr 
group (p = 0.06) over CHO alone 
 
Nelson et al., 2001 12 physically active but not 
structurally trained males  (19-
28 y) 
Glycogen  depleting one 
legged exercise 
5 d of  20 g·d-1 before and after 
a high CHO diet period 
High carb diet 
(80% of daily 
energy intake) 
 
Post creatine load total glycogen content was significantly 
(P> 0.05) greater than pre-creatine load 
Op’t Eijnde et al., 2001 13 males and 9 females (20-23 
y) 
4x 12 unilateral knee-
extensions at 60% max torque 
3x a week for 10 weeks 
20 g·d-1  for 2 wk of 
immobilization, 15 g·d-1 for 
first 3 weeks of rehab, 5 g·d-1 
for following 7 wk 
 
N/A Muscle glycogen levels were higher in the creatine group 
after 3 weeks of rehab (P<0.05) but not after 10 weeks. 
Derave et al., 2003 26 male and 7 female  6 weeks of resistance training 
following 2 weeks of leg 
immobilization 
15  g·d-1 during 
immobilization, 2.5  g·d-1 
during training 
N/A Increased muscle glycogen content and GLUT4 protein 
Van Loon et al., 2004 20  fit, non-vegetarian  males 
with no regular training (~20 
y) 
 
N/A 20 g·d-1 for 5 d (initial 
loading), 2  g·d-1 Cr for 37 d 
(maintenance) 
15g glucose + 10 g 
maltodextrin 
Creatine loading significantly increased (P< 0.05) muscle 
glycogen content, creatine maintenance dose did not maintain 
elevated glycogen levels 
Sewell et al., 2007 6 healthy males with regular 
exercise of 1+ hr at least 3 
d/wk (~26 y) 
Ergometer set against 70% 
VO2 peak until cadence could 
not be maintained 
 
20 g·d-1 Cr for 5 d prior to 
exercise trail 
4-500ml servings 
of a 18.5% glucose 
drink 
Creatine supplementation alone under controlled conditions 
and habitual diet had no effect on muscle glycogen content. 
Safdar et al., 2007 12 healthy, non-smoking, non-
obese males with reported 
exercise <2x a week (~26 y) 
N/A 20 g·d-1 Cr for 3 d (loading); 5  
g·d-1 Cr for 7 d (maintenance) 
 
N/A (Placebo had 
75g dextrose) 
Cr supplementation significantly upregulated (P<0.05)the 
mRNA content of genes and proteins content of genes and 
protein content of kinases involved protein and glycogen 
synthesis regulation 
 
Tang et al., 2014 12 males on a university track 
and field team (~20 y) 
60 minute running exercise 
and a 100 M sprint running 
exercise 
12 g·d-1 Cr for 15 d N/A Creatine supplementation tended to decrease muscle glycogen 
and protein degradation, especially after endurance exercise 
 
Roberts et al. , 2016 14 recreationally active males Cycling to fatigue @ 70% 
VO2peak 
20 g·d-1 Cr  37.5 kcal·kg-1·d-1, 
>80% calories 
CHO 
Augmented post-exercise muscle glycogen content (P<0.05); 
greatest difference during initial 24 h 
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2.4.4  Insulin Mediation of Creatine Transport  
Insulin plays a vital metabolic role in increasing free fatty acid, amino acid and 
glucose uptake (Robergs and Roberts 2000). Glucose uptake has been extensively 
characterised by the insulin-stimulated translocation of glucose transporter 4 (GLUT4) to the 
cell membrane, thereby facilitating glucose transport from the bloodstream into muscle 
(Richter and Hargreaves 2013, Leto and Saltiel 2012, Oldham and Hafen 2003, Mora et al. 
2004, Zierath 2002) (Figure 2.9).  Furthermore, insulin, amongst a number of factors 
previously described (section 2.3.2), regulates creatine transport into skeletal muscle via the 
insulin-sensitive creatine transporter. Odoom and colleagues (1996) observed a two fold 
increase in intracellular creatine content after 48 h of insulin treatment in cultured G8 
myotubes (Odoom, Kemp, and Radda 1996). This finding was confirmed by the in vivo work 
of Steenge et al. (1998) who found increased creatine uptake in subjects infused with varying 
rates of insulin concomitant with creatine consumption (Steenge et al. 1998). Subsequent 
studies have showed that insulin secretion in response to carbohydrate ingestion facilitates 
sodium-dependent creatine transport by increasing muscle Na
+
/K
+
 pump activity (Steenge et 
al. 1998, Loike, Somes, and Silverstein 1986, Odoom, Kemp, and Radda 1996), which 
results in  increased total muscle creatine content (Koszalka and Andrew 1972, Haugland 
and Chang 1975, Green, Hultman, et al. 1996, Steenge, Simpson, and Greenhaff 2000, 
Steenge et al. 1998). In addition to the protein synthetic response elicited by creatine, the 
anabolic action of insulin in vitro has been shown to have mitogenic effects on stimulating 
muscle protein synthesis (subsequently discussed in section 1.6) (Reeds and Palmer 1983, 
Florini et al. 1986, Palmer et al. 1997).  
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Figure 2.9:  Schematic of insulin activity in vivo. Insulin signal transduction though the 
insulin receptor, insulin receptor substrate (IRS)-1/2 and phosphatidylinositol 3-kinase (PI3-
kinase) is enhanced in skeletal muscle following ingestion of carbohydrates in non-diabetic 
individuals as well as in the hours after an exercise bout. These changes may enhance insulin 
sensitivity and promote glucose uptake via GLUT4, affect the uptake of creatine via the 
SLC6A8 creatine transporter and regulate the expression of several downstream signalling 
targets involved in protein synthesis and/or mitochondrial biogenesis. (Reproduced from 
Zierath 2002. Journal of Applied Physiology) 
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Given that increased creatine transport into skeletal muscle can be enhanced via an 
insulin-stimulated mechanism, it is possible that compounds which mimic insulin‘s effects 
may also be able to modulate substrate uptake. Several natural (Patel et al. 2012, Zaid 2013) 
and chemically-derived (Sakurai et al. 1998, Stapleton 2000, Orvig et al. 1995) products 
have been evaluated for their insulinotropic properties. For example, Trigonella foenum-
graecum (commonly known as fenugreek), an herb widely used across the Indian 
subcontinent, has been used in alternative medicine practice as a therapeutic agent to control 
glucose levels in diabetics (Srinivasan 2006, Jaiswal et al. 2012, Vijayakumar et al. 2005, 
Sauvaire et al. 1998). Fenugreek, like insulin, has been found to stimulates glucose uptake by 
enhancing translocation of GLUT4 to the plasma membrane in rodent/rat skeletal muscle 
cells (Jaiswal et al. 2012). 
A comprehensive examination of creatine‘s interactive role with insulin-mimicking 
compounds is presently lacking. Only one study to date had reported an ergogenic interaction 
between fenugreek and creatine. Taylor et al. (2011) found that, in a resistance trained 
population,  supplementation with 3.5 g of creatine and 900 mg of fenugreek over 8 wk of  
periodised resistance training (4 d·wk
-1
) resulted in significant increases in 1 repetition 
maximum (RM) strength along with an increasing lean BM (Taylor et al. 2011). These 
results were deemed to be as effective as supplementation with creatine and dextrose (70 g·d
-
1
) with regard to the improvements observed in upper (+9% dextrose; +6% fenugreek) and 
lower body (+19% dextrose; +17% fenugreek) strength. However, the authors reported only 
minimal differences between creatine-fenugreek and control creatine-carbohydrate 
supplemented cohorts with respect to strength and provided no direct measures of creatine 
content either via muscle biopsies or magnetic resonance spectroscopy. Thus, it is unclear to 
what degree fenugreek supplementation actually affected their main outcome variable (i.e. 
muscular strength) or by what mechanism creatine transport and uptake were promoted (if 
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any). Nevertheless, this study demonstrated a potential role for fenugreek in the 
augmentation of intramuscular creatine concentration, which may occur via a mechanism 
similar to previously reported insulin-induced modulations of the creatine transport system 
(Steenge et al. 1998).  
2.5  Creatine’s Role in Muscle Tissue Growth and Regeneration  
A number of pathways involved in the regulation of glucose uptake, glycogen 
synthesis, and creatine transport have also been implicated in promoting cell growth and 
differentiation, muscle proteolysis, and regulation of hypertrophy (Glass 2003, Heszele and 
Price 2004, Sartorelli and Fulco 2004, Taniguchi, Emanuelli, and Kahn 2006). Before 
characterising the specifics of substrate-mediation of these mechanisms, a context for 
skeletal muscle myogenesis and hypertrophy (i.e. increase in myofibre size) will be 
provided. 
2.5.1 Myogenesis 
New skeletal muscle formation is a complex and highly regulated process that 
involves the proliferation of myoblasts and subsequent differentiation to multinucleated 
myotubes (Grabiec et al. 2014). Satellite cells, the progenitors for skeletal myotube 
formation,  are the primary contributors to muscle growth via the provision of myonuclei for 
the production of new or repair of existing muscle (Wang and Rudnicki 2012). Post-natal 
muscle growth occurs via myofibrillar hypertrophy. Concurrent with increasing myofibril 
size, muscle cells also increase in nuclei number (Dangott, Schultz, and Mozdziak 2000, 
Olsen et al. 2006, Vierck et al. 2003). Given that post-embryonic muscle cells cannot 
undergo mitosis, new growth and development of skeletal muscle involves the emergence of 
satellite cells from a quiescent state into the cell cycle as active myoblasts where they either 
leave the cell cycle to the quiescent pool or to enter the differentiation pathway to become 
myotubes (Dumont, Wang, and Rudnicki 2015). Satellite cells, located between the 
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sarcolemma and the basal lamina surrounding muscle fibres become activated (i.e. following 
muscle injury or sheer stress from exercise) (Macpherson, Dennis, and Faulkner 1997, 
McCully and Faulkner 1985) and proliferate to provide additional myonuclei for the repair 
maintenance of the muscle milieu (Mauro 1961, Sestili et al. 2009, Olsen et al. 2006). During 
regeneration, the normally inactive satellite cells proliferate until molecular signalling brings 
mitotic activity to an end wherein differentiation and specialization to muscle precursor cells 
is initiated and promoted to the site of regeneration (Charge and Rudnicki 2004). The fusion 
of satellite cells to form myotubes is a morphological endpoint in the satellite cell‘s 
involvement in muscle hypertrophy (Vierck et al. 2003).  
Various transcription factors along with a network of myogenic regulatory factors 
(MRFs) drive the progression of satellite cells toward the formation of new muscle (Collins 
et al. 2009). Paired-box transcription factor Pax7 plays important roles in developmental and 
regenerative myogenesis (Collins et al. 2009). Pax7 is specifically expressed in quiescent and 
newly activated satellite cell populations throughout adulthood (Seale et al. 2000, Kuang et 
al. 2006). Furthermore, it has been shown that constitutive expression of Pax7 by satellite 
cells increases the rate of proliferation (Collins et al. 2009). In muscle progenitor cells, Pax7 
also function to maintain the timely expression of MRFs and promote population expansion 
(Dangott, Schultz, and Mozdziak 2000) (Figure 2.10). 
MRFs are the primary regulators of satellite cell activation (Sestili et al. 2009, Louis 
et al. 2004). Moygenic differentiation factor (MyoD), myogenic factor 5 (Myf-5) and 
myogenin are among the most well-characterized MRFs responsible for governing the 
initiation of satellite cell proliferation and differentiation (Zammit et al. 2006, Zammit et al. 
2004). These factors are members of family of basic helix-loop-helix proteins that act as 
transcriptional activators due to their properties as DNA-binding proteins (Burattini et al. 
2009). DNA binding initiates transcription to regulate the expression  level of muscle-
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specific genes, myosin heavy and light chains, α-actin, and creatine kinase (Lowe, Lund, and 
Alway 1998). Activation of satellite cells in muscle which enter the cell cycle involves the 
rapid upregulation of MyoD just before proliferation begins which carries on through the 
differentiation phase while Myf-5 expression is a marker indicating satellite cell self-renewal 
(promotion of proliferation)(Kitzmann et al. 1998). Myogenein upregulation occurs as a 
marker of terminal satellite cell differentiation (Wang and Rudnicki 2012, Collins et al. 
2005) (Figure 2.10). 
In humans, the regulation of muscle hypertrophy and myogenesis via the activation 
of progenitor satellite cells is subject to the availability of nutrients, such as carbohydrates 
and amino acids, and hormones, such as insulin (Grabiec et al. 2014). Furthermore, 
molecular adaptations to exercise training are specific to the type of activity performed- with 
resistance exercise stimulating myofibrillar protein synthesis and hypertrophy (Fry 2004, 
Hawley 2009) while endurance training stimulates mitochondrial protein synthesis and 
aerobic metabolic adaptations (i.e. reduced rates of glycogen utilisation, increased fat 
oxidation, and lowered lactate production) (Hawley 2009, Holloszy and Coyle 1984). 
Therefore, an understanding of the effect nutrient availability on the signalling pathways is 
important to elucidate the role creatine plays in promoting adaptation that underpins 
improved exercise capacity/performance.  
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Figure 2.10: The activation and differentiation of skeletal muscle satellite cells. Satellite cells remain in a quiescent state in the sarcolemma of existing 
myofibrils. Mechanical damage (i.e. from resistance exercise) perturbs muscle fibres and signals the activation of satellite cells into a specialized 
lineage of myogenic cells and can fuse to existing fibres to repair muscle damage or fuse together to form new muscle fibre. Pax7 (stained red, image 
1) is a transcription factor which regulates myogenesis via promotion of satellite cells from quiescence to early-stage proliferation. MyoD (stained 
green, image 2), an early marker of myogenic commitment to skeletal myoblast lineage, is expressed in the nuclei of activated satellite cells/myoblasts 
in response to muscle damage or exercise stimuli. Desmin (stained green, image 3) is a muscle-specific intermediate filament present in the lamina 
around mature muscle myotubes which is an early protein marker of muscle tissue that increases in expression as cells near terminal differentiation.  
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2.5.2  Effects of Exercise on Muscle Repair  
Training-induced activation of satellite cells is essential for post-natal skeletal muscle 
hypertrophy. While satellite cells are essential for muscle regeneration, several studies 
contend that they are not necessary for post-natal muscle hypertrophy, particularly in animal 
models. Work by McCarthy and colleagues (2011) demonstrated that Pax7-DTA mice 
(conditional ablation of greater than 90% of satellite cells in mature skeletal muscle) which 
were subjected to 2 wk of mechanical overload showed the same increase in muscle mass 
(~2 fold) and fibre cross sectional area as those observed in a vehicle –treated group with the 
commonly observed increase in myonuclei with hypertrophy being absent in satellite cell-
depleted muscle fibres (McCarthy et al. 2011).  This suggests that skeletal muscle fibres are 
capable of mounting a robust hypertrophic response to mechanical overload that is not 
necessarily dependent on satellite cells per se.  Fry and associates (2014) later established 
that, in this same mouse model, 8 wk of overload resulted in an accumulation of extracellular 
matrix and fibroblast expansion that resulting in reduced specific force of the plantaris 
muscle (Fry, Lee, et al. 2014). Furthermore, there was an attenuation of hypertrophy 
measured by both muscle wet weight and fibre cross-sectional area in satellite cell-depleted 
muscle (Fry, Lee, et al. 2014). In vivo work by Fry (2014) following 12 weeks of aerobic 
training performed on a cycle ergometer by sedentary adults resulted increase in satellite cell 
content, specifically in myosin heavy chain type I fibres with no change in satellite cell 
numbers in type II  (Fry, Noehren, et al. 2014). These data therefore provide evidence for a 
fibre type-specific role for satellite cells in muscle adaptations following aerobic training. 
 Most commonly, resistance-based exercise increases the number of satellite cells and 
their fusion to myofibre, hence increasing myonuclei in muscle (Olsen et al. 2006, Kadi and 
Thornell 2000, Roth et al. 2001). It is currently accepted that a contraction stimulus is 
involved in all stages of muscle hypertrophy. Exercise induces satellite cell activation 
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(thereby maintaining an intramuscular pool following proliferation) promotes withdrawal 
from the cell cycle back to quiescence or towards differentiation, and allows formation of 
new myofibres via the donation of myonuclei (Kadi et al. 2005). As myonuclei in mature 
myofibres are unable to undergo further cell division, growth occurs via the addition of 
myonuclei added to a fibre by satellite cells.  Each myonuclei in adult muscle fibres controls 
the production of mRNA and protein synthesis over a limited amount of cytoplasm (i.e. the 
myonuclear domain). In order for the mRNA abundance to increase, each myonuclei needs 
to increase the rate of transcription for a given gene or be incorporated into the parent fibre 
thereby providing additional myonuclei (Kadi et al. 2005). Crameri et al. (2004) 
demonstrated that the pool of satellite cells in muscle can be increased in as little as 4 d 
following an acute bout of intense resistance-based exercise (50 one-leg ‗drop down‘ jumps, 
8x10 maximal eccentric knee extensions and 8x10 maximal eccentric knee extensions; 30 
sec rest between sets and 5 min rest between each exercise) (Crameri et al. 2004).  
Furthermore, this increase in satellite cell number was maintained with continual training (8 
d), while a cessation of training gradually reduced the pool.  
Resistance-based exercise, owing partly to the breakdown and repair of muscle 
fibres, is the primary modality which promotes satellite cell activation. A single bout of 
resistance-based contractile activity can result in increased MyoD and myogenin mRNA in 
both human and rodent skeletal muscle (Adams, Haddad, and Baldwin 1999, Haddad and 
Adams 2002, Yang et al. 2005).  Roth et al. (2001) reported a 36% increase in the total 
number of satellite cells compared to undamaged muscle in individuals following a single 
bout of resistance exercise (Roth et al. 2001). Furthermore, Kosek et al. (2006) identified 
that sustained resistance training  (3 d·wk
-1
 for 16 wk) induced an elevated MyoD and 
myogenin response equal to that seen after a single acute bout of resistance exercise, 
implicating MRFs in actively promoting hypertrophy following strength training exercise 
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(Kosek et al. 2006).  
The fusion of daughter cells arising from proliferating satellite cells to generate new 
myotubes has also been observed following endurance exercise, although to a lesser extent. 
Work by Kadi et al. (1999) has identified increased myosin heavy chain expression in about 
half of a cohort of young women undertaking endurance exercise (Kadi and Thornell 2000). 
While endurance activities like cycling and swimming are unlikely to induce substantial 
satellite cell activation (due to a lack of contractile-induced muscle perturbation), MyoD and 
myogenin‘s response to endurance exercise has been hypothesized to regulate pathway(s) 
which involves mitochondrial enzyme and/or transformations of muscle fibre type (Kadi et 
al. 2004, Siu et al. 2004, Vissing et al. 2005).  
2.5.3  Cellular Signalling Associated with Muscle Repair 
Hypertrophy is regulated by phosphorylation events which determine the rate of 
protein synthesis (Farrell et al. 2000, Richter and Sonenberg 2005). Translation initiation is 
an important step in the regulation of hypertrophy, particularly in response to external stimuli 
such as exercise or nutrient availability, and is generally considered a rate limiting step in 
protein synthesis (Richter and Sonenberg 2005). Generally, the initiation of protein synthesis 
is regulated via the phosphorylation of eukaryotic initiation factors (eIF) which mediate the 
binding of the 40S ribosomal subunit to mRNA- an event which is further mediated by the 
interaction of a number of eIFS and ribosomal S6 protein, the distal components of insulin-
like growth factor -1 (IGF-1) and mitogen-activated protein kinase signalling cascades. The 
promotion of hypertrophy through translation initiation via insulin/IGF-1 binding and 
subsequent downstream signalling resulting in functional contractile protein, has been 
thoroughly reviewed (Coffey and Hawley 2007). Downstream targeting of 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K) by IGF-1 promotes the activation of 
protein kinase B (also known as AKT), which not only plays a role in insulin signalling 
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(Mora et al. 2004) but is also responsible for the activation of a number of key signalling 
intermediates of the protein synthetic pathway including mechanistic target of rapamycin 
(mTOR) and p70 S6 kinase (p70S6K) (Baar and Esser 1999) which are critical for promoting 
hypertrophy in skeletal muscle (Figure 2.11).  
 
Protein Kinase B/AKT 
AKT represents the ―crossroads‖ in insulin/IGF signalling wherein it is not only 
responsible for the regulation of GLUT4 translocation to the cell membrane but also for the 
maintenance of skeletal muscle cell size. Three isoforms of AKT exist, two of which are 
specifically expressed in skeletal muscle (AKT1 and AKT2) (Sumitani et al. 2002, Nader 
2005). AKT1 has been associated with muscle hypertrophy whereas AKT2 has been 
associated with glucose transport (Taniguchi, Emanuelli, and Kahn 2006).  For full 
activation, AKT which is co-localized to the cell membrane, is phosphorylated and 
subsequently activated by phosphorylation of the threonine 308 residue in the activation loop 
of pyruvate dehyodrogenase kinase 1 (PDK1) and the serine 473 residue  in the hydrophobic 
motif by mechanistic target of rapamycin complex 2 (mTORC2). The former is mostly 
association with insulin stimulation (Kim et al. 1999, Vincent et al. 2011, McManus et al. 
2004, Sarbassov et al. 2005).  
  47 
 
 
 
Figure 2.11: Schematic of intermediates involved in hypertrophy signalling. Combined 
resistance exercise and/or stimulation by nutritional/hormonal factors optimize protein 
translation initiation via the mammalian target of rapamycin complex 1 (mTORC1) by 
potentially enhancing the activity of its direct regulators phosphatidic acid (PA) and Ras 
homologue enriched in brain (Rheb) that are modulated upstream by diacylglycerol kinase δ 
(DGKδ) and tuberous sclerosis complex catalytic subunit 2 (TSC2), respectively. The 
mTORC1 kinase promotes protein synthesis by phosphorylating its substrates eIF4E binding 
protein 1 (4E-BP1) and p70 rpS6 kinase (p70S6K). (Adapted from Smiles, Hawley and 
Camera 2016. Journal of Experimental Biology) 
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The putative mechanism of AKT regulation of insulin-mediated glucose uptake is 
characterized by the binding and subsequent localization of the PI3-K subunit to the plasma 
membrane (Oldham and Hafen 2003). Phosphorylation of PI3-K causes the PDK1-driven 
recruitment of AKT to the plasma membrane for its subsequent activation (Mora et al. 2004). 
Insulin signalling can also proceed via activation of a divergent pathway involving the 
intermediate protein kinase C (PKC) (Vijayakumar et al. 2005).  AKT directs activation of 
distal regulator, AS160 (GTP-ase activating protein), promoting insulin induced GLUT4 
translocation to the cell membrane facilitating glucose transport (Richter and Hargreaves 
2013, Leto and Saltiel 2012). In addition to regulating glucose uptake, AKT also regulates 
the process of glycogen synthesis via the phosphorylation and inhibition of glycogen 
synthase kinase 3 (GSK-3) which activates glycogen synthesis (Graham et al. 2010).  
The phosphorylation and activation of AKT prevents the upregulation of pathways 
controlling muscle protein breakdown. Instead, AKT functions to activate downstream target 
mTOR for the promotion of protein synthesis via the activation of translation initiation and 
increased ribosomal protein content (Bodine et al. 2001, Nader 2005). Furthermore, AKT has 
been implicated in the regulation of the 5' AMP-activated protein kinase (AMPK), a ―master 
switch‖ implicated in several metabolic systems including the cellular uptake of glucose, 
the β-oxidation of fatty acids and the biogenesis of mitochondria. (Rommel et al. 2001). 
AMPK phosphorylates tuberous sclerosis complex 2 (TSC2) and GSK3β, with the former 
inhibiting the action of mTOR and the latter preventing the activation of eIF-2B (Hahn-
Windgassen et al. 2005, Garami et al. 2003, Vyas et al. 2002). As such, AKT plays a role in 
enhancing translation initiation and protein synthesis through an inhibition of AMPK-
mediated targets in addition to regulating the hypertrophic action of mTOR. 
mTOR 
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AKT has the ability to phosphorylate downstream signalling kinase mTOR, which 
plays a key role in regulating translation of muscle protein synthesis. Two mTOR complexes 
exists wherein mTOR binds with a G-β-L protein and either rapamycin-sensitive (raptor, 
forming mTORC1) or rapamycin-insensitive (rictor, forming mTORC2) companion of 
mTOR protein. mTORC1 has been shown to be a positive regulator of cell growth and 
development whereas mTORC2 has been implicated in AKT activation and actin 
cytoskeleton regulation (Wang et al. 2005, Sarbassov et al. 2004, Park et al. 2005, Bodine et 
al. 2001).   
Like AKT, mTOR is activated by a wide range of stimuli, both mechanical and 
metabolic (Miniaci et al. 2015). Amino acids play a role in the upregulation of mTOR, both 
in vivo and in vitro (Areta et al. 2014, Kim et al. 2008). Furthermore, it has been suggested 
that both PI3-K, an upstream effector of AKT, and mTOR are both required for insulin-
specific induction of myogenic differentiation and furthermore myosin heavy chain (MHC) 
expression. (Sumitani et al. 2002). mTORC1 activity has also been shown to be related to 
levels of mitochondrial metabolism via its role in regulating mitochondrial-related gene 
expression (Cunningham et al. 2007). The primary role of mTOR, however, lies in the 
regulation of protein synthesis which  is mediated primarily though the downstream 
activation of  ribosomal protein S6 kinase (S6K) and eukaryotic initiation factor 4E binding 
protein 1 (4E-BP1) (Van Wessel et al. 2010) (Figure 2.11). 
 
p70S6K and 4E-BP1 
Ribosomal protein S6 kinase (S6K) and 4E-BP1 are well-characterised downstream 
effectors of the AKT/mTOR hypertrophy signalling pathway. S6K has been shown to have 
two isoforms (S6K1 and S6K2). Knock-out mouse models have determined that S6K1 is the 
predominant regulator of cell size in skeletal muscle (Shima et al. 1998, Ohanna et al. 2005, 
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Ruvinsky and Meyuhas 2006). Subsequently, S6K also has duel cytosolic (p70S6K) and 
nuclear (P85 S6K) isoforms (Ruvinsky and Meyuhas 2006). S6K exerts its effect through 
several substrate targets and has been linked with a regulatory role in a number of cellular 
processes, with the most prominent being its central role in skeletal muscle hypertrophy 
(Ruvinsky and Meyuhas 2006, Baar and Esser 1999, Bodine et al. 2001). Furthermore, early 
studies have established that resistance training stimuli promotes the upregulation of p70S6K  
whereas endurance training does not (Nader and Esser 2001)   
eIF4E binds to small phosphoproteins termed 4E-binding proteins of which 4E-BP1 
the best characterized (Wang and Proud 2006). 4E-BP1 is regulated and suppressed by 
mTORC1 via phosphorylation to depress 4E-BP1 inhibition of translation initiation cap 
binding protein eIF4E (Richter and Sonenberg 2005). 4E-BP1 emulates the function and 
activity of S6K1 in that there is an mTOR-mediated upregulation of 4E-BP1 phosphorylation 
that occurs under situations of mechanical stress (Bodine et al. 2001, Thomson and Gordon 
2006). Resistance exercise increases the phosphorylation of 4E-BP1 with skeletal muscle 
overload decreasing the binding of 4E-BP1-eIF4E binding, allowing for greater rates of 
translation initiation (Bodine et al. 2001, Kubica et al. 2005). Atherton et al. (2005) 
demonstrated that in rats, endurance-like stimuli decreases 4E-BP1 which indicates a 
negative effect of endurance exercise on translational mechanisms and protein synthesis 
(Atherton et al. 2005).  
 
p38 MAPK 
The mitogen activated protein kinase (MAPK) pathway is stimulated by a number of 
factors and regulates a diverse array of cellular functions in mammalian cells. Of the five 
distinct MAPK groups: extracellular signal-regulated kinases (ERK) 1 and 2 and p38 
isoforms alpha (α), beta (β), gamma (γ) and delta (δ), the p38 MAPK  is the most responsive 
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to stress stimuli (Roux and Blenis 2004).  Upon activation, both ERK 1/2 and p38 modulate 
gene expression and protein synthesis via phosphorylation of targets such as transcription 
factors and cytosolic proteins (Sakamoto and Goodyear 2002) 
P38 MAPK is responsible for regulating numerous processes including myogenic and 
mitochondrial gene expression in addition to ubiquitin ligase activity (Lluís et al. 2006). p38 
MAPK has been implicated in the activation of a number of transcription factors necessary 
for differentiation of myoblasts to myotubes (Lechner et al. 1996) which promote fusion of 
myoblasts and increase the expression of muscle specific genes, such as MHC (Deldicque et 
al. 2007). This process is primarily coordinated through p38‘s ability to act as a molecular 
switch for the activation of satellite cells (Lluís et al. 2006) Several studies have shown that 
p38 MAPK activity increases muscle differentiation and forced activation of this pathway 
could stimulate differentiation and promote myotube formation (Wu et al. 2000, Zetser, 
Gredinger, and Bengal 1999, Serra et al. 2007). Work by Gardner and colleagues (2015) 
found that blocking p38 MAPK expression, thereby promoting IGF-1 mediated signalling, 
results in a lack of C2 muscle cell fusion suggesting p38 MAPK is essential for the later 
stages of myotube differentiation resulting in multinucleated tubes (Gardner et al. 2015).  
2.5.4 Creatine’s Effects on Muscle Repair  
Creatine supplementation can increase and prevent the inhibition of MRF expression 
in murine myoblasts (Louis et al. 2004, Sestili et al. 2009). In vitro studies have shown that 
creatine is able to enhance differentiation of myogenic C2C12 cells by activating both 
MAPK and AKT signalling pathways (Deldicque et al. 2007). In humans, creatine 
supplementation has been demonstrated to stimulate muscle hypertrophy during 
rehabilitation following muscle immobilization, an effect ascribed to increased Myogenic 
factor-4 (MRF-4) and myogenin expression (Hespel et al. 2001). Combining 12 weeks of 
creatine supplementation (6 g·d
-1
) with resistance training also resulted in increased 
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myogenin and MRF-4 mRNA abundance and protein concentration (Willoughby and Rosene 
2003). Dangott et al. (2000) reported that creatine supplementation in combination with 
compensatory hypertrophy (i.e. training stimulus) results in an increase in functional load 
and satellite cell proliferative activity in the skeletal muscle of Sprague-Dawley rats 
(Dangott, Schultz, and Mozdziak 2000).  Furthermore, creatine increased satellite cell 
activity only when combined with the increased functional activity of the muscle (Dangott, 
Schultz, and Mozdziak 2000). This aligns with observations from previous work by Brannon 
et al. (1997) showing creatine‘s central role in hypertrophy is dependent on contractile 
stimuli (Brannon et al. 1997). 
As discussed previously (section 2.4), creatine increases muscle mass and strength 
following resistance-based exercise (Cooper et al. 2012, Mesa et al. 2002, Hultman et al. 
1996, Taylor et al. 2011, Harris, Soderlund, and Hultman 1992, Vierck et al. 2003) and also 
affects the rate of satellite cell proliferation (Vierck et al. 2003). An in vitro investigation by 
Vierck et al. (2003) determined the effects of creatine monohydrate, creatine pyruvate, L-
glutamine, dehydroepiandrosterone (DHEA), androstenedione, ephedra sinensis extract, and 
citrus aurantium extract on ovine-derived satellite cells. It was found that following 96 h 
incubation, only creatine monohydrate was able to induce cell differentiation (Vierck et al. 
2003). Notably, it was reported that with creatine incubation, insulin was deemed necessary 
for increasing fusion and muscle myotube number  (Vierck et al. 2003). Skeletal muscle is 
one of the major targets for the anabolic action of insulin with in vitro studies having 
identified its mitogenic effects on cell metabolism as well as its role in stimulating muscle 
protein synthesis (Reeds and Palmer 1983, Florini et al. 1986, Palmer et al. 1997). Vierck et 
al. concluded that creatine-mediated hypertrophy occurs within a narrow concentration 
window via the stimulation of satellite cell proliferation and differentiation underpinned by 
insulin.  
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2.5.5 Interactive Effects of Creatine, Carbohydrates and Insulin on Cell Signalling 
Both carbohydrate and creatine loading elicit a small but acute increase in BM (on 
average 1-2 kg), principally via the additional storage of intra-cellular water (Nygren et al. 
2001, Ziegenfuss, Lowery, and Lemon 1998, Safdar et al. 2008). Creatine, especially, has 
been reported to increase intracellular water retention and alter cell volume (Francaux and 
Poortmans 1999, Juhn and Tarnopolsky 1998b, Powers et al. 2003, Kreider et al. 1998, 
Ziegenfuss, Lowery, and Lemon 1998). Augmented cell size may be the catalyst underlying 
increases in glycogen storage. Indeed, the cellular swelling caused by the storage of 
additional water within the muscle cell has been associated with the upregulation of a large 
number of genes involved in protein and glycogen synthesis, satellite cell proliferation and 
differentiation, and DNA replication and repair (Kreider et al. 1998, Powers et al. 2003, 
Ziegenfuss, Lowery, and Lemon 1998, Francaux and Poortmans 1999, Olsson and Saltin 
1970b, Baker and Jeukendrup 2014, Sherman et al. 1982, Juhn and Tarnopolsky 1998b, 
Safdar et al. 2008). 
Creatine supplementation alters various signalling pathways involved in myogenesis, 
mitochondrial biogenesis and protein synthesis. In vitro investigations by Delidcque et al. 
(2007) on anabolic signalling has shown that creatine incubation (5 mM) increases the 
expression of key hypertrophy-related proteins p38 MAPK, AKT and p70S6K in C2C12 
mouse muscle cells (Deldicque et al. 2007). Additionally, the authors identified creatine 
stimulated myogenic differentiation via activation of the p38 MAPK signalling pathway, 
which subsequently up regulates MyoD, indicative of satellite cell activation (Deldicque et 
al. 2007). Interestingly, subsequent in vivo creatine supplementation (21 g for 5 d) 
investigation showed a reduction in the phosphorylation of AKT
Thr308
 and 4E-BP1 24 h post 
exercise with no effect on p38 MAPK signalling when creatine supplementation was coupled 
with resistance exercise (Deldicque et al. 2008). There was however, an increase in MHC 
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mRNA both at rest and post exercise, suggesting that the modification of genes associated 
with hypertrophy by creatine does not require the mechanical stimulus of exercise 
(Deldicque et al. 2008).  
Carbohydrate-mediated  insulin  induction of myogenic differentiation has shown to 
require both PI3-K, an upstream effector of AKT, and mTOR for increasing functional 
hypertrophy, specifically increased MHC expression (Sumitani et al. 2002). Work by 
Sumitani et al. (2002) demonstrated that while insulin-stimulated proliferation occurs via 
both the activation of PI3-K and mTOR, transcription of myogenin, which is required for 
fusion of myogenic precursor cells to form new myofibres, requires PI3-K activation but not 
mTOR (Sumitani et al. 2002).   
Chromatographic analysis of fenugreek seeds has revealed substantial quantities of 
(2S,3R,4S)-4-hydroxyisoleucine (4-HIL) (Narender et al. 2006, Sauvaire et al. 1998), a 
naturally-occurring plant amino acid that is unique to fenugreek and bacillus thuringiensis 
thought to be the major constituent responsible for the observed glucose-lowering effect 
(Ogawa et al. 2011). Broca et al. (2000) demonstrated that an acute dose of 4-HIL extracted 
from fenugreek seeds activated PI3-K in the liver and muscle cells of both diabetic and non-
diabetic rats (Broca et al. 2004). AKT  phosphorylation is widely associated with insulin 
stimulation (Kim et al. 1999).  Vijayakumar et al. (2005), however, observed that fenugreek 
treatments had little effect on AKT expression in either hepatocytes or adipocytes, 
particularly at the serine 473 residue (Vijayakumar et al. 2005). The authors hypothesized 
that fenugreek signalling occurs via a divergent pathway involving protein kinase C (PKC) 
as an intermediate rather than AKT (Figure 2.12). 
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Figure 2.12: A proposed model for cellular signalling by fenugreek seed extracts. Previous 
work has suggested fenugreek effects glucose homeostasis via a protein kinase C (PKC) 
dependent pathway rather than protein kinase B (also known as AKT). (Reproduced from 
Vijayakumar et al. 2005. British Journal of Pharmacology) 
 
In contrast, Jaiswal et al. (2012) examined the effect of 4-HIL on glucose uptake and 
translocation of GLUT4 to the plasma membrane in L6 skeletal muscle cells and showed that 
4-HIL stimulated glucose uptake by enhancing translocation of GLUT4 to the cell surface in 
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a PI3-K/AKT-dependent mechanism (Jaiswal et al. 2012) Such discrepancies indicate that 
there may indeed be tissue-specific mechanisms which underpin fenugreek‘s reported 
therapeutic effects. These conflicting reports on substrate interactions on cellular level 
hypertrophy signalling pose an interesting conundrum that warrants further investigation. 
Endurance athletes benefit from a greater mitochondrial capacity due to their 
increased requirement for oxygen-dependent energy turnover. Initially, creatine and PCr 
were thought to inhibit the activation of AMPK (Winder 2001). However, in vitro research 
by Ceddia et al. (2004) indicated that creatine supplementation (0.5 mM for 48 h) increases 
AMPK phosphorylation with a concurrent shift in basal glucose metabolism towards 
oxidation and a concomitant reduction in lactate production (Ceddia and Sweeney 2004). 
Lower lactate levels are indicative of reduced carbohydrate utilization and reflect the 
potential role of increased muscle creatine availability in sparing muscle glycogen use.   
Taken collectively, creatine, carbohydrate and insulin‘s interactions suggest a 
synergistic, ergogenic relationship beneficial for both resistance-based hypertrophy and 
endurance-based mitochondrial biosynthesis (Figure 2.13). Carbohydrate-mediated insulin 
secretion increases creatine transporter activity, resulting in greater transport of extracellular 
creatine into the intracellular space (Green, Hultman, et al. 1996), thus also promoting 
greater hypertrophy via satellite cell activation. Augmented intracellular creatine content 
increases AMPK phosphorylation (Ceddia and Sweeney 2004), of which the 160 kDa AKT 
substrate (AS160), is a downstream target (Treebak et al. 2006). 
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Figure 2.13: A theoretical schematic of signalling pathways involved in protein and 
mitochondrial synthesis as a result of creatine and carbohydrate supplementation. Glycogen 
concentration increases when creatine is co-ingested with carbohydrates as a result of 
creatine-mediated water retention promoting an increase in cell volume. Creatine 
supplementation per se does not alter insulin-stimulated glucose uptake via GLUT4 and 
glucose metabolism but has been shown to upregulate AMPK activity. A complex system of 
regulation between AMPK, creatine kinase, PCr and creatine, AMPK may play a role in 
regulating intramuscular creatine to PCr ratios. Arrows indicate activation; flat bars indicate 
inhibition of signalling. 
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The proposed schema outlined in Figure 2.13 suggests that creatine-mediated activation of 
AMPK phosphorylates AS160, leading to a greater degree of recruitment of GLUT4 to the 
cell membrane, thus allowing for additional glucose to enter the cell to be stored as 
glycogen. The co-transport of water along the concentration gradient produced by 
intracellular creatine (and, to a lesser extent, transported glucose) may increase the volume 
of the cell, further augmenting the capacity for glycogen storage. AMPK, which functions as 
a metabolic ―fuel gauge‖ in response to glycogen levels and exercise stimuli, promotes 
downstream activation of peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α), resulting in a rapid increase in mitochondrial biogenesis and subsequent 
aerobic capacity. However, the role creatine plays on GLUT4 translocation itself (Op't 
Eijnde et al. 2001, Ju et al. 2005, van Loon et al. 2004) as well as what occurs under 
endurance-based training scenarios are yet to be characterised. 
2.6 Summary 
Creatine has intrigued scientists and athletes with its capacity to augment muscle creatine 
stores and enhance performance. Strategies to alter intramuscular creatine stores not only 
influence the amount of energy available to undertake exercise, but also affect a variety of 
acute and chronic adaptations of muscle physiology to training. An abundance of research 
has been performed to rigorously evaluate the soundness of creatine supplementation 
strategies for enhanced performance, both through in vivo and in vitro testing. Through these 
testing models, it has been determined that creatine‘s ergogenic properties can be enhanced 
by a manipulation of co-supplemented substrates (i.e. carbohydrates, insulin mimetics) and, 
through these manipulations, the application of creatine has expanded beyond the scope of 
strength power training exercise.  The aims of the studies described in the subsequent 
chapters were developed to elucidate the functional outcomes associated with various 
creatine co-supplementation strategies and protocols using both in vitro and in vivo models.  
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These studies determined physiological and mechanistic differences resulting from various 
creatine-based treatment strategies which provide a better understanding of creatine‘s role in 
metabolism and performance.  
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CHAPTER 3: Methodology and Design
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As per university guidelines, methods utilised within each study presented in this thesis are 
described in their entirety in the section below. Chapter 4, 6 and 8 contain the specific 
methods used in each study presented according to the guidelines provided by the respective 
journals in which these studies were submitted for review.  
3.1   Study 1 - Effects of Creatine and Carbohydrate Loading on Cycling Time Trial 
Performance 
3.1.1  Subjects 
Sample size was calculated on an expected difference in muscle phosphocreatine 
concentrations of 18 mmol·kg
-1
 between placebo and creatine + carbohydrate supplemented 
cohorts (van Loon et al. 2004, Roberts et al. 2016).
 
With a standard deviation of 9 mmol·kg
1
, 
a minimum number of 18 people (allowing for ~10% attrition) was calculated to be required 
to detect a difference (power = 90%, α = 0.05). This calculation was performed based on the 
formula n = f (α/2, β) x 2 x σ2 / (µ1 - µ2)
2
  with f (α,β) =[ φ-1(α) + φ-1(β)] ( µ1 and  µ2 are the 
mean outcomes in the control (placebo) and experimental (creatine) group of previous 
studies respectively, undertaken using creatine and carbohydrate supplementation strategies, 
α is the significance level, β is the power, σ is the standard deviation and φ-1  is the 
cumulative distribution function of a standardized normal deviate. As such, eighteen 
endurance-trained male cyclists and triathletes with > 2 y racing history and currently 
cycling >250 km/wk commenced the study with age, body mass (BM), maximum oxygen 
uptake (VO2max), and peak power output (PPO) (mean values ± SD) of 31.2 ± 5.8 y, 78.2 ± 
8.7 kg, 65.1 ± 7.1 mL∙kg-1∙min-1, and 388 ± 42 W, respectively. Subjects who had taken any 
form of creatine supplement within 6 wk of the first performance trial (PT) or who had a 
history of abnormal bleeding, clotting, or history of seizure were excluded from the study. 
Experimental procedures and risks associated with the study were explained to all subjects 
who gave written informed consent prior to participating. The study was approved by the 
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Human Research Ethics Committees at the Australian Catholic University (Reference: 
20140612) and the Australian Institute of Sport (Register Number: 2014 254N). The study 
was registered with the World Health Organization‘s International Clinical Trials Registry 
(UTN: U1111-1161-0890) and conducted in conformity with the policy statement regarding 
the use of human subjects according to the latest revision of the Declaration of Helsinki.
 
3.1.2  Study Overview 
On separate days following familiarization (described subsequently), subjects 
completed three cycling PTs which consisted of a 120 km time trial (TT) ride on an 
electromagnetically-braked cycle ergometer immediately followed by a ride to volitional 
fatigue on an inclined treadmill set at a speed which elicited ~90% VO2max. Following the 
first baseline (standardized 6 g·kg
-1
 BM CHO diet) PT, subjects were pair-matched into 
creatine (CR) or placebo (PLA)  supplemented groups based on peak power output (PPO), 
performance measures from PT1 and DXA lead body mass measures in a double-blinded 
allocation. All subjects then undertook a randomized cross-over application of the 
carbohydrate intervention, consuming either a moderate-(6 g∙kg-1 BM/d; MOD) or CHO-
loaded (12 g∙kg-1 BM/d; LOAD) diet 2 d before PT2 or PT3. A total of four muscle biopsies 
were obtained prior to PT1, 18 h following PT1 (i.e. glycogen depleted), and prior to PT2 
and PT3 for biochemical analysis of intramuscular metabolites (as diagrammed subsequently 
in Figure 4.1) 
3.1.3  Preliminary Testing 
Upon arrival to the laboratory and after voiding, a nude measure of BM was obtained 
for VO2max and energy intake calculations. Subjects were subsequently weighed in full racing 
kit (e.g. jersey, cleats, knicks, socks, and helmet) and bicycle in order to calculate a relative 
treadmill speed for the hill climb simulation (described subsequently). The VO2max and PPO 
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of each subject were determined using an incremental test to volitional fatigue on an 
electromagnetically-braked cycle ergometer (Lode, Groningen, The Netherlands). The test 
protocol commenced at 150 watts (W) for 5 min and progressed to 250 W. Following 150 s, 
work load increased by 50 W with all subsequent work load increasing by 25 W every 150 s 
until volitional fatigue which was determined by the inability to maintain cadence >70 
revolutions∙min-1 (RPM). PPO was determined to be the power output of the highest stage 
completed plus the fraction of any uncompleted workload (W). Expired gases were collected 
into a calibrated customized Douglas bag gas analysis system, which incorporated an 
automated piston that allowed the concentrations of O2 and CO2 and the volume of air 
displaced to be quantified. VO2max was calculated as the highest average O2 consumption 
recorded over 60 s.  
Following the VO2max test, subjects undertook a 60 km familiarization time trial (TT) 
on a cycle ergometer (Velotron, Seattle, USA) with 1 km and 4 km sprint efforts (e.g. ―as 
fast as possible‖) alternating every 10 km during which time they consumed 60 g of CHO∙h-1 
in the form of a sports drink or gel. Upon the completion of the TT, subjects performed a 
timed ride to exhaustion (criteria subsequently defined) on a customized treadmill 
(Australian Institute of Sport, Canberra, Australia) set at an 8% gradient at a speed which 
elicited ~90% of a subject‘s VO2max as previously established (Ebert et al. 2007). This 
intensity was chosen to mimic hill climb durations (~10-30 min) commonly observed in 
international road cycling races. The first study PT commenced within 7 d of familiarization. 
3.1.4  Study Diet and Exercise Protocol 
Dietary control was implemented for the 2 d prior to each PT using a pre-packaged 
standardized diet protocol. An individualised menu was constructed for each subject using 
FoodWorks Professional Edition, Version 7.0 (Xyris Software, Brisbane, Australia) based on 
their BM and food preferences. Subjects received a moderate-CHO (MOD) diet providing 6 
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g∙kg-1 BM/d CHO; 1.5 g∙kg-1 BM/d protein; 1.5 g∙kg-1 BM/d fat, with a total energy of ~215 
kJ∙kg-1 BM/d 2 d prior to undertaking their first baseline PT. Subjects refrained from any 
intake of alcohol during the dietary standardisation period.  Caffeine intake was allowed ad 
libitum up to 2 d prior to each PT and up to 2 standard servings (e.g. 1 cup of coffee or 1 can 
caffeinated soft drink) the day before the experimental trial.  Subjects recorded their caffeine 
intake and this was repeated during the dietary standardisation period of subsequent PTs. 
Subjects were provided with all food and drinks in their standardised menu in portion-
controlled packages and were given verbal and written instructions on how to follow the diet.  
Checklists were used to record each menu item as it was consumed and to note any 
deviations from the menu.  On arrival at the laboratory for each PT, this checklist was cross-
checked for compliance with study requirements. Hydration status was assessed using the 
specific gravity test (UG-a, Atago Refractomer, Japan) on an ―on waking‖ urine sample. 
On the morning of each PT, subjects reported to the laboratory at the same time 
(0700-0800 h) following an overnight fast. Following 20 min of rest in a supine position, a 
muscle biopsy was obtained under local anaesthetic (2-3 mL of 1% Xylocaine) from the 
vastus lateralis using a 5 mm Bergstrom needle modified for manual suction (Bergstrom 
1975). Muscle samples were immediately snap-frozen in liquid N2 and stored at -80°C until 
later analysis. A standardized ―pre-race‖ meal providing 2 g∙kg-1 BM CHO was consumed 2 
h prior to the start of each PT. Subjects were asked to void prior to the start of the PT in 
order to obtaining a starting weight and began the PT exactly 2 h post breakfast. 
PTs consisted of a 120 km self-paced cycling TT on a cycle ergometer during which 
subjects performed maximal intermittent high-intensity sprint efforts alternating between 1 
and 4 km every 10 km. A fan that maintained air circulation (15-17 m∙s-1) and cooling was 
positioned 3 m away from the subject for all trials. Heart rate (HR) readings (RS300, Polar 
Electro, Kempele, Finland) were obtained both before and after the completion of each 
  67 
 
sprint. Rating of perceived exertion (RPE) was obtained at the completion of each sprint 
effort. Subjects were required to follow a standardized hydration and CHO intake (60 g∙h-1) 
plan which was recorded and repeated in subsequent PTs. Upon the completion of the TT, 
subjects quickly dismounted the ergometer where they voided, towelled off and were 
reweighed. Subjects then rode their own bicycle on an inclined treadmill set at an 8% 
gradient at a speed which elicited ~90% of a subject‘s VO2max. Subjects rode until volitional 
fatigue which was determined to be three verbal warnings that they had drifted back beyond 
a predetermined safety zone on the treadmill or when subjects grabbed onto the side of the 
treadmill safety bar. The transition from ergometer to treadmill was <5 min. Subjects 
received similar encouragement through all PTs and did not receive any feedback on their 
performance until the completion of the study.  
Following the completion of the first PT, subjects were fed a pre-packaged 
standardised low-CHO diet (<1 g∙kg-1 BM) for the remainder of the day to minimise 
resynthesis of muscle glycogen stores (Camera et al. 2012).  Participants then reported to the 
laboratory in a fasted state the next morning (―glycogen depleted‖) where a second muscle 
biopsy was taken under rested and fasted conditions. Following the biopsy, subjects were 
randomised into either creatine loaded (20 g∙d-1 for 5 d followed by 3 g∙d-1 until the end of 
the trial; CR) or placebo (PLA) cohorts using a pair-matched design based on PPO (W·kg
-1
), 
results of the first PT, and DXA lean mass estimates.  In the 2 d prior to each of the two 
additional PTs (commenced 1 wk apart), subjects receive either a repeat of the MOD diet or 
a CHO loaded (LOAD) diet (12 g∙kg-1 BM/d) in a cross-over allocation (Figure 1). These 
dietary treatments were implemented using a PLA-controlled design whereby the overall 
menu for the day was kept constant, but key items were provided either as a low-energy/low-
CHO option or an indistinguishable high-energy/CHO-enriched form. Protein and fat intake 
each remained constant at 1.5 g∙ kg-1∙d-1 in these diets but energy intake was increased in the 
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CHO LOAD diet (~320 kJ∙kg-1∙d-1). Subjects completed all subsequent biopsy and PTs as 
described, however no dietary restriction or follow up biopsy was given after the second and 
third PT.  Analysis of all the diets consumed by participants was undertaken on completion 
of the study by a registered dietitian.  
3.1.5  Determination of Muscle Creatine Content  
For the measurement of muscle creatine content, 20-30 mg wet weight muscle tissue 
was freeze dried, weighed and extracted with 1M perchloric acid. Samples were analysed in 
duplicate for free-creatine, PCr, and ATP using fluorimeter. Total creatine was measured as a 
sum of free creatine and PCr. 
3.1.6  Determination of Muscle Glycogen Content  
For the measurement of muscle glycogen content, ~20 mg muscle tissue was freeze-
dried and powdered with all blood and connective tissue removed. The freeze dried samples 
were extracted with 500 µL of 2M HCl, heated to 100°C for 2 h to hydrolyse the glycogen to 
glycosyl units, and then neutralized with 1.5 mL of 0.67 M sodium hydroxide. Glycogen 
concentrations were determined via enzymatic analysis with ﬂuorometric detection (Jasco 
FP-750 spectroﬂuorometer, Easton, MD) at excitation 365 nm/emission 455 nm. 
3.1.7  SDS-PAGE and Immunoblotting Analysis 
Quantification of protein expression was carried out as previously described (Camera 
et al. 2012). Approximately 20 mg of skeletal muscle was homogenized using a motorized 
pellet pestle in an ice-cold buffer containing 50 mM TrisHCl (pH 7.5), 1 mM EDTA, 1mM 
EGTA, 10% glycerol, 1% Triton X-100, 50 mM NaF, 5 mM sodium pyruvate, 1 mM DTT, 
10 µg/mL trypsin inhibitor, 20 µg/ml aproptinin, 1mM benzmidine, and 1 mM PMSF. 
Samples were spun at 16,000 g for 30 min at 4°C with supernatant collected for analysis. 
Total protein concentration was determined using a BCA protein assay (Pierce 
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Biotechnology, Rockford, IL) with lysate re-suspended in Laemmli sample buffer, separated 
by SDS-PAGE, and transferred to polyvinylidene fluoride membranes blocked with 5 % 
non-fat milk, washed with 10 mM Tris–HCl, 100 mM NaCl, and 0.02 % Tween 20, and 
incubated with primary antibody (1:1000) overnight at 4°C on a shaker. Membranes were 
incubated with secondary antibody (1:2000), and proteins were detected via enhanced 
chemiluminescence (Amersham Biosciences, Buckinghamshire, UK; Pierce Biotechnology) 
and quantified by densitometry (Chemidoc, BioRad, Gladesville, Australia). All samples for 
each individual were run on the same gel. Antibodies for total expression of peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α; no. 2187), mechanistic 
target of rapamycin (mTOR; no. 2972) 5' AMP-activated protein kinase (AMPK; no. 2532) 
were from Cell Signaling Technology (Danvers, MA, USA). SLC6A8 (no. AV42248) 
creatine transporter was from Sigma-Aldrich (St. Louis, MO, USA). For all proteins, volume 
density of each target band was normalized to the total protein loaded into each lane using 
stain-free technology (Gürtler et al. 2013). 
3.1.8  Statistical Analysis 
Normal distribution and equal variance of the data were tested using Shapiro-Wilk 
and F tests, respectively. All data (except for creatine concentrations by time point) were 
analysed using two-way repeated measures ANOVA where the independent, between subject 
factor was Treatment (Placebo or Creatine) and the within subject, repeated measure was 
Carbohydrate conditions (baseline, depleted, moderate-CHO diet or CHO-loaded diet).  
Time (P1, Post-PT1, P2 and PT3) was not a factor in theses analyses because CHO-diet 
order was randomly assigned. Data comparing creatine content (irrespective of CHO-
treatment) were also analysed using a two-factor ANOVA where the independent, between 
subject factor was Treatment (Placebo or Creatine), and the within subject, repeated 
measures factor was Time (PT1, Post-PT1, PT2 and PT3). Where there were significant main 
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effect differences for treatments or time, pre-planned Student-Newman-Keuls post-hoc 
analysis were used to locate these differences. All data were analysed using Sigma Plot 
(version 3.1). Statistical significance was set at P < 0.05 with data being represented as mean 
± standard deviation (SD).  
 
3.2  Study 2 – The in vitro Effects of Creatine and Insulin on Skeletal Muscle 
Myotubes Cultured in Different Glucose Concentrations  
3.2.1  Cell Culture 
C2C12 murine satellite cells (LONZA, Mount Waverley, VIC, AUS) were cultured 
on 2% gelatine- (Life Technologies, Mulgrave, VIC, AUS) coated T-75 flasks (Thermo 
Fisher, Scoresby, VIC, AUS) in 4.5 g·L
-1
 glucose Dulbecco‘s Modified Eagle Medium 
(DMEM; Life Technologies) supplemented with 10% foetal bovine serum (FBS; Life 
Technologies) and 0.5% penicillin/streptomycin (PenStrep; Life Technologies) and 
maintained at 37°C in a humidified incubator at 5% CO2.  
At 70-90% confluence cultures were treated with serum free trypsin-EDTA (Life 
Technologies) at 37°C for 3-5 min before DMEM + 10% FBS were added to stop the 
reaction. Dissociated cells were collected and spun down (3 min at 3,000 rpm), resuspended 
in proliferation medium composed of DMEM + 10% FBS and seeded onto gelatine-coated 6-
well culture dishes (Thermo Fisher) at a density of 10,000 cells/mL. At 70% confluence, the 
proliferation medium was replaced with differentiation medium composed of 4.5 g·L
-1
 
glucose DMEM + 2% horse serum (HS; Sigma Aldrich, Castle Hill, NSW, Australia) and 
PenStrep for 168 h to allow myotube formation. Differentiation solution was replaced every 
48 h. At 168 h (―baseline‖), differentiation medium was replaced with either 1 g·L-1 glucose 
(―low‖; LG) or 4.5 g·L-1 glucose (―high‖; HG) DMEM containing 2% HS and 0.5% 
PenStrep supplemented with either 0.5 mM creatine (CR; Sigma Aldrich), 100 nM insulin 
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(INS; Sigma Aldrich) or 0.5 mM CR + 100 nM INS (CR+INS) for an additional 2 wk. In 
total 8 groups were established: control no treatment (NT) creatine treatment (CR), insulin 
treatment (INS) and creatine + insulin treatment (CR+INS) in either LG or HG 
concentrations. Treatment medium was changed every 24 h for the following 2 wk (Figure 
3.1).  
3.2.2  Myotube Size and Fusion Index 
Myotubes were measured at baseline, 1 and 2 wk from treatment using the AVOS 
imaging system (Life Technologies). Pictographs were taken under 10x magnification (400 
µm scale) with 5 image fields (one in the centre of the well and four others around the 
centre) taken from each treatment at baseline, 1 and 2 wk of culture time. Images were taken 
from the same culture wells at each of the time points. A total of 10 myotubes per field were 
chosen at random with myotube width measured in µm at the centre of each myotube (total 
of 50 myotubes per treatment per time point). This was carried out in two separate biological 
replicate experiments. Measurements at 1 and 2 wk were normalized to the average size at 
baseline. 
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Figure 3.1: Timeline of Study II C2C12 cell culture protocol. 
 
Based on the myotube diameter results, the number of fused nuclei to myotubes 
treated with CR and CR+INS in HG cultures were examined using immunofluorescence 
methods as  detailed previously (Saiti and Lacham-Kaplan 2007). Cultures were fixed and 
incubated with anti-mouse Desmin. Following a series of washes in phosphate buffer (Life 
Technologies), cultures were incubated with anti-mouse-GFP secondary antibody. Stained 
cultures were visualized under the AVOS imaging system following co-staining with DAPI 
for nuclear staining. Antibodies and DAPI were purchased from Life Technologies. A total 
of 20 myotubes were randomly selected from four microscopic fields from two repeats and 
the number of nuclei within each myotube was recorded.  
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3.2.3  SDS-PAGE and Immunoblotting Analysis 
Cultures were rinsed twice with 1X PBS (Life Technologies) before 1x cell lysis 
buffer (Cell Signalling Technology, Danvers, MA) supplemented with 1 mM PMSF was 
added to cultures. To ensure cell lysis, cells were collected and passed through an 18-gauge 
needle 10 times. Samples were centrifuged at 13,000 rpm for 10 min at 4ºC and the 
supernatant collected for total protein analyses using a BCA protein assay (Pierce, Rockford, 
IL, USA).  Western blotting was carried out as previously described (Tomcik et al. 2016). 
Briefly, lysates were re-suspended in Laemmli sample buffer, separated by SDS-PAGE, and 
transferred to polyvinylidine fluoride membranes blocked with 5% non-fat milk, washed 
with 10 mM Tris·HCl, 100 mM NaCl, and 0.02% Tween 20, and incubated with primary 
antibody (1:1,000) overnight at 4°C. Membranes were incubated with secondary antibody 
(1:2,000), and proteins were detected via enhanced chemiluminescence (Amersham 
Biosciences, Buckinghamshire, UK; Pierce Biotechnology) and quantified by densitometry 
(Chemidoc, BioRad, Gladesville, Australia). For all proteins, volume density of each target 
band was normalized to the total protein loaded into each lane using stain-free technology 
(Gürtler et al. 2013). Each treatment was run on the same gel according to time point. 
 The total and phosphorylated forms of the following proteins with putative roles in 
muscle growth were determined: mechanistic target of rapamycin (mTOR), ribosomal 
protein S6 kinase beta-1 (p70S6K), protein kinase B (AKT) and eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1).  Additionally, Solute Carrier Family 6 
Member 8 (SLC6A8) creatine transporter, Myosin Heavy Chain (MHC), and the total and 
phosphorylated form of the osmotic stress related p38 mitogen-activated protein kinase (p38 
MAPK) were measured. Antibodies against p-mTOR
Ser2448
 (no. 2971), total mTOR (no. 
2972), p-p70S6K
Thr389 
  (no. 9205), total p70S6K (no. 9202), p-AKT
Thr308
 (no. 9275), total 
AKT (no. 9272), p-4E-BP1
Thr37/46
 (no. 2855) and total 4E-BP1 (no. 2452), p-p38 MAPK 
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Th180/Ty182 
(no. 9211) and total p38 MAPK (no. 9212) were obtained from Cell Signaling 
Technology (Danvers, MA, USA). MHC antibody (no. PA5-31466) was obtained from Life 
Technologies. SLC6A8 antibody (no. AV42248) was obtained from Sigma-Aldrich (St. 
Louis, MO, USA).  
3.2.4  Statistical Analysis 
Data were analysed using two-way repeated measures ANOVA (treatment x time) 
and student t-test for paired analyses. Myotube size and protein relative expression were 
compared between treatment groups (No treatment, Creatine, Insulin, or Creatine + Insulin 
within high and low glucose) and time (at 1 and 2 wk) following relative adjustment to 
baseline measures. Where there were significant main effect differences for treatment or 
time, pre-planned LSD Fisher post-hoc analysis was used to locate these differences. All data 
were analysed using Sigma Plot (version 3.1). Normal distribution and equal variance of the 
data were tested using Shapiro-Wilk and F tests, respectively. Statistical significance was set 
at P < 0.05 with data being represented as mean ± standard error of the mean (SEM).  
 
3.3  Study 3- Fenugreek Increases Insulin-Stimulated Creatine Content in L6C11 
Muscle Myotubes 
3.3.1  Preparation of Fenugreek Extracts 
Raw fenugreek seeds were obtained locally (origin: India) and dried at 105°C for 3 h 
before being ground into a fine powder. The ground seeds were placed into a sample cell and 
loaded into an ASE ™ 100 System (Dionex, Sunnyvale, CA) and extracted as per 
manufacturer‘s instructions. Prepared samples were extracted using 50% ethanol. Upon the 
completion of the extraction process, ethanol and water were evaporated and any residual 
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solution removed via overnight freeze drying. Fenugreek extract materials were stored in a 
dry environment until treatment. 
3.3.2  Fenugreek Extract Analysis 
Known amounts of fenugreek seed extract samples and a commercially available 
extract (Sigma Aldrich, St Louis, MO USA) were dissolved in 1mL of AR methanol and 
sonicated for 5min to extract 4-HIL. Standards of 4-HIL (Sigma Aldrich) (Isostd mg/mL) 
were run on an Electrospray Ionization (ESI) mass spectrometer (Micromass Platform II) to 
determine peak areas of the standards (Mass 148 was monitored). All samples and standards 
were made up in acetonitrile: water 50:50 with 0.1% formic acid. A calibration curve was 
produced using four standard concentrations of 4-HIL. The fenugreek sample areas were 
read from the curve to determine the concentrations of 4-HIL (recorded as % weight) in each 
extract. 
3.3.3  Cell Culture 
L6C11 myoblasts were maintained in high glucose Dulbecco‘s modified Eagle 
medium (DMEM) (Life Technologies, CA) supplemented with 10% foetal bovine serum 
(FBS) (Life Technologies), 0.5% Fungizone (Life Technologies) and penicillin streptomycin 
(Life Technologies). Cells were cultured in T-75 flasks and maintained at 37°C in a 
humidified incubator at 5% CO2. Culture medium was changed every 2-3 d and cells were 
sub-cultured when >80% confluent. All experiments were performed in passages 6-11. 
3.3.4  Cell Viability 
Cell viability was measured using the CellTiter Blue® Cell Viability Assay Kit 
(Promega, Madison, WI). Cells were cultured at a density of 2.5 x 10
3
 cells per well in flat-
bottomed 96-well plates and equilibrated for 24 h prior to the addition of varying doses (0-25 
µg/mL) of fenugreek extract. Following treatment, CellTiter Blue® reagent was added to 
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each well according to manufacturer‘s instructions. Cell viability was assessed by measuring 
the fluorescence excited at 550 nm and read at 600 nm using a SpectraMax Paradigm plate 
reader (Molecular Devices, Sunnyvale, CA). All assays were performed in quadruplicate and 
independently repeated twice. 
3.3.5  Determination of Creatine Content 
Total cellular creatine content was determined using modified versions of 
fluorometric determination methods. Myoblasts were cultured at a density of 12 x 10
3
 cells 
per well into 24-well plates. When 80-90% confluent, differentiation of L6C11 myoblasts to 
myotubes was initiated by replacing the mitogen-rich media with DMEM supplemented with 
2% horse serum (Life Technologies), 0.5% Fungizone and penicillin streptomycin for 4 d. 
Myotubes underwent treatments made with control DMEM (CON), 0.5 mM creatine (CR), 
CR  and 20 µg/mL fenugreek extract (CR+FEN), CR and 100nM insulin (CR+INS), and 
CR+INS+FEN for up to 24 h (n=6; obtained from 2 independent experiments). Myotubes 
were rinsed then lysed with 0.1 M NaOH. Lysates were hydrolysed with 1 M HCl and water 
at 60°C for 40 min. Freshly prepared 1% ninhydrin and 10% KOH (in EtOH) were 
subsequently added. Following 8 min incubation at room temperature, fluorescence was 
excited at 410 nm and read at 525 nm using a SpectraMax Paradigm plate reader. Total 
creatine content was calculated from a creatine standard curve and further normalized to total 
cellular protein, as determined using the bicinchoninic acid (BCA)-based protein assay kit 
(Pierce Biotechnology, IL USA) according to manufacturer‘s instructions. Absorbance was 
read at 562 nm.  
3.3.6  SDS-PAGE and Immunoblotting Analysis 
Myotubes were rinsed twice with 1X PBS before lysis with cell lysis buffer (Cell 
Signaling Technology, Danvers, MA) supplemented with 1 mM PMSF. Extracts were 
incubated with continuous rotation at 4°C for 1 h then centrifuged at 13,000 rpm at 4°C for 
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15 min to pellet cell debris. The supernatant was analysed for total protein and sample 
protein concentration using a BCA protein assay (Pierce, Rockford, IL, USA).  Cell lysate 
was re-suspended in Laemmli sample buffer, separated by SDS-PAGE, and transferred to 
polyvinylidine fluoride membranes blocked with 5% non-fat milk, washed with 10 mM 
Tris·HCl, 100 mM NaCl, and 0.02% Tween 20, and incubated with primary antibody 
(1:1,000) overnight at 4°C on a shaker. Membranes were incubated with secondary antibody 
(1:2,000), and proteins were detected via enhanced chemiluminescence (Amersham 
Biosciences, Buckinghamshire, UK; Pierce Biotechnology) and quantified by densitometry 
(Chemidoc, BioRad, Gladesville, Australia). All samples for each treatment group were run 
on the same gel. Phospho-AKT
Thr308
 (no. 4056), total AKT (no. 9272), PKCδ/λ (no. 9378), 
and GLUT4 (no. 9001) were from Cell Signaling Technology (Danvers, MA, USA). 
SLC6A8 (no. AV42248) was from Sigma-Aldrich (St. Louis, MO, USA). Data are expressed 
relative to α-tubulin (no. 3873; Cell Signaling Technology) in arbitrary units.  
3.3.7  Statistical Analysis 
All data were analysed by one- or two-way ANOVA comparing factors of Treatment 
(Creatine, Creatine + Fenugreek, Creatine + Insulin, and Creatine + Insulin + Fenugreek) 
made relative to a control baseline and Time (at 1, 4, and 24 h post treatment) and validated  
for equal variance by Mauchly‘s sphericity test. Where there were significant main 
differences between treatment and time, pre-planned Tukey‘s post hoc analysis was used to 
locate the difference. Statistical significance was established when P<0.05.  All data are 
expressed as arbitrary units ± standard error of the mean (SEM). 
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CHAPTER 4:  
The Effects of Creatine and Carbohydrate Loading on Cycling Time Trial 
Performance 
 
 
This chapter is comprised of the following paper which has been submitted and is under 
second review in Medicine & Science in Sport & Exercise (MSSE): 
 
Effects of Creatine and Carbohydrate Loading on Cycling Time Trial Performance 
 
Tomcik KA, Camera DM, Bone JL, Ross ML, Jeacocke NA, Tachtsis B, Senden J, van 
Loon LJC, Hawley JA, Burke LM. 
  80 
 
  81 
 
4.1  Abstract  
Introduction 
Creatine- and carbohydrate-loading are dietary strategies used to enhance exercise 
capacity. Creatine loading may increase muscle glycogen storage and delay fatigue during 
prolonged exercise. This study examined the effect of combined creatine and CHO-loading 
on cycling performance, associated changes in muscle metabolites, and select anabolic 
signalling markers. 
Methods 
Eighteen well-trained males completed three performance trials (PT) comprising a 
120-km cycling TT with 1- and 4-km sprints followed by an inclined ride to fatigue (~90% 
VO2max). Following the completion of PT1, subjects were pair-matched into creatine-loaded 
(20 g∙d-1 for 5 d + 3 g∙d-1 for 9 d; CR) or placebo (PLA) groups (n=9). All subjects undertook 
a cross-over application of the carbohydrate interventions, consuming  either moderate 
carbohydrate (6 g∙kg-1 BM/d; MOD) or carbohydrate-loaded (12 g∙kg-1 BM/d; LOAD) diets 
before the  remaining PTs. Muscle biopsies were taken prior to PT1, 18 h post-PT1 and prior 
to PT2 and PT3.. 
Results 
Power output with CR was greater than PLA during 1-km (357±73 vs 330±45 W; 
P<0.001) and 4-km (294±54 vs 279±42 W; P<0.01) sprints, with a significant increase 
above baseline observed with CR in the last 4-km sprint. No differences in PT times were 
observed. CR increased BM compared to PLA (+1.54% vs +0.99% from baseline; P<0.05). 
LOAD induced greater muscle glycogen concentrations than baseline and MOD (704±111 vs 
584±135 vs 579±123 mmol·kg
-1
 dry wt., respectively; P<0.01) and greater total creatine 
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concentrations compared to PLA (P=0.053). Mechanistic target of rapamycin (mTOR) 
decreased from baseline following glycogen depletion (~30%; P< 0.05).  
Conclusion 
Power output in sprints undertaken within a prolonged cycling time trial, particularly 
in the late stages of a race, are affected by creatine independent of muscle glycogen content. 
Therefore, in spite of a creatine-mediated increase in weight, creatine and carbohydrate co-
supplementation may be beneficial for intense bursts which occur during breakaway 
moments in endurance events. 
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4.2  Introduction 
The bioenergetics of athletic training and competition require readily available pools 
of energy-generating substrates to support the demands of skeletal muscle metabolism. 
Athletes involved in endurance-type sports (e.g. stage cycling, marathons, triathlons) 
commonly maximize carbohydrate (CHO) availability through CHO loading to increase 
glycogen stores, while athletes involved in brief or intermittent high-intensity events (e.g. 
weightlifting, sprinting) target strategies to increase their capacity to utilize the phosphagen 
pathway, through creatine supplementation. 
Adenosine triphosphate (ATP) is the metabolic intermediary in the energy flow from 
stored energy substrates (e.g. creatine, glycogen) to muscular contraction as well as 
numerous other cellular processes (Holloszy and Coyle 1984). The primary role of 
intramuscular creatine is to rapidly re-phosphorylate adenosine diphosphate (ADP) to ATP 
for energy. Both dietary and endogenous creatine enters muscle cells via the insulin-sensitive 
SLC6A8 creatine transporter where ~60% is bound to a phosphate group and stored as 
phosphocreatine (PCr). The concentration of PCr in muscle is 3-4 fold greater than that of 
ATP but can be exhausted quickly during high intensity resistance and sprint exercise. The 
co-ingestion of CHO with creatine potentiates an insulin-mediated increase in creatine 
transport, maximizing intramuscular creatine stores (Green, Hultman, et al. 1996) which, 
when combined with resistance-type exercise training, has been shown to result in greater 
lean body mass (BM) and strength. 
There is evidence  that creatine loading (20 g∙d-1 for 5 d) in conjunction with a 
moderate-CHO diet (~6 g∙kg-1 CHO for 3 d) results in a substantial (53%) increase in muscle 
glycogen content when compared to CHO consumption alone (Nelson et al. 2001). Recent 
studies have also determined that enhanced glycogen capacity resulting from creatine 
supplementation (20 g/d) peaks within 24 h following exhaustive (70% VO2peak) exercise 
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(Roberts et al. 2016). This response is thought to be the result of increased cell size due to 
creatine- and CHO-induced water retention (Kreider et al. 1998) and is associated with the 
upregulation of signalling pathways mediating glycogen and protein synthesis, namely 5‘ 
AMP-activated protein kinase (AMPK)- and mechanistic target of rapamycin (mTOR)-
mediated signalling (Kreider et al. 1998, Safdar et al. 2008). However, it is presently 
unknown whether concomitant creatine and CHO loading strategies can enhance endurance 
exercise performance outcomes during the course of, rather than following, glycogen 
limiting events (e.g. time trial cycling). Hence, the aim of this study was to investigate 
whether glycogen ‗super-compensation‘ with creatine and high-CHO intake leads to 
improved performance in well trained cyclists over a laboratory protocol involving a 120 km 
time trial and a simulated hill climb, with the latter element being included to investigate the 
effect of the increased body mass (BM) expected as a result of the loading strategies. In light 
of previous research reporting water retention/changes in cell size as a result of creatine and 
CHO supplementation altering signalling pathways associated with protein and glycogen 
synthesis, the present study investigated proteins with putative roles in creatine and/or CHO 
metabolism to provide further insight into the molecular adaptations associated with the 
present exercise and dietary intervention. 
4.3  Methods 
4.3.1  Subjects 
Eighteen endurance-trained male cyclists and triathletes with > 2 y racing history and 
currently cycling >250 km/wk commenced the study with age, body mass (BM), maximum 
oxygen uptake (VO2max), and peak power output (PPO) (mean values ± SD) of 31.2 ± 5.8 y, 
78.2 ± 8.7 kg, 65.1 ± 7.1 mL∙kg-1∙min-1, and 388 ± 42 W, respectively (Table 4.1). Subjects 
who had taken any form of creatine supplement within 6 wk of the first performance trial 
(PT) or who had a history of abnormal bleeding, clotting, or history of seizure were excluded 
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from the study. Experimental procedures and risks associated with the study were explained 
to all subjects who gave written informed consent prior to participating. The study was 
approved by the Human Research Ethics Committees at the Australian Catholic University 
(Reference: 20140612) and the Australian Institute of Sport (Register Number: 2014 254N). 
The study was registered with the World Health Organization‘s International Clinical Trials 
Registry (UTN: U1111-1161-0890) and conducted in conformity with the policy statement 
regarding the use of human subjects according to the latest revision of the Declaration of 
Helsinki. 
Table 4.1: Subject characteristics 
 Creatine Placebo TOTAL 
Participants 9 9 18 
Age (years) 30.0 ± 5.8 32.3 ± 6.0 31.2 ± 5.8 
Body Mass (kg) 76.3 ± 8.5 80.1 ± 9.1 78.2 ± 8.7 
VO2max (ml·kg
-1) 66.8 ± 7.5 63.4 ± 6.6 65.1 ± 7.1 
PPO (W) 394.2 ± 44.8 381.7 ± 39.9 387.9 ± 41.7 
PPO (W·kg-1) 5.2 ± 0.6 4.8 ± 0.5 5.0 ± 0.6 
 
 
4.3.2  Study Overview 
On separate days following familiarization (described subsequently), subjects 
completed three cycling PTs which consisted of a 120 km time trial (TT) ride on an 
electromagnetically-braked cycle ergometer immediately followed by a ride to volitional 
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fatigue on an inclined treadmill set at a speed which elicited ~90% VO2max. Following the 
first baseline (standardized 6 g·kg
-1
 BM CHO diet) PT, subjects were pair-matched into 
creatine (CR) or placebo (PLA)  supplemented groups based on peak power output (PPO), 
performance measures from PT1 and DXA lead body mass measures in a double-blinded 
allocation. All subjects then undertook a randomized cross-over application of the 
carbohydrate intervention, consuming either a moderate-(6 g∙kg-1 BM/d; MOD) or CHO-
loaded (12 g∙kg-1 BM/d; LOAD) diet 2 d before PT2 or PT3. A total of four muscle biopsies 
were obtained prior to PT1, 18 h following PT1 (i.e. glycogen depleted), and prior to PT2 
and PT3 for biochemical analysis of intramuscular metabolites (Figure 4.1). 
4.3.3  Preliminary Testing 
Upon arrival to the laboratory and after voiding, a nude measure of BM was obtained 
for VO2max and energy intake calculations. Subjects were subsequently weighed in full racing 
kit (e.g. jersey, cleats, knicks, socks, and helmet) and bicycle in order to calculate a relative 
treadmill speed for the hill climb simulation (described subsequently). The VO2max and PPO 
of each subject were determined using an incremental test to volitional fatigue on an 
electromagnetically-braked cycle ergometer (Lode, Groningen, The Netherlands). The test 
protocol commenced at 150 watts (W) for 5 min and progressed to 250 W. Following 150 s, 
work load increased by 50 W with all subsequent work load increasing by 25 W every 150 s 
until volitional fatigue which was determined by the inability to maintain cadence >70 
revolutions∙min-1 (RPM). PPO was determined to be the power output of the highest stage 
completed plus the fraction of any uncompleted workload (W). Expired gases were collected 
into a calibrated customized Douglas bag gas analysis system, which incorporated an 
automated piston that allowed the concentrations of O2 and CO2 and the volume of air 
displaced to be quantified. VO2max was calculated as the highest average O2 consumption 
recorded over 60 s.  
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Figure 4.1:  Study I cycling and diet intervention schematic. Subjects completed three performance trials (PT) on a cycle ergometer comprising a 120 
km TT with alternating 4 km and 1 km sprints undertaken every 10 km. Immediately following, subjects cycled to volitional fatigue on an inclined 
treadmill set at speeds eliciting ~90% of individual VO2max. Two days prior to each PT, participants in each group consumed either a moderate (6 g∙kg
-
1 
body mass (BM)/d; MOD) or CHO-loaded (12 g∙kg-1 BM/d; LOAD) diet.  Muscle biopsies were taken prior to each PT as well as 18 h following the 
first PT while glycogen depleted. Following the glycogen depleted biopsy, subjects were randomly allocated into either creatine loaded or placebo 
cohorts. Groups were pair matched based on weight, peak power output, and VO2max. 
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Following the VO2max test, subjects undertook a 60 km familiarization time trial (TT) 
on a cycle ergometer (Velotron, Seattle, USA) with 1 km and 4 km sprint efforts (e.g. ―as 
fast as possible‖) alternating every 10 km during which time they consumed 60 g of CHO∙h-1 
in the form of a sports drink or gel. Upon the completion of the TT, subjects performed a 
timed ride to exhaustion (criteria subsequently defined) on a customized treadmill 
(Australian Institute of Sport, Canberra, Australia) set at an 8% gradient at a speed which 
elicited ~90% of a subject‘s VO2max as previously established (Ebert et al. 2007). This 
intensity was chosen to mimic hill climb durations (~10-30 min) commonly observed in 
international road cycling races. The first study PT commenced within 7 d of familiarization. 
4.3.4  Study Diet and Exercise Protocol 
Dietary control was implemented for the 2 d prior to each PT using a pre-packaged 
standardized diet protocol. An individualised menu was constructed for each subject using 
FoodWorks Professional Edition, Version 7.0 (Xyris Software, Brisbane, Australia) based on 
their BM and food preferences. Subjects received a moderate-CHO (MOD) diet providing 6 
g∙kg-1 BM/d CHO; 1.5 g∙kg-1 BM/d protein; 1.5 g∙kg-1 BM/d fat, with a total energy of ~215 
kJ∙kg-1 BM/d 2 d prior to undertaking their first baseline PT (Figure 4.1). Subjects refrained 
from any intake of alcohol during the dietary standardisation period.  Caffeine intake was 
allowed ad libitum up to 2 d prior to each PT and up to 2 standard servings (e.g. 1 cup of 
coffee or 1 can caffeinated soft drink) the day before the experimental trial.  Subjects 
recorded their caffeine intake and this was repeated during the dietary standardisation period 
of subsequent PTs. Subjects were provided with all food and drinks in their standardised 
menu in portion-controlled packages and were given verbal and written instructions on how 
to follow the diet.  Checklists were used to record each menu item as it was consumed and to 
note any deviations from the menu.  On arrival at the laboratory for each PT, this checklist 
was cross-checked for compliance with study requirements. Hydration status was assessed 
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using the specific gravity test (UG-a, Atago Refractomer, Japan) on an ―on waking‖ urine 
sample. 
On the morning of each PT, subjects reported to the laboratory at the same time 
(0700-0800 h) following an overnight fast. Following 20 min of rest in a supine position, a 
muscle biopsy was obtained under local anaesthetic (2-3 mL of 1% Xylocaine) from the 
vastus lateralis using a 5 mm Bergstrom needle modified for manual suction (Bergstrom 
1975). Muscle samples were immediately snap-frozen in liquid N2 and stored at -80°C until 
later analysis. A standardized ―pre-race‖ meal providing 2 g∙kg-1 BM CHO was consumed 2 
h prior to the start of each PT. Subjects were asked to void prior to the start of the PT in 
order to obtaining a starting weight and began the PT exactly 2 h post breakfast. 
PTs consisted of a 120 km self-paced cycling TT on a cycle ergometer during which 
subjects performed maximal intermittent high-intensity sprint efforts alternating between 1 
and 4 km every 10 km (Figure 4.1). A fan that maintained air circulation (15-17 m∙s-1) and 
cooling was positioned 3 m away from the subject for all trials. Heart rate (HR) readings 
(RS300, Polar Electro, Kempele, Finland) were obtained both before and after the 
completion of each sprint. Rating of perceived exertion (RPE) was obtained at the 
completion of each sprint effort. Subjects were required to follow a standardized hydration 
and CHO intake (60 g∙h-1) plan which was recorded and repeated in subsequent PTs. Upon 
the completion of the TT, subjects quickly dismounted the ergometer where they voided, 
towelled off and were reweighed. Subjects then rode their own bicycle on an inclined 
treadmill set at an 8% gradient at a speed which elicited ~90% of a subject‘s VO2max. 
Subjects rode until volitional fatigue which was determined to be three verbal warnings that 
they had drifted back beyond a predetermined safety zone on the treadmill or when subjects 
grabbed onto the side of the treadmill safety bar. The transition from ergometer to treadmill 
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was <5 min. Subjects received similar encouragement through all PTs and did not receive 
any feedback on their performance until the completion of the study.  
Following the completion of the first PT, subjects were fed a pre-packaged 
standardised low-CHO diet (<1 g∙kg-1 BM) for the remainder of the day to minimise 
resynthesis of muscle glycogen stores (Camera et al. 2012).  Participants then reported to the 
laboratory in a fasted state the next morning (―glycogen depleted‖) where a second muscle 
biopsy was taken under rested and fasted conditions. Following the biopsy, subjects were 
randomised into either creatine loaded (20 g∙d-1 for 5 d followed by 3 g∙d-1 until the end of 
the trial; CR) or placebo (PLA) cohorts (Figure 4.1) using a pair-matched design based on 
PPO (W·kg
-1
), results of the first PT, and DXA lean mass estimates.  In the 2 d prior to each 
of the two additional PTs (commenced 1 wk apart), subjects receive either a repeat of the 
MOD diet or a CHO loaded (LOAD) diet (12 g∙kg-1 BM/d) in a cross-over allocation (Figure 
4.1). These dietary treatments were implemented using a PLA-controlled design whereby the 
overall menu for the day was kept constant, but key items were provided either as a low-
energy/low-CHO option or an indistinguishable high-energy/CHO-enriched form. Protein 
and fat intake each remained constant at 1.5 g∙ kg-1∙d-1 in these diets but energy intake was 
increased in the CHO LOAD diet (~320 kJ∙kg-1∙d-1). Subjects completed all subsequent 
biopsy and PTs as described, however no dietary restriction or follow up biopsy was given 
after the second and third PT.  Analysis of all the diets consumed by participants was 
undertaken on completion of the study by a registered dietitian.  
4.3.5  Determination of Creatine Content  
Muscle creatine content was measured as described previously (Harris, Hultman, and 
Nordesjö 1974). Briefly, 20-30 mg wet weight muscle tissue was freeze dried, weighed and 
  91 
 
extracted with 1M perchloric acid. Samples were analysed in duplicate for free-creatine, PCr, 
and ATP using fluorimetry. Total creatine was measured as a sum of free creatine and PCr. 
4.3.6  Determination of Glycogen Content  
Muscle glycogen content was measured as described previously (Camera et al. 2012). 
Briefly, ~20 mg muscle tissue was freeze-dried and powdered with all blood and connective 
tissue removed. The freeze dried samples were extracted with 500 µL of 2M HCl, heated to 
100°C for 2 h to hydrolyse the glycogen to glycosyl units, and then neutralized with 1.5 mL 
of 0.67 M sodium hydroxide. Glycogen concentrations were determined via enzymatic 
analysis with ﬂuorometric detection (Jasco FP-750 spectroﬂuorometer, Easton, MD) at 
excitation 365 nm/emission 455 nm. 
4.3.7  SDS-PAGE and Immunoblotting Analysis 
Quantification of protein expression was carried out as previously described (Camera 
et al. 2012). Approximately 20 mg of skeletal muscle was homogenized using a motorized 
pellet pestle in an ice-cold buffer containing 50 mM TrisHCl (pH 7.5), 1 mM EDTA, 1mM 
EGTA, 10% glycerol, 1% Triton X-100, 50 mM NaF, 5 mM sodium pyruvate, 1 mM DTT, 
10 µg/mL trypsin inhibitor, 20 µg/ml aproptinin, 1mM benzmidine, and 1 mM PMSF. 
Samples were spun at 16,000 g for 30 min at 4°C with supernatant collected for analysis. 
Total protein concentration was determined using a BCA protein assay (Pierce 
Biotechnology, Rockford, IL) with lysate re-suspended in Laemmli sample buffer, separated 
by SDS-PAGE, and transferred to polyvinylidene fluoride membranes blocked with 5 % 
non-fat milk, washed with 10 mM Tris–HCl, 100 mM NaCl, and 0.02 % Tween 20, and 
incubated with primary antibody (1:1000) overnight at 4°C on a shaker. Membranes were 
incubated with secondary antibody (1:2000), and proteins were detected via enhanced 
chemiluminescence (Amersham Biosciences, Buckinghamshire, UK; Pierce Biotechnology) 
and quantified by densitometry (Chemidoc, BioRad, Gladesville, Australia). All samples for 
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each individual were run on the same gel. Antibodies for total expression of peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α; no. 2187), mechanistic 
target of rapamycin (mTOR; no. 2972) 5' AMP-activated protein kinase (AMPK; no. 2532) 
were from Cell Signaling Technology (Danvers, MA, USA). SLC6A8 (no. AV42248) 
creatine transporter was from Sigma-Aldrich (St. Louis, MO, USA). For all proteins, volume 
density of each target band was normalized to the total protein loaded into each lane using 
stain-free technology (Gürtler et al. 2013). 
4.3.8  Statistical analysis 
All data were compared using two-way repeated measures ANOVA (treatment x 
time). Where there were significant main effect differences for treatment or time, pre-
planned Student-Newman-Keuls post-hoc analysis were used to locate these differences. All 
data were analysed using Sigma Plot (version 3.1). Statistical significance was set at P < 0.05 
with data being represented as mean ± standard deviation (SD).  
4.4  Results 
4.4.1  Dietary Compliance 
Assessment of individual records revealed universal (100%) compliance with the 
dietary protocols. Cross-checked intakes of energy, CHO, protein and fat intakes were 
similar to the prescribed diets and there were no differences in nutrient intakes for each 
dietary protocol between intervention groups or between dietary protocols that were repeated 
within the same group (e.g. MOD diet, or pre-race diet) (Table 4.2). 
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Table 4.2: Dietary intake for each of the dietary standardisation protocols 
Nutrient Moderate CHO diet 
(n=72 days; 18 subjects 
x 2 days x 2 trials) 
CHO loading diet 
(n=36; 18 subjects 
x 2 days x 1 trial) 
Pre-race diet 
(n=54; 18 subjects 
x 3 trials) 
Post-race CHO 
restriction (n=18; 
18 subjects x 1 day) 
Energy (kJ·kg
-1
·d
-1
) 216 ± 2 317 ± 2 n/a n/a 
CHO (g·kg
-1
·d
-1
) 6.0 ± 0 12.0 ± 0 2.0 ± 0 0.9 ± 0.1 
Protein (g·kg
-1
·d
-1
) 2.0 ± 0 2.1 ± 0 n/a n/a 
Fat (g·kg
-1
·d
-1
) 2.0 ± 0 2.0 ± 0 n/a n/a 
Caffeine (serves) 1.3 ± 1.2 1.3 ± 1.2 0 0.3 ± 0.7 
  
 
4.4.2  Changes in Body Mass 
In weights obtained prior to the start of the TT portion of the PT (i.e. at rest), 
irrespective of the CHO diet, CR significantly increased BM compared to PLA (+1.54% vs 
+0.99% from baseline; P< 0.05). CR resulted in an increase in BM compare to PLA with 
both MOD (+1.13% vs +0.21%; P< 0.05) and LOAD (+2.49% vs +1.76%; P< 0.05) diets. 
Within the CR cohort, BM increased with LOAD above baseline (+1.49%; P< 0.001) and 
MOD (+1.36%; P< 0.001). Within the PLA group, BM was reduced below baseline when 
subjects consumed MOD (-0.78%; P<0.05) but increased above baseline when consuming 
LOAD (+1.54%; P< 0.001). LOAD also increased BM above MOD (+1.36%; P<0.05) in the 
PLA group. LOAD resulted in an overall increase in BM above both baseline (+1.12%; P< 
0.001) and MOD (+1.45%; P< 0.001) diets irrespective of CR/PLA treatments (Figure 
4.2A).  
In body mass obtained just prior to commencement of the hill climb portion of the 
PT, differences between CR and PLA groups were no longer significant (Figure 4.2B). 
Within the CR cohort, BM increased with LOAD above baseline (+1.49%; P< 0.001) and 
MOD (+1.34%; P< 0.001). Within the PLA group, BM increased with the LOAD diet above 
baseline (+0.72%; P< 0.05) and MOD (+1.40%; P<0.001) diets. LOAD resulted in an 
overall increase in BM above both baseline (+1.11; P< 0.001) and MOD (+1.37%; P< 0.001) 
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diets irrespective of CR/PLA treatments (Figure 4.2B). There was no significant difference 
in total weight lost between pre-TT and pre-hill climb weights (i.e. sweat loss) between the 
different trial dates or treatment interventions. 
4.4.3  Performance Trial Outcomes  
There were no differences in 120 km TT time or between treadmill cycling time to 
exhaustion between trials (CHO diets or supplement) (Table 4.3).  
4.4.4  Power Output and Aerobic Capacity 
There were no differences in mean power output or percentage of maximal aerobic 
power (MAP) between the supplemented cohorts or CHO diet interventions compared to 
baseline measures (Table 4.3). There was a significant treatment effect of creatine 
supplementation on overall 1 km (357 ± 72 vs 330 ± 45 W; P< 0.001) (Figure 4.3A) and 4 
km (294 ± 54 vs 279 ± 42 W; P< 0.01) (Figure 4.3B) sprint power compared to PLA with a 
significant effect of LOAD (P<0.01) observed on 1 km sprint efforts (Table 4.3).  Power 
generated during the 4 km (P<0.05) and 1 km (P<0.05) sprint bouts was significantly greater 
with CR than PLA across all sprint efforts (Table 4.3). An increase in MAP was observed 
with CR (P<0.05) above PLA across all PTs. Within the PLA cohort, greater power and 
MAP was achieved with both MOD (P< 0.05) and LOAD (P<0.05) significantly increasing 
above baseline (Table 4.3). Within the 1 km sprint efforts, LOAD improved MAP above 
baseline (P<0.05) during the final sprint effort in the PLA treated group (Figure 4.3C). 
Within the 4 km sprint efforts, CR with both MOD and LOAD significantly increased 
(P<0.05) MAP above baseline during the final sprint effort (Figure 4.3D). 
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Figure 4.2: Change in body mass between treatments. (A) Change in body mass relative to 
baseline measures for all dietary intervention groups prior to the commencement of the TT 
portion of the performance trial (i.e. prior to any exercise). (B) Change in body mass relative 
to baseline measures for all dietary intervention groups prior to the commencement of the 
hill climb portion of the performance trial. Values are expressed as percent change relative to 
baseline (dotted line) ± SD. * (P<0.05), ** (P<0.01), *** (P<0.001) denotes significant 
difference to baseline; # (P<0.05) denotes significant difference between supplement (PLA 
vs CR) under that CHO diet, % (P<0.001) denotes significant difference to CHO treatment 
(MOD vs LOAD) within the supplement. 
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Table 4.3: Summary of cycling time trial and treadmill performance associate measures. Time values are reported in hh:mm:ss.oo, power output is 
reported in watts (W), and maximal aerobic power (MAP) is reported in percentage (%). All values presented as a mean ± SD using two-way ANOVA 
analysis for supplement and CHO condition. * denotes significant difference (P<0.05) to placebo within the specified CHO intervention (i.e. creatine + 
baseline, MOD or LOAD compared to placebo baseline, MOD or LOAD, respectively).  † denotes significant difference (P<0.05) to baseline within 
the specified supplement s (i.e. within creatine/placebo MOD or LOAD to baseline only). 
 
 
Intervention 
 
 
120 km TT time 
(h:mm:ss.oo) 
 
 
Treadmill Time 
(h:mm:ss.oo) 
 
POWER 
Overall  
  
 
4 km Sprint  
  
 
1 km Sprint  
 
 
W 
 
% MAP 
 
W 
 
% MAP 
 
W 
 
% MAP 
Creatine          
 
Baseline 
 
3:09:40.96 ± 0:14:01.52 
 
0:05:04.15 ± 0:04:01.81 
 
238 ± 44.1 
 
60.3 ± 5.0 
 
289 ± 52.7* 
 
73.2 ± 8.6 
 
350 ± 66.9* 
 
89.1 ± 15.6* 
 
MOD 
 
3:12:33.94 ± 0:15:15.51 
 
0:06:00.25 ± 0:03:05.88 
 
232 ± 43.9 
 
58.9 ± 5.4 
 
295 ± 50.2* 
 
74.7 ± 8.8 
 
360 ± 72.7* 
 
90.9 ± 13.3* 
 
LOAD 
 
3:11:10.51 ± 0:17:36.33 
 
0:07:17.58 ± 0:04:59.17 
 
235 ± 48.6 
 
59.4 ± 6.1  
 
296 ± 60.5* 
 
74.7 ± 10.8 
 
360 ± 79.6* 
 
91.0 ± 16.1* 
Placebo          
 
Baseline 
 
3:11:33.71 ± 0:10:36.45 
 
 
0:05:00.78  ± 0:02:34.10 
 
224 ± 35.5 
 
58.6 ± 5.3 
 
278 ± 42.7 
 
72.7 ± 7.5 
 
318 ± 44.6 
 
83.4 ± 10.1 
 
MOD 
 
3:10:08.14 ± 0:10:49.02 
 
 
0:06:25.81  ± 0:03:07.85 
 
231 ± 35.1 
 
60. 2 ± 4.6 
 
277 ± 44.3 
 
72.4 ± 7.5 
 
336 ± 47.4 † 
 
88.4 ± 11.9 † 
 
LOAD 
 
3:11:32.18 ± 0:09:23.49 
 
0:06:35.29  ± 0:04:16.93 
 
227 ± 29.3 
 
59.6 ± 4.4 
 
282 ± 39.7 
 
73.8 ± 6.3 
 
337 ± 41.2 † 
 
88.7 ± 11.0 † 
Combined         
 
Baseline 
 
3:10:37.33 ± 0:12:06.11 
 
0:05:02.46 ± 0:03:16.71 
 
231 ± 39.4  
 
59.4 ± 5.1 
 
284 ± 48.1 
 
73.0 ± 8.0 
 
334 ± 58.9 
 
86.3 ± 13.4 
 
MOD 
 
3:11:21.04 ± 0:12:53.48 
 
 
0:06:13.03 ± 0:03:01.76 
 
 
231 ± 38.6 
 
 
59.6 ± 4.9 
 
 
286 ± 48.0 
 
73.6 ± 8.2 
 
348 ± 62.2 
 
89.7 ± 12.6 
 
LOAD 
 
3:11:21.35 ± 0:13:41.37 
 
 
0:06:56.44  ± 0:04:31.40 
 
231 ± 39.1 
 
59.5 ± 5.1 
 
289 ± 51.4 
 
74.3 ± 8.8 
 
349 ± 64.2 
 
89.8 ± 13.7 
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Figure 4.3: Power output during time trial sprint efforts. (A) 1 km and (B) 4 km sprint effort power output (W) between treatments and relative to 
baseline (C and D for 1 and 4 km sprints, respectively) Data are presented as mean ± SD using two-way ANOVA analysis for supplement and CHO 
condition. *** (P<0.001), ** (P<0.01) denote significant overall treatment effect between supplement groups (CR vs PLA only).  # (P<0.05) denotes 
significance relative to baseline at that specific sprint interval. 
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4.4.5  Rating of Perceived Exertion 
There was a significant interaction between CHO diets and supplementation on RPE 
(P<0.001). CR elicited a greater overall perceived exertion (16 vs 15; P<0.001) than PLA. 
There was also a significant difference in perceived exertion between LOAD and baseline 
(P< 0.001). LOAD decreased RPE (P<0.001) from baseline with CR. CR subjects reported 
significantly greater RPE when on both MOD (P< 0.001) and LOAD (P<0.001). 
4.4.6  Muscle Glycogen  
Muscle glycogen concentrations were significantly decreased (P< 0.05) following the 
first PT (―depleted‖; 264 ± 102 mmol·kg-1 dm) compared to baseline (584 ± 135 mmol·kg-1 
dm), MOD (579 ± 123 mmol·kg
-1
 dm) and LOAD (704 ± 111 mmol·kg
-1
 dm) irrespective of 
supplemented cohorts. The ingestion of LOAD resulted in greater muscle glycogen 
concentrations than baseline, depleted and MOD (P<0.05). There were no differences in 
glycogen contents between baseline and MOD. There were also no significant differences in 
muscle glycogen concentrations between CR and PLA conditions (Figure 4.4A).  
4.4.7  Muscle Creatine and ATP Concentrations 
CR supplementation resulted in a near significant increase in total Cr (P = 0.059) 
above placebo by Day 7 but this was not sustained by the maintenance dose at Day 14 
(Figure 4.4B). CR loaded subjects had a near significant increase in total Cr above PLA 
when CHO loaded (P = 0.053; Table 4.4). Subsequently, values for Total Cr and PCr at 
MOD and LOAD in the Cr group were higher than at baseline for the CR supplemented 
group, and higher than the placebo group, with a significant change from baseline observed 
in the CR loaded cohort when on the LOAD diet  (P <0.05; Table 4.4).   
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Figure 4.4: Analysis of muscle glycogen and total creatine. (A) Skeletal muscle glycogen 
concentrations at Baseline (CHO = 6 g∙kg-1 BM∙d-1), after PT1 (Depleted), and following 
Moderate CHO intake (6 g∙kg-1 BM∙d-1) and CHO Loading (12 g∙kg-1 BM∙d-1) in groups who 
took undertook Creatine loading or Placebo. Values are presented as a mean ± SD using two-
way ANOVA analysis for supplement and CHO condition. * denotes significant difference 
(P < 0.05) CHO treatment irrespective of supplement (Baseline, Depleted, MOD CHO or 
CHO LOAD). (B) Total creatine content in muscle at Baseline (Day 0), after PT1 (Day 1), 
creatine loading (5 d x 20 g∙d-1 and 2 d x 3 g∙d-1; Day 7) and creatine maintenance (5 more d 
x 3 g∙d-1; Day 14). Values are presented as a mean ± SD using two-way ANOVA analysis for 
supplement and CHO condition.  
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Table 4.4: Free and total creatine, phosphocreatine, and ATP data at Baseline and following moderate (MOD) CHO intake and CHO loaded (LOAD), 
noting that MOD and LOAD days were crossed over between Day 7 and Day 14. Values are presented as a mean ± SD using two-way ANOVA 
analysis for supplement and CHO condition. * denotes significant difference (P < 0.05) from baseline within supplement group (i.e. within CR or 
PLA), # denotes significant difference (P < 0.05) between supplement groups at the CHO intervention (i.e. CR vs PLA). 
 
 Placebo 
(n=9) 
   Creatine 
(n=9) 
  
 Baseline MOD LOAD  Baseline MOD LOAD 
Free Creatine 49.4 ± 8.4 48.7 ± 11.2 45.2 ± 11.5  50.5 ± 8.7 51.9 ± 8.5 50.3 ± 7.3 
Phosphocreatine 87.9 ± 7.2 84.3 ± 13.3 80.7 ± 10.8  83.7 ± 15.8 89.5 ± 10.0 95.4 ± 9.8 
Total Creatine 137.3 ± 11.4 133.0 ± 21.1 125.9 ± 18.3  134.3 ± 21.2 141.4 ± 17.1 144.1 ± 16.2 # * 
ATP 23.1 ± 1.9 23.1 ± 2.3 21.2 ± 2.4  22.9 ± 1.9 22.2 ± 2.1 21.9 ± 2.1 
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4.4.8  Protein Expression 
The expression of total mTOR significantly decreased following glycogen depletion 
compared to baseline (~30%; P< 0.05) (Figure 4.5A). No significant changes were observed 
with total AMPK, although a trend toward reduced expression was observed following 
glycogen depletion with CR relative to baseline (Figure 4.5B). No changes were observed in 
PGC-1α (Figure 4.5C) and SLC6A8 (Figure 4.5D) total protein expression.  
4.5  Discussion 
CHO loading is a common tactic utilised by endurance athletes as a means of 
increasing intramuscular glycogen stores with research indicating that creatine and CHO co-
ingestion can increase muscle glycogen storage which may enhanced endurance-based 
exercise tasks (Nelson et al. 2001, van Loon et al. 2004). The present study reports for the 
first time greater power output during repeated high intensity sprint efforts undertaken in the 
late-stages of a simulated 120 km TT when cyclists combined creatine and CHO loading. 
This response was independent of muscle glycogen concentrations and total mTOR 
expression. These outcomes suggest that creatine, when co-ingested with CHO, may have a 
beneficial effect on specific in-competition aspects of endurance cycling performance which 
mimicked the demands typical observed in multi-stage tours (i.e., multiple sprints and hill 
climbing) and typically results in glycogen depletion (Arkinstall et al. 2004).  The changes in 
power output observed during sprints are likely to have a major practical impact on the final 
outcome of a race, as both cycling and running events are often won by the athlete who can 
either stay with the leading pack during breakaways or sprint to the finish line in the latter 
stages of a race. Although a significant difference in overall performance times as a result of 
either creatine and/or CHO loading was not observed, an increase in BM as a result of these 
strategies did not negatively impact the weight-sensitive ―hill climbing‖ simulation included 
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at the end of the performance trial, suggesting that an avoidance of creatine use in endurance 
cycling may be unfounded. 
 
 
Figure 4.5: Expression of select signalling proteins prior to cycling performance trials and 
following glycogen depletion. (A) Total mechanistic target of rapamycin (mTOR), (B) total 
5‘adenosine monophosphate-activated protein kinase (AMPK), (C) total peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), and (D) SLC6A8 
creatine transporter protein in skeletal muscle taken prior to  time trials completed under 
baseline, glycogen depleted, moderate-CHO (MOD), or CHO-loaded (LOAD) diets with or 
without creatine supplementation. Images are representative blots and values are expressed 
relative to total protein and presented in arbitrary units ± SD (n=9 per supplement group).  * 
denotes significant difference (P<0.05) between CHO treatments (baseline, depleted, MOD 
or LOAD), irrespective of CR or PLA supplement. 
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The estimates of muscle creatine concentrations in this study suggest that the loading 
protocol was effective in increasing muscle creatine above baseline values; however, there is 
some uncertainty about the efficacy of the maintenance dose in sustaining these elevations in 
muscle creatine content.  This may be an artefact of the variability of the technique (biopsy 
sampling plus the co-efficient of variation of the creatine assays) or an indication that a 
creatine dose of 3 g·d
-1
 is insufficient, at least in the short period following high creatine 
doses, or maintaining such elevations (van Loon et al. 2003).  An inability to maintain 
elevated creatine concentrations may explain a lack of change in glycogen content between 
CR and PLA groups and furthermore be a factor contributing to a lack of change in 
performance times. Studies have showed that  creatine transporter activity can be 
regulated/enhanced by extracellular creatine concentrations (Loike et al. 1988) and the 
presence of insulin (Tomcik et al. 2016, Steenge et al. 1998). Little further difference 
between groups in terms SLC6A8 protein expression was observed; however, this is in line 
with previous studies on both short and long term creatine supplementation (0.125 g∙kg-1∙d-1 
either 2 or 4 months) which showed no change in SLC6A8 mRNA content when combined 
with a standardised cycle exercise program (Tarnopolsky et al. 2003). It is also possible that 
the exogenous loading dose downregulated endogenous creatine production to such a large 
extent that there was an undershoot in total muscle creatine in the phase immediately 
following the cessation of this dose (van Loon et al. 2003, Snow and Murphy 2001).  
Regardless, since the present study followed a protocol that is evidence-based and showed 
numerical increases in muscle creatine content at both loading (P = 0.059) and maintenance 
phases (LOAD day; P = 0.053), there is confidence that the creatine supplement group 
achieved muscle creatine content at both the MOD and LOAD performance trials that was 
functionally higher than in their baseline trial, and in comparison with the placebo group.  
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 Creatine‘s ergogenic benefits stem from its ability to act as a ―reservoir‖ for 
substrates which are required for the rapid regeneration of energy during brief periods of 
high intensity, maximal effort. In contrast to previous work which showed that creatine did 
not increase power output during short (200 m) sprint efforts during a 25.2 km cycling sprint 
trial (Levesque, Kenefick, and Quinn 2007), the present work reports that creatine loading 
increases power output during the late-stages of maximal sprint efforts performed during a 
120 km cycling time trial lasting ~3 h. Work by Vandebuerie  and colleagues  reported a 
~9% increase in power output in sprint efforts (5 x 10 s) of creatine loaded (25 g∙d-1 for 5 d) 
elite cyclists only after a 2.5 h TT cycling protocol (Vandebuerie et al. 1998). Oliver and 
colleagues  subsequently demonstrated that a creatine loading protocol (20 g∙d-1 for 6 d) 
further supplemented with glucose (15 g∙d-1) was able to reduce lactate concentrations during 
exercise but with no difference in maximal power output or total time to fatigue during 
incremental cycling (Oliver et al. 2013). This study is the first to show increased sprint 
power with creatine during the course of, rather than following, a prolonged endurance 
cycling bout.  Although the creatine and/or carbohydrate loading did not provide a detectable 
benefit to overall performance of the 120 km cycling time trial, this study noted that the 
increase in BM associated with the single and combined use of these strategies did not 
impair capacity for a weight-sensitive exercise element in the present cycling protocol.  This 
latter finding is of practical significance since many endurance athletes are disinclined to use 
creatine as an performance supplement due to fears that the associated BM gain will impair 
performance in events where power to mass ratios are important. 
While it is likely that the observed increase in power output is due to the ability of 
creatine to rapidly re-phosphorylate ATP for rapid energy generation, recent evidence 
indicates that this response may also be a result of decreased muscle glycogen utilization and 
muscle protein degradation (Tang, Chan, and Kuo 2013). Specifically, Tang and colleagues  
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observed consistent decreased lactate levels indicative of decreased muscle glycogenolysis in 
subjects supplemented with creatine (12 g∙d-1 for 15 d) following an endurance exercise 
session involving a 60 min run followed by 100 m sprint efforts (Tang, Chan, and Kuo 
2013). Lactate measures obtained from subjects after the sprint bouts tended to be lowered in 
the creatine loaded cohort (data not shown) which may suggest ―glycogen sparing‖ but direct 
measures would be needed to confirm such a notion. 
  Seminal work by Gollnick, Piehl, and Saltin (1974) observed selective glycogen 
depletion patters in human muscle fibres after varying intensities of exercise. Glycogen 
depletion dramatically increases ~2-7 time with increasing exercise intensities of ~60-85% 
VO2max (Gollnick, Piehl, and Saltin 1974). Type I fibres are the first to become depleted of 
glycogen at all workloads below VO2max with further depletion occurring in type II fibres 
as work continues (Gollnick, Piehl, and Saltin 1974). At workloads exceeding MAP 
however, initial depletion of glycogen occurs in both fibre types. Overall, there is a primary 
reliance on slow twitch fibres during submaximal endurance exercise with fast twitch fibres 
being recruited after slow twitch fibres are depleted.   The rate of glycogen resynthesis, 
which has a higher initial rate in slow twitch fibres, may attribute to fibre-type differences in 
glucose uptake and disposal (Casey et al. 1995). 
  In humans, while total creatine and phosphocreatine content has been shown to be 
greater in fast twitch muscle (Meyer, Brown, and Kushmerick 1985, Casey et al. 1996), 
creatine supplementation leads to higher expression of creatine transporter protein in slow 
twitch muscle fibres (Murphy et al. 2003). Willot et al. (1999) suggest that the rate of 
creatine loss from fast twitch fibres is lower than slow twitch fibres. Hence, although the rate 
of creatine entry into type II fibres is lower than type I, type II fibres have greater creatine 
content than type I (Willott et al. 1999) and are therefore able generate more explosive power 
during exercise. In the present study, mixed muscle glycogen concentrations were measured. 
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Muscle fibre composition, therefore, could contribute to variations between glycogen content 
and MAP. Furthermore, pacing strategies may have been adopted following baseline trials 
which may explain increased MAP with MOD and in the PLA group above baseline 
measures.  
The addition of CHO to a traditional creatine loading strategy (20 g∙d-1 for 3-5 d) has 
previously been reported to increase muscle glycogen stores (Nelson et al. 2001, van Loon et 
al. 2004). The basis for this response has centred around the idea that greater intracellular 
water retention is associated with increased creatine transport which subsequently increases 
cell volume, promoting a greater capacity for glycogen storage (Safdar et al. 2008, van Loon 
et al. 2004, Powers et al. 2003, Kreider et al. 1998, Ziegenfuss, Lowery, and Lemon 1998). 
Nelson and colleagues (2001) showed that subjects who consumed a moderate CHO (~6.6 
g∙kg-1 BM) diet following traditional creatine loading increased muscle glycogen content by 
53% above those  consuming high CHO alone (Nelson et al. 2001). Similarly, Van Loon and 
colleagues  demonstrated that 7 wk of prolonged creatine supplementation (20 g∙d-1 for 5 d 
followed by 6 wk of 2 g∙d-1) resulted in an 18% increase in muscle glycogen content (van 
Loon et al. 2004). Neither of these studies, however, involved any exercise modality to test 
the implications or benefits of elevated glycogen stores on training and performance. The 
present study showed that CHO-loading increased muscle glycogen by ~17% above baseline, 
but observed no further increase in muscle glycogen contents or performance time when 
CHO loading was combined with creatine loading. Previous studies had failed to observe a 
change in a  similar cycling protocol (100 km with 1 and 4-km sprint efforts) following 
carbohydrate loading alone, suggesting that CHO consumed during exercise, such the 
subjects of the present study did, offsets any detrimental performance on lower pre-exercise 
glycogen concentrations (Burke et al. 2000). This may further be explained by recent 
findings indicating that the optimal window for increasing glycogen stores using a 
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concomitant creatine and CHO supplementation strategy occurs within a narrow timeframe 
(Roberts et al. 2016). Roberts and colleagues  reported that 5 d of creatine supplementation 
(20 g∙d-1) and high CHO (37.5 kcal·kg-1 BM/d) intake following an exhaustive bout of 
exercise (70% VO2max) resulted in augmented muscle glycogen contents within 24 h (↑~82% 
compared to placebo) with no subsequent changes in glycogen contents observed between 
creatine and placebo cohorts (Roberts et al. 2016). These data, however, represent the potent 
effects of creatine and CHO loading on recovery rather than its effects on performance.  
Creatine induced a significant increase in BM compared to PLA, indicating that the 
current ingestion protocol promoted additional intra-cellular water storage. Cell swelling 
caused by creatine and CHO loading via the storage of additional water within the muscle 
cells has been associated with the upregulation of a large number of signalling markers 
involved in protein and glycogen synthesis (Kreider et al. 1998, Powers et al. 2003, 
Ziegenfuss, Lowery, and Lemon 1998, Safdar et al. 2008). It has been hypothesised that 
creatine-mediated cell swelling may further result in the increased expression of key proteins 
involved in hypertrophy-related signal transduction (Fry et al. 2010), namely mechanistic 
target of rapamycin (mTOR) (Loenneke et al. 2012). However, no studies have directly 
examined cell signalling responses when performing glycogen-depleting exercise (i.e. TT 
cycling/sprints to exhaustion) in concert with concomitant creatine and CHO loading.  
 Several lines of evidence indicate little involvement of creatine in myofibrillar and 
sarcoplasmic protein turnover both following resistance type exercise and at rest (Louis, 
Poortmans, Francaux, Berré, et al. 2003, Louis, Poortmans, Francaux, Hultman, et al. 2003). 
A decrease in total mTOR abundance in biopsies taken 18 h following a glycogen-depleting 
TT and exhaustive hill climb was observed in the current study. However, in contrast to the 
original hypothesis, mTOR expression was similar irrespective to whether participants were 
creatine and/or carbohydrate loaded (Figure 4.5). While this indicates creatine 
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supplementation exerts no further beneficial effect on mTOR signalling, this finding further 
supports the glycogen data between conditions by demonstrating creatine was unable to 
increase cell size through mTOR-mediated mechanisms to enhance glycogen storage 
capacity. mTOR has also been implicated in stimulating SLC6A8 creatine transporter via the 
serum and glucocorticoid-inducible kinase (SGK1) which is also involved in the regulation 
of cell volume and activity of various Na+/K+ carriers such as SLC6A8 (Shojaiefard, 
Christie, and Lang 2006). It is plausible that the decreased mTOR expression observed in 
this study attenuated activation of SGK1 resulting in submaximal transport of creatine into 
muscle and therefore negating any increase in cell volume and glycogen storage. 
Endurance athletes benefit from a greater mitochondrial capacity due to their 
increased requirement for available energy. The activation of 5‘adenosine monophosphate-
activated protein kinase (AMPK) monitors metabolic and energetic states in muscle which is 
affected by exercise stimuli (Winder 2001) and is furthermore modulated by the PCr:creatine 
ratio (Ponticos et al. 1998). The data from the present study showed no change in AMPK 
status despite observing a slight (~5%) drop in the PCr:creatine ratio following a glycogen 
depleting PT. Other studies have reported that muscle with augmented glycogen content 
tended to have lower resting levels of AMPK and were also less sensitive to activation in 
response to stimuli such as exercise (Richter et al. 2001, Wojtaszewski et al. 2002). A failure 
to detect changes in AMPK expression may be because subjects had adequate CHO (6 or 12  
g∙kg-1 BM CHO∙d-1) in their diet two days prior to the completion of the first (and 
subsequent) PT as well as the fact that they consumed 60 g∙h-1 of CHO during the ride itself. 
Furthermore, no change in PGC-1α, a signalling target of AMPK, was observed. A  
limitation to the present study was the time at which biopsies were taken which may have 
been too late to observe any changes in PGC-1α signalling as a result of nutrient or exercise 
interventions (Pilegaard et al. 2005). Future studies should investigate long-term creatine and 
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CHO loading strategies with muscle samples obtained both pre and immediately post bouts 
of exercise to further elucidate any beneficial adaptations.  
In summary, the present study presents novel data to demonstrate that the 
combination of creatine and CHO loading can increase power output during repeated high 
intensity sprint efforts undertaken during late stages of prolonged simulated time trial cycling 
which mimicked the physiological demands typically observed in multi-stage cycle tours 
(i.e., multiple sprints and hill climbing).  The increased power outputs were independent of 
muscle glycogen content. Even though creatine loading increased BM at the start of the 
performance trial, these differences became less significant over the course of the time trial 
and, despite being heavier, did not interfere with performance of the weight-sensitive part of 
the TT (the hill climb).  In fact, if anything, the performances were longer (better endurance) 
with the loaded conditions. As cycling and running events are often won by the athlete who 
can either stay with the leading pack during breakaways or sprint to the finish line in the 
latter stages of a race, it is likely that the higher power outputs observed during these late 
intense sprints would have a major impact on the final outcome of such races. 
 
 
 
 
 
 
 
  
  110 
 
 
  
  111 
 
CHAPTER 5: 
The in vitro Effects of Creatine and Insulin on Skeletal Myotubes Cultured 
in Different Glucose Concentrations  
 
 
This chapter is comprised of the following paper which has been submitted and is under 
review in the Journal of Nutritional Biochemistry. 
 
The in vitro Effects of Creatine and Insulin on Skeletal Myotubes Cultured in Different 
Glucose Concentrations 
 
Tomcik KA, Hawley JA, Lacham-Kaplan O. 
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Preface to Chapter Five  
Carbohydrate ingestion stimulates the release of insulin, which not only regulates 
both glucose and creatine uptake into muscle, but also induces anabolic signalling resulting 
in hypertrophy. Both creatine (Kreider et al. 1998, Powers et al. 2003, Ziegenfuss, Lowery, 
and Lemon 1998, Francaux and Poortmans 1999) and carbohydrate (Olsson and Saltin 
1970b, Baker and Jeukendrup 2014, Sherman et al. 1982) augment intracellular water 
retention, resulting in an increase in muscle cell size. Early studies by Low et al. (1996) first 
reported that osmotic swelling in rat myotubes modulates glycogen synthesis independent of 
changes in glucose uptake (Low, Rennie, and Taylor 1996). Short-term creatine 
supplementation, in vitro and in vivo, also alters cell osmolarity which upregulates signalling 
pathways associated with hypertrophy (Safdar et al. 2008, Deldicque et al. 2007). The 
majority of research investigating the metabolic effects of creatine has been undertaken in 
vivo. Few studies have tested the cellular effects of novel in vivo creatine supplementation 
strategies, such as those investigated in Chapter Four, using in vitro models to elucidate 
potential mechanistic changes as a result of dietary intervention. Therefore, to further 
investigate the interplay between creatine, carbohydrates (glucose) and insulin, cell culture 
models were implemented in the following studies.  
In general, muscle-specific primary cells (i.e. isolated directly from tissue) known as 
satellite cells are able to proliferate in growth medium for several days and differentiate into 
mono-nucleated muscle precursor cells known as myoblasts (Spurway and Wackerhage 
2006). Changes in the nutrient content of growth medium or external stimuli drive cell 
development toward terminal differentiation in which myoblasts fuse to become mature, 
multi-nucleated muscle fibres known as myotubes. Most primary cells can normally only 
divide a limited number of times before the ability to proliferate is lost. Some cell lines, 
known as immortalized cell lines, contain a genetic mutation which allows myoblasts to 
  114 
 
divide indefinitely. These secondary cells (i.e. derived, or passaged, from established 
primary cells) are able to be suspended in liquid nitrogen for extended time periods, thawed 
and used to initiate new cultures, thus requiring no further muscle samples to be obtained 
(Spurway and Wackerhage 2006). Each passage of these cells results in a genetically 
homogeneous population that allows for controlled testing of various conditions or 
treatments in growth medium using a number of biological techniques. 
A number of different cell lines have been validated for use in investigating skeletal 
muscle growth and regeneration, with C2C12 and L6 muscle cells being the most widely 
utilized immortalized skeletal muscle cell lines. Mouse-derived C2C12  and rat-derived L6 
cells display a number of characteristics analogous to differentiated skeletal muscle (Pittner 
et al. 1996). Both cell types are able to fuse to form multinucleated myotubes which are 
subsequently able to express key metabolic enzymes, including creatine kinase, myokinase 
and a number of glycogen-metabolizing enzymes (Yaffe 1968, Shainberg, Yagil, and Yaffe 
1971, Kubo 1991). 
Derived from mouse satellite cells, C2C12 cells differentiate rapidly upon serum 
removal and form contractile myotubes (formation appearing within 3-5 d) which produce 
characteristic muscle proteins (Burattini et al. 2004). Undifferentiated C2C12 cells are flat, 
star-shaped mono-nucleated cells which become elongated once they are ready to fuse with 
other activated cells to form young myotubes which mature during culture (Burattini et al. 
2004). Mature C2C12 myotubes express sarcomeric and filamentous actin as well as skeletal 
myosin (Kataoka et al. 2003), the main components of contractile function (Salamon et al. 
2003). Hence, C2C12 cells appear to be better suited for studies of contractile ability as a 
result of better sarcomere development during differentiation (Nedachi, Fujita, and Kanzaki 
2008).   
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Rat-derived L6 cells are also able to undergo a high degree of differentiation to 
myotubes.  The L6 line naturally expresses GLUT4 glucose transporter protein and, as such, 
exhibit a significant insulin-stimulated glucose uptake response. Compared to C2C12 cells, 
L6 cells also contain a higher ratio of GLUT1:GLUT4, making them an excellent model for 
testing glucose transport and the mechanisms associated with the progression of diabetes 
(Sarabia et al. 1992). The major limitation when using cells to identify distinct stages of 
growth and development is the alteration of growth characteristics over time. Both L6 and 
C2C12 cell lines decrease their proliferation rate and ability to form myotubes the more they 
are subcultured (i.e. phenotype drift) (Table 5.1) Therefore, the cells used in the present 
study were limited to passages 3-5.  
C2C12 cells have previously been used to investigate the role of creatine on 
differentiation (Deldicque et al. 2007, Sestili et al. 2009), identify the osmotic effects of 
creatine supplementation on creatine transport (Alfieri et al. 2006), elucidate the role of 
insulin on cell proliferation and differentiation (Xiong et al. 2013) and to expound upon the 
effects of extracellular glucose and the role of insulin in promoting transport and signalling 
alterations (Nedachi et al. 2008, Sumitani et al. 2002). Thus, the C2C12 cell line provides a 
simple and effective platform for further examination of creatine‘s interaction with other 
substrates. The work presented in Chapter Five determined the magnitude by which creatine, 
insulin and glucose, independently or combined, affect muscle morphology and hypertrophy 
signalling.  
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Table 5.1: Select differences between L6 and C2C12 cell lines 
 
Study Cell Line 
 
 L6 C2C12 
Kubo 1991 Display infrequent ATP 
response 
ATP response  shown  before 
differentiation induction; lost 
after differentiation 
 
 Partial fibronectin expression Intense fibronectin expression pre 
differentiation 
 
   
Sarabia et al. 1992 Normally expresses GLUT4 
glucose transporter protein 
 
 
 Higher ratio of GLUT1/GLUT4 
transporters 
 
Detectable levels of GLUT 1 
   
Portier et al. 1999 Creatine kinase MM already 
near maximum expression in 
myoblast stage 
Higher % of creatine kinase-
muscle isoenzyme with 
differentiation 
 
  Greater creatine kinase activity1 
 
 5 fold increase in acetylcholine 
receptor  
9 fold increase in acetylcholine 
receptor 
 
  Forms a continuous basement 
membrane  
 
   
Nedachi et al. 2008  Better sarcomere development 
 
  Greater contractile activity 
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5.1  Abstract 
Introduction 
Muscle cell proliferation, differentiation and size are augmented by creatine and 
glucose availability with substrate transport mediated by insulin. The present study aimed to 
determine the magnitude by which creatine, insulin and glucose, independently or combined, 
affect muscle growth.  
Methods 
C2C12 myotubes were cultured in low (1g·L
-1
; LG) or high (4.5 g·L
-1
; HG) glucose 
DMEM supplemented with 0.5 mM creatine (CR), CR + 100 nM INS (CR+INS) or INS 
alone for 2 wk. Myotube size (i.e. diameter), fusion and expression of putative signalling 
proteins associated with muscle growth were measured following 1 and 2 wk.  
Results 
Myotube size was highest in HG cultures compared to baseline at 1 wk (P < 0.001). 
Only HG+CR potentiated myotube growth (1.2 to 1.5 fold change from 1 to 2 wk, 
respectively; P < 0.001). Myosin Heavy Chain (MHC) expression increased under both LG 
and HG concentrations with CR+INS (10 and 6 fold increase, respectively; P < 0.001) by 2 
wk. Differences in MHC expression correlated with p38 MAPK expression but not mTOR, 
p70S6K or 4E-BP1.  
Conclusion 
Creatine‘s anabolic role in vitro is more dependent on the prevailing insulin than 
glucose concentration. Creatine treatment resulted in larger myotubes, while insulin 
treatment resulted in small size myotubes but increased MHC protein expression, which may 
be a result of upregulation of the p38 MAPK pathway. 
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5.2  Introduction 
The development of skeletal muscle involves the exit of satellite cells, the progenitors 
for skeletal myotube formation, from the cell cycle into the myogenic differentiation 
pathway (Dumont, Wang, and Rudnicki 2015). Both dietary creatine and glucose availability 
have been associated with satellite cell proliferation and differentiation, protein synthesis and 
DNA replication and repair (Juhn and Tarnopolsky 1998b, Safdar et al. 2008, Collins et al. 
2009). Creatine acts as an ‗anabolic agent‘ which can directly increase the expression of key 
intermediates involved in protein synthesis, such as myosin heavy chain (MHC) and 
mechanistic target of rapamycin (mTOR) both in vivo and in vitro (Loenneke et al. 2012, 
Deldicque et al. 2007).  
Creatine‘s effects on cell signalling (Deldicque et al. 2008) and muscle fibre 
adaptations (Volek et al. 1999) have largely been studied in vivo and concomitant with 
resistance exercise. Few investigations have examined the nutrient-specific effects of 
creatine on mature myotubes in vitro and the potential mechanisms associated with the 
greater creatine-induced muscle accretion. Furthermore, insulin, which activates signalling 
pathways that stimulate glucose and creatine uptake (Odoom, Kemp, and Radda 1996, 
Steenge et al. 1998, Elkalaf, Anděl, and Trnka 2013, Tomcik et al. 2016), has also been 
associated with the proliferation and differentiation of skeletal muscle cells (Ball and Sanwal 
1980, Kumegawa et al. 1980). Investigations into the effects of creatine and insulin on 
skeletal muscle proliferation and differentiation have been undertaken over short-term 
treatment periods (hours to days) (Tsuka et al. 2015). Furthermore, there is presently a lack 
of insight on the treatment of already established myotubes, a model which more closely 
resembles in vivo skeletal muscle fibres.  
The present study determined the effects of creatine and insulin treatments with 
varying glucose concentrations on established myotube morphology and putative cellular 
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signalling responses associated with myogenic growth. It was hypothesised that a 2 wk 
treatment with creatine and insulin combined with high glucose culture medium would result 
in increased myotube size compared to creatine treatment alone. Furthermore, this would be 
reflected in the upregulation of putative signaling proteins associated with hypertrophy. 
5.3  Methods 
5.3.1  Cell Culture 
C2C12 murine satellite cells (LONZA, Mount Waverley, VIC, AUS) were cultured 
on 2% gelatine- (Life Technologies, Mulgrave, VIC, AUS) coated T-75 flasks (Thermo 
Fisher, Scoresby, VIC, AUS) in 4.5 g·L
-1
 glucose Dulbecco‘s Modified Eagle Medium 
(DMEM; Life Technologies) supplemented with 10% foetal bovine serum (FBS; Life 
Technologies) and 0.5% penicillin/streptomycin (PenStrep; Life Technologies) and 
maintained at 37°C in a humidified incubator at 5% CO2.  
At 70-90% confluence cultures were treated with serum free trypsin-EDTA (Life 
Technologies) at 37°C for 3-5 min before DMEM + 10% FBS were added to stop the 
reaction. Dissociated cells were collected and spun down (3 min at 3,000 rpm), resuspended 
in proliferation medium composed of DMEM + 10% FBS and seeded onto gelatine-coated 6-
well culture dishes (Thermo Fisher) at a density of 10,000 cells/mL. At 70% confluence, the 
proliferation medium was replaced with differentiation medium composed of 4.5 g·L
-1
 
glucose DMEM + 2% horse serum (HS; Sigma Aldrich, Castle Hill, NSW, Australia) and 
PenStrep for 168 h to allow myotube formation. Differentiation solution was replaced every 
48 h. At 168 h (―baseline‖), differentiation medium was replaced with either 1 g·L-1 glucose 
(―low‖; LG) or 4.5 g·L-1 glucose (―high‖; HG) DMEM containing 2% HS and 0.5% 
PenStrep supplemented with either 0.5 mM creatine (CR; Sigma Aldrich), 100 nM insulin 
(INS; Sigma Aldrich) or 0.5 mM CR + 100 nM INS (CR+INS) for an additional 2 wk. In 
total 8 groups were established: control no treatment (NT) creatine treatment (CR), insulin 
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treatment (INS) and creatine + insulin treatment (CR+INS) in either LG or HG 
concentrations. Treatment medium was changed every 24 h for the following 2 wk.  
5.3.2  Myotube Size and Fusion Index 
Myotubes were measured at baseline, 1 and 2 wk from treatment using the AVOS 
imaging system (Life Technologies). Pictographs were taken under 10x magnification (400 
µm scale) with 5 image fields (one in the centre of the well and four others around the 
centre) taken from each treatment at baseline, 1 and 2 wk of culture time. Images were taken 
from the same culture wells at each of the time points. A total of 10 myotubes per field were 
chosen at random with myotube width measured in µm at the centre of each myotube (total 
of 50 myotubes per treatment per time point). This was carried out in two separate biological 
replicate experiments. Measurements at 1 and 2 wk were normalized to the average size at 
baseline. 
Based on the myotube diameter results, the present study examined the number of 
fused nuclei to myotubes treated with CR and CR+INS in HG cultures using 
immunofluorescence methods as  detailed previously (Saiti and Lacham-Kaplan 2007). 
Cultures were fixed and incubated with anti-mouse Desmin. Following a series of washes in 
phosphate buffer (Life Technologies), cultures were incubated with anti-mouse-GFP 
secondary antibody. Stained cultures were visualized under the AVOS imaging system 
following co-staining with DAPI for nuclear staining. Antibodies and DAPI were purchased 
from Life Technologies. A total of 20 myotubes were randomly selected from four 
microscopic fields from two repeats and the number of nuclei within each myotube was 
recorded.  
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5.3.3  SDS-PAGE and Immunoblotting Analysis 
Cultures were rinsed twice with 1X PBS (Life Technologies) before 1x cell lysis 
buffer (Cell Signalling Technology, Danvers, MA) supplemented with 1 mM PMSF was 
added to cultures. To ensure cell lysis, cells were collected and passed through an 18-gauge 
needle 10 times. Samples were centrifuged at 13,000 rpm for 10 min at 4ºC and the 
supernatant collected for total protein analyses using a BCA protein assay (Pierce, Rockford, 
IL, USA).  Western blotting was carried out as previously described (Tomcik et al. 2016). 
Briefly, lysates were re-suspended in Laemmli sample buffer, separated by SDS-PAGE, and 
transferred to polyvinylidine fluoride membranes blocked with 5% non-fat milk, washed 
with 10 mM Tris·HCl, 100 mM NaCl, and 0.02% Tween 20, and incubated with primary 
antibody (1:1,000) overnight at 4°C. Membranes were incubated with secondary antibody 
(1:2,000), and proteins were detected via enhanced chemiluminescence (Amersham 
Biosciences, Buckinghamshire, UK; Pierce Biotechnology) and quantified by densitometry 
(Chemidoc, BioRad, Gladesville, Australia). For all proteins, volume density of each target 
band was normalized to the total protein loaded into each lane using stain-free technology 
(Gürtler et al. 2013). Each treatment was run on the same gel according to time point. 
 The total and phosphorylated forms of the following proteins with putative roles in 
muscle growth were determined: mechanistic target of rapamycin (mTOR), ribosomal 
protein S6 kinase beta-1 (p70S6K), protein kinase B (AKT) and eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1).  Additionally, Solute Carrier Family 6 
Member 8 (SLC6A8) creatine transporter, Myosin Heavy Chain (MHC), and the total and 
phosphorylated form of the osmotic stress related p38 mitogen-activated protein kinase (p38 
MAPK) were measured. Antibodies against p-mTOR
Ser2448
 (no. 2971), total mTOR (no. 
2972), p-p70S6K
Thr389 
  (no. 9205), total p70S6K (no. 9202), p-AKT
Thr308
 (no. 9275), total 
AKT (no. 9272), p-4E-BP1
Thr37/46
 (no. 2855) and total 4E-BP1 (no. 2452), p-
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p38MAPK
Th180/Ty182 
(no. 9211) and total p38 MAPK (no. 9212) were obtained from Cell 
Signaling Technology (Danvers, MA, USA). MHC antibody (no. PA5-31466) was obtained 
from Life Technologies. SLC6A8 antibody (no. AV42248) was obtained from Sigma-
Aldrich (St. Louis, MO, USA).  
5.3.4  Statistical Analysis 
Data were analysed using two-way repeated measures ANOVA (treatment x time) 
and student t-test for paired analyses. Where there were significant main effect differences 
for treatment or time, pre-planned LSD Fisher post-hoc analysis was used to locate these 
differences. All data were analysed using Sigma Plot (version 3.1). Statistical significance 
was set at P < 0.05 with data being represented as mean ± standard error of the mean (SEM).  
5.4  Results 
5.4.1  Cultures 
Myotubes began forming in all groups at 72 h post-differentiation with fully 
differentiated myotubes present by 168 h. Myotubes became gradually more crowded over 
time with the greatest qualitative density observed in CR+INS and INS alone in HG cultures 
(Figure 5.1A). Myotubes in cultures that contained only CR were less crowded at 1 and 2 wk 
for both LG and HG concentrations (Figure 5.1A and 5.1B). Branching of myotubes was 
qualitatively more prevalent in CR+INS treated cultures in HG (Figure 5.1C) and to a lesser 
degree in LG concentrations. Also, more incidences of contracting myotubes were observed 
in cultures treated with CR+INS in HG concentrations.  
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Figure 5.1: Representative myotube culture images at baseline, 1 week and 2 weeks of treatment. Differentiated cells were treated with (A) low  (LG) 
or (B) high glucose (HG) no-treatment groups (NT) supplemented with creatine (CR), creatine and insulin (CR+INS), or insulin (INS) for up to 2 
weeks. (C) Myotube branching in CR+INS culture treatment (x10 magnification; Scale bar = 400 µm).  
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5.4.2  Myotube Size 
There was a significant interaction between treatment and time for myotube size (P < 
0.001). When comparing treatments within the same glucose concentration, the relative size 
of myotubes cultured with LG showed no change in size except for CR+INS which had the 
greatest myotube diameter at 1 wk compared to baseline and 2 wk (P < 0.05; Figure 5.2A). 
There was a significant difference in myotube size with time in all HG treated cultures by 1 
wk compared to baseline (P < 0.001). Significant differences in size were observed between 
1 and 2 wk with CR, CR+INS and INS treatments (P < 0.05) with only CR-treated myotubes 
increasing in size from 1 to 2 wk (from 1 to 1.5 fold; P < 0.001; Figure 5.2A). Myotube size 
shifted with time from small (<20 µm) to mid-range (20-40 µm) and large (> 40 µm) in all 
groups except for those treated with INS.  The greatest proportion of large myotubes was 
observed with CR at 2 wk in HG concentrations (40%) concomitant with a decrease in the 
small size tubes (3%) rather than the mid-range sized tubes (57%; Figure 5.2B).  
5.4.3  Fusion Index 
Nuclei in mature myotubes were observed to be either aligned in a row or clumped in 
groups within myotubes. The latter was more typical in larger CR-treated myotubes (Figure 
3A). The former was more frequently observed in the thinner CR+INS and INS-treated 
myotubes (Figure 5.3B) with both LG and HG culture concentrations.  
To identify if differences in myotube size were associated with the number of 
myonuclei within myotubes, the fusion index of myotubes treated with CR and CR+INS in 
HG cultures was compared. The fusion index (nuclei per myotube) was higher but not 
significantly different for myotubes treated with CR+INS compared to CR (23 ± 2 vs 17 ± 2 
nuclei/myotube; P = 0.06; Figure 5.3C). 
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Figure 5.2:  Myotube size following treatments with low (LG) or high (HG) glucose 
medium supplemented with creatine (CR), creatine and insulin (CR+INS) and insulin (INS) 
for 2 weeks. Myotube size was obtained from 10 randomly selected myotubes from each of 5 
microscopic fields per time point (n=50) in 3 separate repeats. (A) Fold change in myotube 
size relative to baseline(―1‖) ± SEM. (B) Relative distribution of myotubes by size; <20 µm, 
20-40 µm >40 µm. The proportion of myotubes in each size category is a percentile from the 
total tubes measured in the field at one time point of each treatment. *,**, *** = Difference 
(P < 0.05, 0.01 and 0.001, respectively) compared to baseline. %, #, $ = Difference (P < 0.05, 
0.01 and 0.001, respectively) between glucose treatment (LG vs HG) within treatment 
condition in similar weeks.  a, b, c, d = Difference (P < 0.05) between treatment conditions 
within glucose conditions in similar weeks,  where a: no treatment (NT), b: CR, c: CR+INS, 
d: INS. † = Difference (P < 0.05) between time points (1 wk vs 2 wk) within similar 
treatment and glucose conditions.  
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Figure 5.3: Multi-nucleated myotubes cultured with high glucose (4.5 g/L; HG) medium supplemented with (A) creatine (CR) and (B) creatine and 
insulin (CR+INS)  after 2 weeks (x20 magnification; scale bar = 200 µm).  (C) Fusion index calculated as the mean number of nuclei (stained blue 
with DAPI) within myotube boarders (stained green with Desmin) throughout the image ± SEM (n = 20 images).  
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5.4.4  Protein Expression 
The representative blots of the total and phosphorylated forms of the following hypertrophy 
associated proteins are presented in Figure 5.4. 
 
 
 
 
 
Figure 5.4: Representative Blots for SLC6A8, MHC, and total and phosphorylated 
signalling protein expression in response to treatments at baseline, 1 and 2 wk. Lane numbers 
correspond to 1) Baseline; 2) LG; 3) LG+CR; 4) LG+CR+INS; 5) LG+INS; 6) HG; 7) 
HG+CR; 8) HG+CR+INS; 9) HG+INS. The same baseline was measured for each blot at 1 
and 2wk for each respective protein.  
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SLC6A8 
There was no significant effect of treatment or time on the relative expression of SLC6A8 in 
either LG or HG cultures; although an increase of SLC6A8 protein content was identified in 
all treatment groups by 1 and 2 wk of culture (Figure 5.5A). 
MHC 
MHC levels were significantly affected by treatment as well as time with a 
significant interaction effect observed for both LG and HG concentrations (P < 0.001). 
Treatment with CR+INS in LG cultures resulted in significantly greater levels of MHC 
compared to NT and all other treatment groups at both 1 and 2 wk (8-10 fold increase; P < 
0.01-0.001; Figure 5.5B). Within 2 wk, cultures treated with CR+INS in HG had 
significantly greater MHC expression compared to CR and INS alone (6 fold increase; P < 
0.05-0.001; Figure 5.5B) with a significant increase from 1 to 2 wk observed (P < 0.05). 
Cultures treated with CR, CR+INS and INS in LG had significantly higher levels of MHC 
than their HG counterpart at 1 and 2 wk (P < 0.05-0.001; Figure 5.5B).  
mTOR  
There was a strong interaction effect between treatment and time with regard to 
relative levels of total mTOR (P < 0.01). Time alone, however, was not an effector of mTOR 
levels within either LG or HG conditions. In LG treated cultures, levels of mTOR increased 
above baseline and NT with all treatment groups at 1 wk and with CR+INS and INS at 2 wk 
(1-3 fold change; P < 0.05-0.001; Figure 5.5C). There was a significant difference between 1 
and 2 wk with CR and CR+INS-treated groups cultured in LG (P < 0.05; Figure 5A). LG 
treated groups increased significantly with CR, CR+INS, and INS at 1 wk and CR+INS and 
INS at 2 wk above their respective HG counterparts (P < 0.001). Increased expression of 
phosphorylated mTOR was observed with all treatments by 2 wk (Figure 5.5D).  
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Figure 5.5: (A) SLC6A8 creatine transporter, (B) Myosin Heavy Chain (MHC), (C) total 
mTOR and (D) phospho-mTOR
Ser2448
 
46
protein expression following  1 and 2 wk treatment 
with low (LG) or high glucose (HG) only (NT) supplemented with creatine (CR), creatine 
and insulin (CR+INS) , and insulin (INS). Values are expressed as total protein determined 
by stain-free technology relative to baseline and presented in arbitrary units (AU) as the 
mean ± SEM (n=3 biological repeats). *,**, *** = Difference (P < 0.05, 0.01 and 0.001, 
respectively) compared to baseline. %, #, $ = Difference (P < 0.05, 0.01 and 0.001, 
respectively) between glucose treatment (LG vs HG) within treatment condition in similar 
weeks.  a, b, c, d = Difference (P < 0.05) between treatment conditions within glucose 
conditions in similar weeks,  where a: no treatment (NT), b: CR, c: CR+INS, d: INS. † = 
Difference (P < 0.05) between time points (1 wk vs 2 wk) within similar treatment and 
glucose conditions.  
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AKT  
There was a significant interaction between treatment and time for AKT expression 
(P < 0.05). No changes between treatments were observed with LG.  Within HG treated 
cultures, the highest AKT expression was observed in those treated with CR+INS at 1 wk (4 
fold increase; P < 0.05; Figure 5.6A). CR and CR+INS treatments increased AKT levels 
above baseline at 2 wk (3 fold increase; P < 0.05; Figure 5.6A). HG cultures treated with CR 
and CR+INS had greater AKT expression than their LG counterpart at 1 and 2 wk (P < 0.05-
0.001). As with phosphorylated mTOR, increased phosphorylated AKT expression was 
observed with all treatments by 2 wk (Figure 5.6B). 
p70S6K  
  A significant interaction effect between treatment and time was observed with 
p70S6K expression (P < 0.001). Within LG cultures, CR+INS and INS treatments resulted in 
greater expression at 2 wk compared to their HG counterpart (P < 0.05- 0.001; Figure 5.6C). 
At 2 wk, CR treated cultures in HG had significantly higher AKT expression than all other 
treatment groups (1.7 fold increase; P < 0.01-0.001; Figure 5.6C). By 2 wk, phosphorylated 
p70S6K expression increased in all treatment groups (Figure 5.6D). 
4E-BP1  
LG cultures with CR+INS and HG cultures treated with INS showed significantly 
greater 4E-BP1 expression above baseline 1 wk (1.5-2 fold increase; P < 0.05; Figure 5.6E)  
CR and CR+INS treated groups had a significantly higher expression of phosphorylated 4E-
BP1 than baseline at 1 wk (1.2-1.7 fold increase; P < 0.01 Figure 5.6F). INS treated groups 
in LG at 1 wk expressed significantly greater phosphorylated 4E-BP1 compared to its HG 
counterpart (P < 0.05). 
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Figure 5.6: (A) Total AKT, (B) phospho-AKT
Thr308
, (C) Total p70S6K, (D) phospho-
p70S6K
Thr389
, (E) Total 4E-BP1 and (F) phospho-4E-BP1
Thr37/46
protein expression following  
1 and 2 wk treatment with low (LG) or high glucose (HG) only (NT) supplemented with 
creatine (CR), creatine and insulin (CR+INS) , and insulin (INS). Values are expressed as 
total protein determined by stain-free technology relative to baseline and presented in 
arbitrary units (AU) as the mean ± SEM (n=3 biological repeats). *,**, *** = Difference (P < 
0.05, 0.01 and 0.001, respectively) compared to baseline. %, #, $ = Difference (P < 0.05, 
0.01 and 0.001, respectively) between glucose treatment (LG vs HG) within treatment 
condition in similar weeks.  a, b, c, d = Difference (P < 0.05) between treatment conditions 
within glucose conditions in similar weeks,  where a: no treatment (NT), b: CR, c: CR+INS, 
d: INS. † = Difference (P < 0.05) between time points (1 wk vs 2 wk) within similar 
treatment and glucose conditions.  
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p38 MAPK  
Differences in p38 MAPK  between 1 and 2 wk time points were found with LG 
+INS and HG+CR treated group (P < 0.05-0.01) with levels at 2 wk being significantly 
higher than baseline or 1wk for both groups (1.3 and 2 fold  increases with LG +INS and 
HG+CR, respectively; P < 0.01-0.001; Figure 5.7A). In HG cultures, CR treatment had 
higher levels of p38 MAPK than the INS+CR and INS treated cultures at 2 wk (P < 0.05-
0.001). HG cultures with CR treatment had significantly higher expression than their LG 
counterparts at 2 wk (P < 0.01; Figure 5.7A). Phosphorylated p38 MAPK levels increased by 
1 wk with all treatment groups with HG+CR treatment significantly higher than baseline 
levels (2.5 fold increase; P < 0.01). 
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Figure 5.7: (A) Total p38 MAPK  and  (B) phospho-p38 MAPK
Th180/Ty182
 
46
protein 
expression following  1 and 2 wk treatment with low (LG) or high glucose (HG) only (NT) 
supplemented with creatine (CR), creatine and insulin (CR+INS) , and insulin (INS). Values 
are expressed as total protein determined by stain-free technology relative to baseline and 
presented in arbitrary units (AU) as the mean ± SEM (n=3 biological repeats). *,**, *** = 
Difference (P < 0.05, 0.01 and 0.001, respectively) compared to baseline. %, #, $ = 
Difference (P < 0.05, 0.01 and 0.001, respectively) between glucose treatment (LG vs HG) 
within treatment condition in similar weeks.  a, b, c, d = Difference (P < 0.05) between 
treatment conditions within glucose conditions in similar weeks,  where a: no treatment 
(NT), b: CR, c: CR+INS, d: INS. † = Difference (P < 0.05) between time points (1 wk vs 2 
wk) within similar treatment and glucose conditions.  
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5.5  Discussion 
In vivo, the uptake and transport of creatine into muscle cells is augmented via the co-
ingestion of carbohydrates, which is mediated, in part, by the effect of insulin on the 
SLC6A8 creatine transporter. However, the direct in vitro effect(s) of creatine and insulin 
treatment on established myotubes has not been characterised. The results of the present 
study demonstrate that morphological differences in size and myofibrillar protein content are 
indeed observed in C2C12 myotubes cultured with creatine and/or insulin which are also 
determined by glucose concentration. Larger myotubes developed when cultures are 
supplemented with creatine in higher glucose concentrations. MHC was upregulated when 
cultures were supplemented with either creatine or insulin more pronounced in low glucose 
concentrations.  These findings suggest that this increase in MHC protein content in 
myotubes may not be regulated by the conventional anabolic pathway, which involves 
mTOR and its downstream substrates, but rather is mediated via p38 MAPK signalling and is 
largely independent of glucose concentrations. 
New skeletal muscle formation is a complex and highly regulated process that 
involves the proliferation of myoblasts and subsequent differentiation to multinucleated 
myotubes (Grabiec et al. 2014). The regulation of muscle size is crucial for the maintenance 
of homeostasis as well as proper skeletal muscle growth and development. Satellite cells are 
the primary contributors to muscle growth via the provision of myonuclei for the production 
of new or repair of existing muscle (Wang and Rudnicki 2012). Previous work has 
demonstrated that an increase in muscle size is not only associated with, but is also 
dependent on the addition of myonuclei to existing muscle fibres, with particular emphasis 
on muscle greater than 25% (Petrella et al. 2006).  
In vivo, co-supplementation of creatine and carbohydrates synergistically enhances 
substrate storage capacity as a consequence of greater water retention and subsequently 
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augmented cell size (Green, Hultman, et al. 1996, van Loon et al. 2004). The addition of 
creatine to a high glucose medium promoted a further increase in myotube size after 2 wk, 
commensurate with a greater percentage of large myotubes, which aligns with the results of 
in vivo investigations. High glucose DMEM is known to have ―anabolic‖ effects and thus is 
commonly recommended for use in C2C12 culture medium for muscle engineering in vitro 
(Khodabukus and Baar 2015). The present study observed that myotubes treated with low 
glucose concentrations maintained their size after one week.  
Previous in vitro as well as in vivo studies have identified creatine‘s ability to 
augment the number of activated satellite cells suggesting that this may lead to greater 
number of proliferating and differentiating cells (Vierck et al. 2003, Olsen et al. 2006, 
Dangott, Schultz, and Mozdziak 2000, Deldicque et al. 2007). The present findings indicate 
that in vitro, creatine‘s ability to enhance fusion to form new tubes is augmented by insulin 
leading to cultures which are highly crowded with thinner myotubes (Figure 5.1A). The 
current study identified two different modes of myonuclei distribution within the myotubes, 
rows and groups (Figure 5.3A). Thin myotubes, which were more likely to appear in in INS 
treated cultures had a greater propensity to have a row-type distribution and also presented a 
higher fusion index than myotubes formed in cultures treated only with creatine. The latter 
were more likely to have groups of myonuclei concentrated in one area of the myotube. The 
distinctive difference in myonuclei distribution in relation to culture conditions and its 
implications on muscle regeneration warrants further investigation. Furthermore, this 
investigation also recognised branching myotubes mainly within CR+INS treated cultures in 
both high and low glucose concentrations. Branching of myofibres can occur via the 
generation of a new myofibre segment fusing to an existing myofibre or by splitting one 
myofibre in two (Faber et al. 2014). The activation of satellite cells has been thought to cause 
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branching in myofibres via the fusion to pre-existing fibres in a non-linear pattern and may 
explain these observations (Anderson 2000).  
Creatine accumulation in skeletal muscle is enhanced via carbohydrate-driven insulin 
secretion and its direct effect on SLC6A8 creatine transporter (Steenge et al. 1998, Steenge, 
Simpson, and Greenhaff 2000, Odoom, Kemp, and Radda 1996). Insulin regulates creatine 
transport into skeletal muscle via the SLC6A8 creatine transporter. Odoom and colleagues 
(1996) observed a two-fold increase in intracellular creatine content as a result of insulin 
treatment in cultured myotubes (Odoom, Kemp, and Radda 1996). This observation was 
confirmed in humans with varying infusion rates of insulin concomitant with creatine 
consumption (Steenge et al. 1998). In the present study, long-term cultures showed a 
consistent level of the transporter at both time points regardless of creatine being present 
suggesting that expression occurs as an outcome of culture conditions. As the primary aim of 
was to measure prolonged treatment effects on myotube size, a limitation of the present 
study was the inability to concomitantly measure intracellular creatine content. While such 
analysis was beyond the scope of the study, the effects of the treatments presented would be 
of great investigative interest to follow up in future studies, particularly to compare insulin‘s 
potential to increase creatine uptake to its effect on muscle size. 
Contractile protein MHC and its various isoforms plays a key role in regulating the 
functionality of skeletal muscle fibres and is subject to a complex system of controls which 
can be affected by insulin (Sullivan et al. 1995). It has been suggested that creatine‘s role in 
increasing muscle protein synthesis occurs by increasing the degree of myosin synthesis 
(Ingwall, Morales, and Stockdale 1972). A significant increase in MHC protein expression 
above baseline was observed in the present study with all treatments. The most pronounced 
effect was observed when CR+INS was added to cultures in low glucose concentrations 
followed by that of CR only and INS only treatments also in low glucose concentrations. 
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Work by Khodabukus and Barr (2015) showed that treatment of engineered muscle 
myotubes in low glucose concentration had significantly lower levels of MHC than 
myotubes treated with high glucose concentrations (Khodabukus and Baar 2015). Their work 
also showed that a reduction in glucose results in a shift towards a more slow-oxidative type 
of MHC, suggesting that glucose plays a prominent role in the regulation of myotube 
phenotype in vitro (Khodabukus and Baar 2015). In the present study, high glucose 
availability did not affect MHC levels significantly unless combined with CR+INS. Several 
differences in culture methods may account for the discrepancies observed between the 
current study and that carried by Khodabukus and Barr (2015). In the present study, myotube 
differentiation was initiated in monolayers while the results of previous work established 
myotubes and maintained them in 3-dimensional cultures. Furthermore, myotubes were 
presently maintained in 2% HS following differentiation for the duration of the treatment 
period to eliminate other factors within high serum levels that could interfere with CR and/or 
INS effects, while Khodabukus and Barr  (2015) replaced their HS with 7% FBS following 2 
days of low serum culture.  It was suggested that relative expression levels of MHC are 
indicative of myotube maturity which, in the present study, was obtained in cultures 
supplemented with CR+INS predominantly in low glucose concentrations.  
In culture, creatine has been shown to upregulate the phosphorylation of a number of 
key signalling intermediates of the AKT/mTOR protein synthetic pathway (Deldicque et al. 
2007). In the present study, the levels of the upstream regulator of mTOR, AKT, were more 
pronounced in high glucose cultures but were not affected by creatine, or insulin. 
Additionally, the present study observed no correlation between AKT activity and that of 
mTOR in the current culture model which is attributed to mTOR‘s ability to be activated by 
nutrient availability/stimuli independent of AKT activation (Wang and Proud 2006, Miniaci 
et al. 2015). mTOR phosphorylates downstream target p70S6K which results in increased 
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translation (direct or indirect) via the activation of elongation factors including eIF-4E (via 
4E-BP1) (Van Wessel et al. 2010). The phosphorylation of p70S6K and inhibition of 4E-
BP1 have been closely linked with AKT and mTOR activation. Miniaci and colleagues 
(2015) demonstrated that an mTOR-mediated increased in p70S6K expression in L6 cells 
was linked to greater rates of protein synthesis, particularly after a period of glucose 
starvation (Miniaci et al. 2015). This corresponded with the increased expression of muscle 
specific proteins, including MHC (Miniaci et al. 2015), which is in agreement with the 
current observations. It should be noted that due to the transient nature of downstream effects 
induced by phosphorylation and the chronic time points of the present study, the 
measurement of total protein were more relevant to the conclusions reached herein. 
Neither glucose concentrations nor the different treatments resulted in changes in the 
expression of total p70S6K or its phosphorylated form. However, the duration of treatment 
appears to affect the levels of phosphorylated p70S6K as its detection increased significantly 
in all treatments after 2 wk. The detection of total and phosphorylated 4E-BP1 was similar 
with increases observed in CR+INS and INS treated groups in LG and CR and CR+INS in 
HG.  Delidicque and colleagues (2007) reported that, when differentiating C2C12 myotubes 
with creatine, an increase in p70S6K activity does not necessarily have an effect on 4E-BP1 
phosphorylation (Deldicque et al. 2007). Furthermore, previous work suggests that 4E-BP1 
and p70S6K are regulated by distinct signalling events downstream of mTOR (Wang et al. 
2005) and may therefore, be effected via different regulatory pathways.   
   The MAPK/ERK signalling pathway has also been shown to promote muscle 
differentiation, growth and repair (Deldicque et al. 2007). p38 MAPK has also been 
implicated in the activation of a number of transcription factors necessary for differentiation 
of myoblasts to myotubes (Lechner et al. 1996).  In the present study, p38 MAPK levels 
were affected by treatment and time and to a lesser degree by glucose concentration. The 
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phosphorylated form of p38 MAPK was more responsive to treatment and time than glucose 
concentrations with the highest levels found in cultures treated with CR+INS. These finding 
suggest that the effects of treatments and the varying outcomes may be a result from MAPK 
signalling pathway. Evidence for ―crosstalk‖ between MAPK and AKT/mTOR  pathways is 
scarce, being limited to observations that one signalling cascade may prevent differentiation 
of myoblasts by the other (Gardner et al. 2015).  Several studies have shown that p38 MAPK 
activity increased muscle differentiation and forced activation of this pathway could 
stimulate differentiation and promote myotube formation (Wu et al. 2000, Zetser, Gredinger, 
and Bengal 1999, Serra et al. 2007). Work by Gardner and colleagues (2015) found that 
blocking p38 MAPK expression, thereby promoting IGF-1 mediated signalling, resulted in a 
lack of C2 muscle cell fusion, suggesting p38 MAPK to be essential for the later stages of 
myotube differentiation which result in multinucleated tubes.  
  The results of the present study determined that creatine supplementation results in 
greater myotube size in vitro, which is not related to an increase in contractile proteins. The 
latter is influenced by insulin‘s anabolic role, which also supports the fusion of differentiated 
myoblasts resulting in greater MHC expression. This outcome observed under the present 
culture conditions is likely mediated, in part, via MAPK signalling cascades. 
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CHAPTER 6: 
Fenugreek Increases Insulin-Stimulated Creatine Content in L6C11 
Muscle Myotubes 
 
 
This chapter is comprised of the following paper which was accepted for publication in the 
European Journal of Nutrition: 
 
Fenugreek Increases Insulin-Stimulated Creatine Content in L6C11 Muscle Myotubes 
 
Tomcik KA, Smiles WJ, Camera DM, H Hügel HM, Hawley JA, Watts R. 
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Preface to Chapter Six  
The results of the study described in Chapter Five showed that while glucose 
concentration can augment the differentiation and growth of muscle, the effects vary over a 
chronic treatment time course.  Insulin, however, appears to play a key role in augmenting 
size and hypertrophy signaling pathways when in the presence of creatine.  In lieu of the in 
vitro observations with combined insulin and creatine treatments in chapter five and in 
conjunction with the implications of training with low carbohydrate availability, it was 
speculated whether similar physiological benefits on creatine uptake could be achieved with 
a compound that mimics the action of insulin to a similar degree of that elicited by insulin 
alone, thereby eliminating the need for carbohydrate/glucose altogether. 
In order to obtain an insulin-like benefit without carbohydrate or insulin present, 
Study III employed the cell culture model described in the previous study to test the effects 
of a reported natural insulin mimicking product. Fenugreek is an herb commonly utilized in 
Indian cooking and has also been studied in alternative Ayurvedic medicine as a treatment 
for diabetics due to its blood glucose lowering profile which is remarkably similar to that 
observed with insulin (Figure 6.1). 
Fenugreek seeds were obtained from several sources all originating from the same 
country of origin (India) as well as a purified chemical extract obtained from a commercial 
vendor. Fenugreek seeds were extracted for their oil components as detailed in the 
proceeding chapter. In order to ensure quality of the extracts as well as to compare it to the 
chemical reagent form, a liquid chromatography-mass spectroscopy (LC-MS) method was 
developed and validated for the analysis of 4-hydroxyisoleucine (4-HIL), the active 
insulinotropic compound found in fenugreek seed extract.  
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Figure 6.1: The blood glucose lowering effects of fenugreek compared to insulin.  (A) 
AXN-induced diabetic Swiss albino mice were injected with vehicle phosphate buffered 
saline (PBS), insulin or fenugreek seed extract (1, 5 or 15 mg·kg
−1
). Fenugreek seed extract 
at a dose of 15 mg·kg
−1
 produced a significant decrease in blood glucose levels compared to 
PBS control (P<0.01). (B) Intraperitoneal glucose tolerance test in glucose-loaded (3 g·kg
−1
) 
normal Swiss albino mice. Fenugreek seed extract injected mice had significantly lower 
levels of blood glucose (P<0.01 vs PBS treated) at 45 and 90 min after its administration. 
(Reproduced from Vijayakumar et al. ( 2005) British Journal of Pharmacology) 
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It was during this process that the present investigation determined the seed extract with the 
highest concentration of 4-HIL and consequently excluded the chemical reagent from the 
experiment because it contained the lowest concentration of 4-HIL.  
The use of C2C12 cell line was initially employed for the study due to its known 
application in insulin and creatine studies. Preliminary experiments, however, indicated that 
the fenugreek extract was toxic to this particular cell line and treatment with a spectrum of 
fenugreek extract concentrations resulted in 20-60% cell death by 24 h (Figure 6.2). In light 
of this finding, the subsequent study employed the use of the L6 cell line which, as 
previously described in the prelude to Chapter Five, have an innate sensitivity to insulin 
stimulation and remained viable following treatment with fenugreek. 
 
 
 
Figure 6.2: Cytotoxic analysis of fenugreek treated C2C12 skeletal muscle cells. Cells were 
treated with varying concentrations (0-100 µg/ml) of fenugreek seed extract for 24 h to 
establish a suitable non-toxic dose for use in further experiments. A fluorescence-based cell 
viability assay was used to estimate viable cell number. Per the methodology of the assay, 
values which fall below the dotted line indicated toxicity and cell death. 
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6.1  Abstract 
Purpose  
Creatine uptake by muscle cells is increased in the presence of insulin. Accordingly, 
compounds with insulin-like actions may also augment creatine uptake. The aim of this study 
was to investigate whether Trigonella foenum-graecum (fenugreek), an insulin-mimetic, 
increases total intracellular creatine levels in vitro.  
Methods 
 Total cellular creatine content was measured fluorometrically in L6C11 muscle 
myot
fenugreek seed extract (CR+FEN), CR and 100 nM insulin (CR+INS), and CR+INS+FEN 
(n=6 per treatment group). Alterations in the expression of the sodium-chloride dependent 
creatine transporter, SLC6A8, and key signalling proteins in the PI3-K/AKT pathway were 
determined.  
Results 
 Compared to control (CON), CR+INS+FEN increased total creatine content after 4 h 
(P<0.05) whereas all conditions increased SLC6A8 protein expression above CON at this 
time (P<0.05). Changes in insulin signalling were demonstrated via increases in Akt
Thr308 
phosphorylation, with CR+INS> CON and CR at 1 h (P<0.05) and with 
CR+INS+FEN>CON, CR, and CR+INS at 4 h (P<0.05). In contrast, no changes in PKCδ/λ 
or GLUT4 phosphorylation were detected.  
Conclusion  
Fenugreek, when combined with insulin, modulates creatine content via a mechanism 
which is independent of the activity of SLC6A8, suggesting an alternative mechanism is 
responsible for the regulation and facilitation of insulin-mediated creatine uptake in skeletal 
muscle cells.  
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6.2  Introduction 
Creatine is an ergogenic supplement commonly used by athletes participating  in 
short-duration, high-intensity exercise (Greenhaff 2001). Creatine becomes phosphorylated 
to produce phosphocreatine (PCr), which provides skeletal muscle with a rapid store of 
energy-generating substrates utilized in the replenishment of adenosine triphosphate (ATP) 
(Wallimann et al. 1992). Basal concentrations of creatine in skeletal muscle can be increased 
up to 20% using short-term (i.e., 5 days) creatine supplementation strategies (Harris, 
Soderlund, and Hultman 1992, Greenhaff et al. 1994). Furthermore, the co-ingestion of 
creatine with carbohydrate (CHO) further augments intramuscular creatine stores by up to 
60% above basal levels (Green, Hultman, et al. 1996), presumably via an insulin-dependent 
mechanism (Odoom, Kemp, and Radda 1996).   
While creatine is an important energy source in muscle (Loike et al. 1988, Walker 
1979), skeletal muscle cells are incapable of synthesizing their own creatine (Walker 1979). 
Indeed, approximately 50% of whole body creatine is endogenously synthesised from the 
amino acids glycine, arginine, and methionine via a series of reactions carried out in the 
kidney and liver (Kingsley et al. 2009, Schoch, Willoughby, and Greenwood 2006). The 
remainder is obtained via dietary consumption of meat and fish (Balsom et al. 1993) or 
nutritional supplementation (Jager et al. 2011). Over 90% of circulating creatine is 
transported directly into skeletal muscle cells via the membrane-localized transporter protein 
of the solute carrier family 6 (SLC6), SLC6A8 (Wallimann et al. 1992, Persky, Brazeau, and 
Hochhaus 2003, Snow and Murphy 2003). The activity of the SLC6A8 creatine transporter 
and subsequent levels of creatine content in skeletal muscle is affected by a number of 
variables (Snow and Murphy 2001) including, but not limited to, fluctuations in the 
sodium/chloride-dependent gradient (Loike, Somes, and Silverstein 1986, Willott et al. 
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1999), muscle fibre type (Murphy et al. 2001), intra- and extra-cellular creatine 
concentrations (Loike et al. 1988), and exercise (Harris, Soderlund, and Hultman 1992).  
Insulin further augments creatine transport into skeletal muscle, predominantly by 
increasing muscle Na
+
/K
+
 pump activity (Steenge et al. 1998, Loike, Somes, and Silverstein 
1986, Odoom, Kemp, and Radda 1996, Green, Hultman, et al. 1996, Steenge, Simpson, and 
Greenhaff 2000, Haugland and Chang 1975, Koszalka and Andrew 1972). Considering the 
evidence that increased creatine transport into skeletal muscle occurs, in part, via an insulin-
stimulated mechanism, it is possible that compounds which mimic insulin‘s effects may also 
increase creatine transport. Trigonella foenum-graecum, commonly known as fenugreek, is 
an herbal plant with a demonstrated safety profile in humans (Smith 2003). Its 
phytochemical constituents include saponins (Kang LP 2013), high-ﬁbre content (Al-Jasass 
and Al-Jasser 2012), (2S,3R,4S)-4-hydroxyisoleucine (4-HIL) (Sauvaire et al. 1998, 
Narender et al. 2006), phenolic antioxidants (Kenny et al. 2013) and trigonelline (Nathan et 
al. 2013) as the major bioactive compounds with reported beneficial effects (Srinivasan 
2006). Fenugreek is also used in alternative medicine as a therapeutic agent for the treatment 
of diabetes due to its inherent insulinotropic effects (Srinivasan 2006, Jaiswal et al. 2012, 
Vijayakumar et al. 2005, Sauvaire et al. 1998).  
Similar to insulin, extracts from fenugreek seeds have been shown to up-regulate key 
proteins in the PI3-K signalling pathway (Broca et al. 2004). However, discrepancies exist in 
the activation of key signalling intermediates in this pathway. Unlike insulin, fenugreek 
treatment does not appear to phosphorylate protein kinase B (herein referred to as AKT), a 
key intermediate in glucose metabolism (Vijayakumar et al. 2005). Instead, fenugreek is 
thought to initiate the translocation of protein kinase C (PKC), a similarly sequenced protein 
kinase. A catalyst for a number of signalling cascades including the insulin signalling 
pathway, PKC has been shown to translocate to the cell surface of hepatic and adipocyte 
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cells treated with fenugreek (Vijayakumar et al. 2005) and may similarly do so in muscle 
cells. Therefore, it was hypothesized that co-incubation of fenugreek with creatine would 
increase total intracellular creatine content of L6C11 skeletal muscle myotubes to a similar 
magnitude to that induced by insulin and creatine co-incubation. Furthermore, the present 
study hypothesized that fenugreek would alter the expression of the principle creatine 
transporter, SLC6A8 and/or key insulin signalling intermediates as a result of its insulin-
mimicking properties. 
6.3  Methods  
6.3.1  Preparation of Fenugreek Extracts 
Raw fenugreek seeds were obtained locally (origin: India) and dried at 105°C for 3 h 
before being ground into a fine powder. The ground seeds were placed into a sample cell and 
loaded into an ASE ™ 100 System (Dionex, Sunnyvale, CA) and extracted as per 
manufacturer‘s instructions. Prepared samples were extracted using 50% ethanol. Upon the 
completion of the extraction process, ethanol and water were evaporated and any residual 
solution removed via overnight freeze drying. Fenugreek extract materials were stored in a 
dry environment until treatment. 
6.3.2  Fenugreek Extract Analysis 
Known amounts of fenugreek seed extract samples and a commercially available 
extract (Sigma Aldrich, St Louis, MO USA) were dissolved in 1mL of AR methanol and 
sonicated for 5min to extract 4-HIL. Standards of 4-HIL (Sigma Aldrich) (Isostd mg/mL) 
were run on an Electrospray Ionization (ESI) mass spectrometer (Micromass Platform II) to 
determine peak areas of the standards (Mass 148 was monitored). All samples and standards 
were made up in acetonitrile: water 50:50 with 0.1% formic acid. A calibration curve was 
produced using four standard concentrations of 4-HIL. The fenugreek sample areas were 
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read from the curve to determine the concentrations of 4-HIL (recorded as % weight) in each 
extract. 
6.3.3  Cell Culture 
L6C11 myoblasts were maintained in high glucose Dulbecco‘s modified Eagle 
medium (DMEM) (Life Technologies, CA) supplemented with 10% foetal bovine serum 
(FBS) (Life Technologies), 0.5% Fungizone (Life Technologies) and penicillin streptomycin 
(Life Technologies). Cells were cultured in T-75 flasks and maintained at 37°C in a 
humidified incubator at 5% CO2. Culture medium was changed every 2-3 d and cells were 
sub-cultured when >80% confluent. All experiments were performed in passages 6-11. 
6.3.4  Cell Viability 
Cell viability was measured using the CellTiter Blue® Cell Viability Assay Kit 
(Promega, Madison, WI). Cells were cultured at a density of 2.5 x 10
3
 cells per well in flat-
bottomed 96-well plates and equilibrated for 24 h prior to the addition of varying doses (0-25 
µg/mL) of fenugreek extract. Following treatment, CellTiter Blue® reagent was added to 
each well according to manufacturer‘s instructions. Cell viability was assessed by measuring 
the fluorescence excited at 550 nm and read at 600 nm using a SpectraMax Paradigm plate 
reader (Molecular Devices, Sunnyvale, CA). All assays were performed in quadruplicate and 
independently repeated twice. 
6.3.5  Creatine Content 
Total cellular creatine content was determined using modified versions of 
fluorometric determination methods previously described (Odoom, Kemp, and Radda 1996, 
Conn 1960). Briefly, myoblasts were cultured at a density of 12 x 10
3
 cells per well into 24-
well plates. When 80-90% confluent, differentiation of L6C11 myoblasts to myotubes was 
initiated by replacing the mitogen-rich media with DMEM supplemented with 2% horse 
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serum (Life Technologies), 0.5% Fungizone and penicillin streptomycin for 4 d. Myotubes 
underwent treatments made with control DMEM (CON), 0.5 mM creatine (CR), CR  and 20 
µg/mL fenugreek extract (CR+FEN), CR and 100nM insulin (CR+INS), and CR+INS+FEN 
for up to 24 h (n=6; obtained from 2 independent experiments). Myotubes were rinsed then 
lysed with 0.1 M NaOH. Lysates were hydrolysed with 1 M HCl and water at 60°C for 40 
min. Freshly prepared 1% ninhydrin and 10% KOH (in EtOH) were subsequently added. 
Following 8 min incubation at room temperature, fluorescence was excited at 410 nm and 
read at 525 nm using a SpectraMax Paradigm plate reader. Total creatine content was 
calculated from a creatine standard curve and further normalized to total cellular protein, as 
determined using the bicinchoninic acid (BCA)-based protein assay kit (Pierce 
Biotechnology, IL USA) according to manufacturer‘s instructions. Absorbance was read at 
562 nm.  
6.3.6  SDS-PAGE and Immunoblotting Analysis  
Myotubes were rinsed twice with 1X PBS before lysis with cell lysis buffer (Cell 
Signaling Technology, Danvers, MA) supplemented with 1 mM PMSF. Extracts were 
incubated with continuous rotation at 4°C for 1 h then centrifuged at 13,000 rpm at 4°C for 
15 min to pellet cell debris. The supernatant was analysed for total protein and sample 
protein concentration using a BCA protein assay (Pierce, Rockford, IL, USA).  Western 
blotting was carried out as previously described (Camera et al. 2012). Briefly, lysate was re-
suspended in Laemmli sample buffer, separated by SDS-PAGE, and transferred to 
polyvinylidine fluoride membranes blocked with 5% non-fat milk, washed with 10 mM 
Tris·HCl, 100 mM NaCl, and 0.02% Tween 20, and incubated with primary antibody 
(1:1,000) overnight at 4°C on a shaker. Membranes were incubated with secondary antibody 
(1:2,000), and proteins were detected via enhanced chemiluminescence (Amersham 
Biosciences, Buckinghamshire, UK; Pierce Biotechnology) and quantified by densitometry 
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(Chemidoc, BioRad, Gladesville, Australia). All samples for each treatment group were run 
on the same gel. Phospho-AKT
Thr308
 (no. 4056), total AKT (no. 9272), PKCδ/λ (no. 9378), 
and GLUT4 (no. 9001) were from Cell Signaling Technology (Danvers, MA, USA). 
SLC6A8 (no. AV42248) was from Sigma-Aldrich (St. Louis, MO, USA). Data are expressed 
relative to α-tubulin (no. 3873; Cell Signaling Technology) in arbitrary units.  
6.3.7  Statistical Analysis 
All data were analysed by one- or two-way ANOVA with Turkey‘s post hoc analysis 
and validated by Mauchly‘s sphericity test. Statistical significance was established when 
P<0.05.  All data are expressed as arbitrary units ± standard error of the mean (SEM). 
6.4  Results 
6.4.1  Extract Sample Quality 
 To assess the quality of whole fenugreek seed extracts, a comparison of the 4-HIL (a 
major amino acid with purported insulinotropic properties) concentration between seed 
extracts and a commercially available fenugreek seed extract was undertaken. Analysis using 
liquid chromatography-mass spectrometry (LC-MS) determined the 4-HIL component of 
whole seed fenugreek extract samples to be 50-75 times greater than that of the commercial 
fenugreek extract. Based on this data, the extract with the greatest 4-HIL concentration 
(0.303%) was used for all subsequent experiments (Figure 6.3). 
6.4.2  Cytotoxicity and Viability in Response to 24 h Fenugreek Treatment 
To establish an effective, non-toxic dose of fenugreek extract, cell viability was 
determined in response to a range of concentrations (0-25 μg/mL). L6C11 cells tolerated 
fenugreek extract at doses up to 20 μg/mL without any reduction in relative fluorescence 
(indicative of cell number, hence viability). Treatment with 25 μg/mL of fenugreek resulted 
in a significant decrease in cell number (-37%, P< 0.05; Figure 6.4).  
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Figure 6.3: A liquid chromatography-mass spectroscopy (LC-MS) method developed and 
validated for the analysis of (2S,3R,4S)- 4-hydroxyisoleucine (4-HIL) in fenugreek seed 
extract.  (A) A representative analytical scale of separation and abundance for fenugreek 
seed extract run on an Electrospray Ionization ESI mass spectrometer. Extract analysis was 
performed by monitoring the area under the 4-HIL peak at mass/charge of 148 which 
corresponds to the [4HIL+1] parent ion in the mass spectrum in each extract sample. (B) A 
comparison of the percentage of 4-HIL per extract by weight. A calibration curve was 
created from 4-HIL standards and fenugreek extract 4-HIL samples. The weight of the 4-HIL 
content from each fenugreek extract sample was determined using area under the curve and 
calculated as a percentage.  
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Figure 6.4: Cytotoxic analysis of fenugreek-treated skeletal muscle cells. L6C11 cells were 
treated with varying concentrations (0-25 µg/ml) of fenugreek seed extract for 24 h to 
establish a suitable non-toxic dose for use in further experiments. A fluorescence-based cell 
viability assay was used to estimate viable cell number by measuring fluorescence excited at 
550 nm and read at 600 nm. Each point represents the mean ± SEM of n=4 from 2 
independent experiments. Statistically significant differences (* P<0.05) between control and 
fenugreek-treated myoblasts were determined by one-way ANOVA. 
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6.4.3  Fenugreek Increases Total Creatine Content by L6C11 Myotubes  
Treatment with CR+INS+FEN induced a significant increase compared to CON in 
total cellular creatine content at 4 h (P<0.05; Figure 6.5). Subsequent pair-wise comparisons 
identified a significant difference between CR+INS and CR+INS+FEN (P<0.05).  In 
contrast, no significant time effects were observed.   
 
 
 
 
Figure 6.5: Fenugreek increases creatine uptake by skeletal myotubes. Following 4 d of 
L6C11 cell differentiation, creatine uptake was fluorometically measured in response to 
creatine (CR), creatine and fenugreek (CR FEN), creatine and insulin (CR INS) or and 
creatine, insulin, and fenugreek (CR INS FEN) relative to control. Fluorescence was excited 
at 410 nm and read at 525 nm. Data points represent the mean of n=6 obtained from 2 
independent experiments. Statistical significance (* P< 0.05) was determined by one-way 
ANOVA with Tukey‘s post hoc analysis. 
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6.4.4  Protein Expression 
 A significant time effect was found between 4 vs. 24 h time points for SLC6A8, 
PKCδ/λ, AKTThr308, and GLUT4 expression (P<0.05), 1 vs. 4 h time points for SLC6A8, 
AKT
Thr308
, and GLUT4 (P<0.05), and 1 vs. 24 h time points for PKCδ/λ and AKTThr308 
(P<0.05; Figure 6.6). There was a significant treatment effect observed with insulin for 
AKT
Thr308 
(P<0.05). A significant interaction of treatment and time was also observed for 
AKT
Thr308
 (P<0.05). SLC6A8 protein was increased above CON (P<0.05) across all 
treatments at 4 h (Figure 6.7A). The phosphorylation of AKT
Thr308 
increased with CR+INS 
above CON and CR at 1 h (P<0.05) and with CR+INS+FEN above CON, CR, and CR+INS 
at 4 h (P<0.05; Figure 6.7B). There were no significant changes observed in PKCδ/λ or 
GLUT4 protein content (Figure 6.7 C and D).   
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Figure 6.6 Representative Western blots of creatine transporter and insulin signalling 
proteins. L6C11 myotubes were treated for 1, 4, and 24 h with control (CON), creatine (CR), 
creatine and fenugreek (CR FEN), creatine and insulin (CR INS) and creatine, insulin, and 
fenugreek (CR INS FEN) treatments. Membranes were incubated overnight with primary 
antibody, washed, and incubated with secondary antibody for 1 h before imaging.  
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Figure 6.7: The expression of signalling proteins in creatine co-incubated myotubes. The 
relative protein expression (A) SLC6A8 creatine transporter and key components of the 
insulin-signalling pathway, (B) AKT
Thr308
 (C) GLUT4, and (D) PKCλ/δ, were assessed by 
Western blot in L6C11 myotubes treated for 1, 4, and 24 h. Columns represent the mean ± 
SEM of n=6 obtained from 2 independent experiments in arbitrary units. Statistically 
significant (P< 0.05) differences between treatments within each time point were determined 
by one-way ANOVA.  * indicates difference vs. CON; 
#
 indicates difference vs. CR; and 
†
 
indicates difference vs. CR+INS 
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6.5  Discussion   
 Previous work has shown a variety of creatine supplementation protocols (Green, 
Hultman, et al. 1996, Greenhaff et al. 1994, Harris, Soderlund, and Hultman 1992) to 
increase intracellular creatine concentrations toward a maximum ‗threshold‘ (Greenhaff 
1996). In this study, and in accordance with the first research hypothesis, the current study 
presents novel data to demonstrate increased total intracellular creatine content in myotubes 
treated with fenugreek seed extract. This increase in intracellular creatine observed when 
muscle cells were concomitantly treated with CR+INS+FEN demonstrates an additive effect 
of fenugreek on increasing creatine content in skeletal muscle. As such, CR+FEN alone was 
unable to elevate intracellular creatine above those levels observed with CR or CR+INS 
treated cells.  
The creatine dose (0.5 mM) corresponds to the intracellular concentration found in 
human muscle following a standard 5 g oral dose of creatine (Ceddia and Sweeney 2004). 
This dose has been demonstrated to elicit maximum creatine uptake in skeletal muscle cells 
in vivo (Sora et al. 1994). The reported insulinotropic effects of fenugreek are largely 
attributed to the anti-hyperglycaemic 4-HIL, a naturally occurring amino acid that is unique 
to fenugreek (Ogawa et al. 2011). Sample analysis revealed substantial 4-HIL in the 
fenugreek seed extracts and is consistent with those obtained in previous studies (Narender et 
al. 2006). Further, it was demonstrated that a 20 µg/mL dose of fenugreek extract was able to 
maintain cell viability in the L6C11 cell line in line with previously observed cell viability 
doses (Shabbeer et al. 2009). 
Data pertaining to fenugreek‘s interaction with creatine, specifically on creatine 
storage, however, is limited. Work undertaken by Taylor et al. (2011) in humans 
demonstrated that supplementation with 900 mg of fenugreek combined with 3.5 g of 
creatine stimulates significant increases in maximum strength measures and increased lean 
  161 
 
mass over an 8-week training period (Taylor et al. 2011). However, in that study, no direct 
measures of creatine content (either via muscle biopsies or magnetic resonance 
spectroscopy) were undertaken to determine whether their dosing protocol was effective in 
increasing creatine content in skeletal muscle. It is, therefore, difficult to attribute the 
changes in strength and body composition to fenugreek‘s supposed effect on modulating 
intracellular creatine stores. 
The present study hypothesized a mechanism whereby fenugreek-driven increases in 
creatine concentration would be attributable to increased SLC6A8 activity. Skeletal muscle 
co-incubation with 0.5 mM creatine and fenugreek seed extract combined with 100 nM 
insulin elevated total intracellular creatine content. Creatine transporter expression appears to 
peak at the 4 h time point with all creatine-containing conditions (CR, CR+INS, CR+FEN, 
and CR+INS+FEN) significantly increasing the expression of SLC6A8 above basal levels. 
However, at this time point, neither CR+FEN nor CR+INS elicited any further increase in 
SLC6A8 expression above that of CR alone. Based on these observations, and in accordance 
with previous work (Willott et al. 1999), the current investigation cannot attribute a role for 
the involvement of the SLC6A8 transporter in insulin-mediated or insulin-mimicked creatine 
content augmentation at this time point. Rather, the present data suggest that either 1) 
fenugreek does not affect creatine uptake via the SLC6A8 transporter in L6C11 skeletal 
muscle fibres, or 2) the creatine dose used may have maximally up-regulated SLC6A8 
expression, thereby masking any potential effects of fenugreek on increased creatine uptake 
via this creatine transporter (Daly and Seifter 1980). Furthermore, it may be possible that 
SLC6A8 up-regulation is affected by the activity of other transmembrane proteins. Work by 
Almilaji et al. (2014) determined that the transmembrane protein Klotho, which provides 
control of insulin sensitivity to an organism, upregulates SLC6A8 expression by stabilizing 
the transport protein in the cell membrane(Almilaji et al. 2014).  
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It was also hypothesized that insulin signalling proteins may act as regulatory 
intermediates by which fenugreek stimulates increased creatine content. Canonical insulin 
signalling is characterized by the binding and subsequent recruitment of the PI3K subunit to 
the plasma membrane (Oldham and Hafen 2003). Broca et al. (2000) demonstrated that an 
acute dose of 4-HIL extracted from fenugreek seeds activates PI3-K in the liver and muscle 
cells of both diabetic and non-diabetic rats, significantly reducing insulin resistance through 
the activation of early steps in insulin signalling (Broca et al. 2004). Jaiswal et al. (2012) 
further examined the effect of 4-HIL on glucose uptake and translocation of GLUT4 to the 
plasma membrane in L6 skeletal muscle cells (Jaiswal et al. 2012). Their findings showed 
that 4-HIL stimulated glucose uptake by enhancing the translocation of GLUT4 to the cell 
surface via a PI-3-kinase/AKT-dependent mechanism (Jaiswal et al. 2012). Based on this 
information, the present study determined the effects of fenugreek treatment on selected 
pathways downstream of PI3-K, specifically on AKT signalling substrates. Previous work 
has shown that fenugreek does not activate AKT at the Ser
473
 residue (Vijayakumar et al. 
2005) and, accordingly, phosphorylation on the Thr
308
 site was measured due to its known 
activation by insulin (Kim et al. 1999). As expected, AKT
Thr308
 levels were significantly 
elevated in response to CR+INS at 1 h. Additionally, CR+INS+FEN significantly increased 
AKT
Thr308
 expression at 4 h. However, in contrast to one of the original hypotheses, no 
additive effect on AKT
Thr308
 expression was observed with CR+FEN treatment alone across 
any of the time points tested. It has previously been observed that treatment with fenugreek 
has little effect on AKT expression in both hepatocytes and adipocytes (Vijayakumar et al. 
2005). Furthermore, creatine (21 g for 5 d) has been demonstrated to significantly reduce 
AKT
Thr308
 phosphorylation in resting skeletal muscle samples (Deldicque et al. 2008). The 
presence of creatine, in the absence of insulin co-incubation, may help explain the low levels 
of phosphorylated AKT at the Thr
308
 residue with CR and CR+FEN treatments.  
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Insulin signalling occurs via two divergent pathways: one that is AKT-dependent; 
and the other that is PKC-dependent. In the absence of altered AKT expression in response 
to treatment with fenugreek, the current study sought to determine whether phosphorylation 
of PKC protein was responsible for the observed increase in creatine content. However, no 
significant change in PKCδ/λ phosphorylation was seen in response to fenugreek. This 
finding is in contrast to those of Vijayakumar et al. (2005) who found that fenugreek seed 
extract induces PI3-K dependent activation of the PKCλ isoform in cultured hepatocytes and 
adipocytes (Vijayakumar et al. 2005).  It may be that PKC signalling is dependent on the cell 
line under investigation, and that the differing metabolic processes and requirements of 
skeletal muscle cells may account for the observed lack of PKC expression in response to 
fenugreek treatment.  
In conclusion, CR+INS+FEN treatment results in a greater degree of total 
intracellular creatine content than CR and CR+INS treatments in L6C11 myotubes. 
However, the increased creatine levels following fenugreek treatment alone occurred 
independently of changes in the phosphorylation state of both AKT and PKC signalling. 
Furthermore, fenugreek modulated total intramuscular creatine levels independent of 
changes in SLC6A8 expression, suggesting the presence of a yet to be identified mechanism 
of fenugreek regulation in this process. Fenugreek, in combination with creatine and insulin, 
induces changes in AKT
Thr308, offering avenues for future investigation of fenugreek‘s 
therapeutic benefits. Based on previous in vivo  research (Taylor et al. 2011) on the efficacy 
of creatine and fenugreek co-supplementation on athletic performance, it seems reasonable to 
hypothesize that a combination of creatine loading, fenugreek supplementation, and a high 
carbohydrate diet may further increase intracellular creatine storage. The in vitro results 
demonstrate that compounds which mimic insulin‘s action can further stimulate 
intramuscular creatine content. These results may provide a platform for future human 
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studies to determine whether this increased storage translates to further increases in muscle 
mass, resulting in increased strength for athletes or, on a wider scale, potential attenuation of 
muscle loss in at risk populations (i.e. sarcopenia). 
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CHAPTER 7: General Discussion, Limitations and Conclusions
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The plasticity of skeletal muscle allows it to alter its phenotype in response to 
repeated contraction- and nutrition-induced perturbations to cellular homeostasis. To date, 
the majority of research investigating the ergogenic effects of creatine has been undertaken 
in vivo with a focus on increasing intramuscular substrate stores to enhance exercise 
capacity. While resistance-based training has been the principal exercise modality studied 
with respect to creatine supplementation, evidence of an insulin-mediated enhancement of 
both glycogen and creatine stores in muscle suggests a plausible application of creatine for 
endurance-based activities. Hence, the primary aims of the studies undertaken for this thesis 
were to investigate the effects of altered energy substrate availability, both in vivo (human) 
and in vitro (mouse and rat cell lines), with specific attention to the effect of creatine 
availability on skeletal muscle metabolism.   
The results of Study I (Chapter Four) showed that creatine and carbohydrate co-
supplementation enhanced power output during maximal intensity efforts undertaken 
during/at the end of a 120 km cycling time trial protocol. This increase in power output was 
1) independent of nutrient-induced weight gain that has been previously associated with 
carbohydrate and creatine loading and 2) independent of increased intramuscular glycogen 
concentrations. Elevated intramuscular creatine content was, however, associated with 
increased carbohydrate intake. While changes in selected signalling proteins measured 
showed no major changes between creatine and placebo groups, a reduction in mTOR was 
observed following the glycogen depleting time trial and treadmill endurance task. Based on 
the outcomes of Study I, reservations about using creatine supplementation for endurance 
events due to a fear of detrimental performance arising from weight gain may be undeserved.  
Future applications of creatine in endurance-based activities should focus on athletes 
participating in events which require intense, short-duration bouts of exercise necessary for 
―breaking away‖ from opponents.  If timed correctly, these sprints may determine the 
  168 
 
outcome of closely contested endurance events (i.e. sprint to the finish line). Creatine 
supplementation may need to be timed cautiously, however, directly prior to events in which 
weight classification is critical for competition, such as powerlifting and combat sports, due 
to the inherent weight gain associate with creatine supplementation.  
There were several limitations to Study I. First, the number of biopsies limited the 
scope of analysis that could be undertaken. A post-time trial biopsy would have allowed for 
measures of creatine utilisation during the cycling protocol and also provided greater insight 
into the signalling effects brought about by prolonged endurance exercise under different 
nutritional conditions. Furthermore, the limited and often inconsistent quantity of muscle 
sample obtained from biopsies restricted the biochemical analysis that could be undertaken. 
The absence of intravenous blood samples prevented measurement of metabolites, such as 
lactate, which may have confirmed the effectiveness of creatine treatment in sparing 
glycogen breakdown.  
To further investigate the combined effect of creatine and carbohydrates, a cell 
culture model was developed for Studies II and III to provide a controlled in vitro 
environment in which to test the metabolic impact of substrate co-supplementation strategies. 
In order to simulate in vivo conditions as close as possible, Study II (Chapter Five) utilised 
established murine myotubes as a model for a 2 wk creatine and insulin treatment with low- 
or high-glucose concentrations. The results showed that culture media supplemented with 
creatine supported a continual increase in myofibre size. Creatine co-treated with insulin 
provided further impetus for myotube development as observed in the increased expression 
of contractile protein myosin heavy chain. However, myotubes treated with insulin were 
smaller in size but greater in density (i.e. quantity). Both of these outcomes were largely 
independent of glucose availability. These results suggest the presence of parallel, yet 
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synergistic, mechanisms in which insulin‘s anabolic role amplifies creatine‘s ability to 
stimulate hypertrophy while also supporting the fusion of differentiated myoblasts.  
Both creatine and glucose transport into muscle is mediated by insulin. As the 
findings from Study II demonstrated, insulin can augment skeletal muscle adaptations arising 
from creatine supplementation in vitro. In humans, however, the major stimulus for the 
release of insulin from the pancreases is the presence of glucose in the bloodstream.  
Previous in vivo research has identified not only clinical benefits arising from compounds 
which mimic insulin‘s regulatory role on blood glucose but also a substantial influence on 
augmenting creatine‘s effect on body composition and strength. Utilising similar in vitro 
methodology to Study II, the final study of this thesis (Chapter Six) compared the role of 
insulin and the natural insulin mimetic fenugreek on creatine uptake. Fenugreek alone did 
not facilitate greater creatine uptake. However, it did have an additive effect on increasing 
total intramuscular creatine concentrations in rat myotubes which were also co-incubated 
with creatine and insulin. While the precise mechanism of action could not be determined, it 
was identified that fenugreek‘s action occurs independent of creatine transporter protein 
expression, suggesting that an alternative mechanism and/or earlier time course of action is 
responsible for the regulation of insulin-mediated creatine uptake in vitro. This finding aligns 
with the observations of Study II. Inherently, the ability to translate the in vitro findings in 
Study II and III to in vivo applications is the primary limitation of tissue culture research. 
Nevertheless, in vitro studies provide a mechanistic framework for future in vivo clinical 
work. 
Taken collectively, the work presented for this thesis provides novel insight into 
creatine‘s application not only as an ergogenic aid but also as a potential therapeutic 
compound for the maintenance of muscle mass.  Future research should examine the roles of 
creatine and insulin as agents that could stimulate muscle hypertrophy, particularly in 
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populations prone to muscle loss (i.e. sarcopenia). Tight regulation of muscle protein 
turnover (breakdown vs synthesis) is crucial for the prevention of muscle atrophy. In 
addition to resistance exercise and protein availability, future research on creatine 
supplementation may further enhance or, at the very least, help maintain total body muscle 
mass with particular respect to age-related muscle loss, disease states, such as cancer 
cachexia, or allow for the establishment of muscle regeneration in vitro for transplant 
purposes. Furthermore, a number of studies have implicated fenugreek as a therapeutic agent 
for the treatment of diabetes. In light of recent evidence on creatine‘s beneficial effects in 
type-2 diabetic populations compounded with the findings of Study III, further clinical 
testing should be employed to further explore creatine and fenugreek‘s interactive effects and 
mechanisms which may be beneficial in the treatment of this disease. In this regard, 
supplementation with fenugreek and/or creatine may serve as a precursor to pharmaceutical-
based therapies for the treatment of diabetes or other muscle-effected disorders.  
In conclusion, an abundance of research has been performed to evaluate the efficacy 
of creatine and creatine supplementation strategies on sports performance and contraction-
induced increase in hypertrophy. In athletic populations, evidence suggested that creatine‘s 
ergogenic properties could be enhanced by co-supplementation with carbohydrate, with 
particular benefits seen in resistance trained athletes. Such evidence warranted a more 
thorough investigation into the application of creatine with carbohydrate which was not 
limited to one modality of exercise, but rather expanded the scope of this synergistic 
relationship to endurance trained athletes. In applying this strategy to an in vitro model 
investigating the impact of nutritionally-induced cellular perturbations, a better 
understanding of the role of creatine on muscle growth was identified, which was highlighted 
by the presence of other anabolic substrates. Thus, in light of emerging multi-disciplinary 
research, muscle-targeted therapies remain a promising future endeavour for creatine-based 
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health research. The work completed over the course of this thesis contributes new evidence 
into the effectiveness of creatine interventions not only in improving athletic performance 
but also as an aid in promoting muscle growth and development. 
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